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1.1  Abstract 
 
Introduction 
The work described in this thesis looks particularly but not exclusively at two recently 
developed molecules which have dual enzyme inhibitor activity. Omapatrilat, a 
molecule which inhibits both angiotensin converting enzyme (ACE) and neutral 
endopeptidase (NEP), and SLV 306 (active metabolite KC12615) a compound with 
both NEP and endothelin converting enzyme (ECE) inhibiting properties.  
Neurohumoral activation characterises the complex chronic heart failure syndrome. 
Clearly there is value in antagonizing neurohumoral systems likely to have detrimental 
effects in patients with heart failure, while simultaneously augmenting potentially 
desirable neurohumoral mediators. However enzyme inhibitors which act on multiple 
vasoactive mediators with complex interactions have unpredictable effects. 
Omapatrilat has received much attention following demonstration of a powerful 
hypotensive effect but a higher than expected incidence of angioedema in patients with 
hypertension or heart failure. GW660511X is another dual ACE/NEP inhibitor at an 
earlier stage in development. The pharmacodynamic profile of neither the ACE inhibitor 
activity nor the NEP inhibitor activity of GW 660511X has been fully described in 
humans. SLV 306 is the first orally available molecule of its kind and its NEP and ECE 
inhibitory properties have not previously been demonstrated in humans either in vitro or 
in vivo.  
The intention of this thesis is further characterisation of these molecules and their 
therapeutic potential while utilising their inhibitory properties in further investigation of 
the human neurohumoral system. I specifically consider the possible mediators of the 
impressive hypotensive effects of these molecules and of the unexpected and potentially 
life threatening side effects associated with them. Having demonstrated the complex 
neurohumoral substrate of these molecules I go on to report, for the first time in heart 
failure patients, the benefits of a more specific approach to neurohumoral manipulation 
using a recently developed renin inhibitor, aliskiren. Aliskiren has been shown to offer 
haemodynamic benefit in patients with hypertension but has not previously been given 
to patients with chronic heart failure.  
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Methods 
1) Small resistance arteries from patients (n=89) with coronary artery disease but 
normal left ventricular function were studied using wire myography. The vasopressor 
response to various neurohormones in the presence of omapatrilat, KC12615 (the active 
metabolite of SLV 306) and other vasoactive enzyme inhibitors is reported.  
2) Following pilot studies of the pressor response to intravenous infusion of big ET-1 
(n=6) and pharmacokinetic modeling of orally dosed SLV 306 in healthy volunteers 
(n=29), the effect of 3 doses of SLV 306 and placebo given at four separate visits one 
week apart, on the pressor and neurohumoral response to intravenous infusion of big 
endothelin-1 in healthy volunteers (n=15) is compared. 
3) The effect of 2 oral doses of GW660511X and a single dose of the ACE inhibitor 
ramipril, given on three separate visits one week apart, on the pressor and neurohumoral 
response to an intravenous infusion of angiotensin I in healthy volunteers (n=16) is 
compared. 
4) Finally, the neurohumoral and blood pressure response to aliskiren an orally active, 
long acting renin inhibitor is compared with placebo for one week and the ACE 
inhibitor ramipril for 6 weeks, in patients with left ventricular systolic dysfunction 
(n=27).  
Results 
1) In patients with coronary artery disease but normal left ventricular systolic 
dysfunction; the vasodilator response to bradykinin was augmented by omapatrilat, KC 
12615, phosphoramidon (NEP/ECE inhibitor), captopril (ACE inhibitor), and thiorphan 
(NEP inhibitor). Of note the augmentation is no greater with omapatrilat than captopril 
and in arteries taken from patients prescribed ACE inhibitor, KC 12615 does not 
augment the response. The vasodilator response to adrenomedullin was augmented by 
omapatrilat, KC 12615 and phosphoramidon. The vasoconstrictor response to 
angiotensin I was inhibited by omapatrilat and captopril and the vasoconstrictor 
response to endothelin-1 was inhibited by KC 12615 and phosphoramidon. 
2) In healthy volunteers, SLV 306 caused a dose dependent attenuation of the 
hypertensive and reflex bradycardia response to big ET-1. There was also a dose  
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dependent increase in ANP, big ET-1 and the ratio big ET-1: ET-1 but no increase in 
ET-1 following big ET-1 infusion. 
3) In healthy volunteers, there was no notable change in blood pressure (pre angiotensin 
I infusion) and no significant inhibition of pressor response to angiotensin I following 
administration of GW660511X. Ramipril 10mg was associated with a reduction in 
blood pressure (pre angiotensin I infusion) and inhibition of the response to angiotensin 
I. There was significantly greater reduction in ACE activity with ramipril than 
GW660511X. GW660511X but not ramipril led to a dose dependent increase in plasma 
ANP concentration. 
4) In patients with chronic heart failure, aliskiren suppressed plasma renin activity and 
reduced plasma angiotensin II. Ramipril in comparison caused an increase in renin 
activity and no change in angiotensin II. There were no significant changes in blood 
pressure with either treatment.  
Conclusion 
I have demonstrated the ACE and NEP inhibitory properties of omapatrilat and for the 
first time in humans, the ECE and NEP inhibitory properties of SLV 306, in vitro in 
patients with coronary artery disease but normal left ventricular dysfunction. I found no 
additional augmentation of bradykinin by omapatrilat or SLV 306 over and above that 
offered by ACE inhibition but significant augmentation by both dual inhibitors of 
adrenomedullin. This contradicts the suggestion that bradykinin has a role in the 
incidence of angioedema offers adrenomedullin as an alternative mediator. 
Adrenomedullin augmentation may also contribute significantly to the hypotensive 
effects of these molecules.  
I have demonstrated for the first time in humans the ECE and NEP inhibitory properties 
of SLV 306 in vivo.  
GW660511X is shown to inhibit NEP but to a much lesser extent ACE. Of note the 
comparison made is with full dose of a powerful pure ACE inhibitor. Any inhibition of 
ACE activity in contrast to the study of pure NEP inhibitors is consistent with the belief 
that dual inhibition offers additional benefit.  
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Finally I have demonstrated for the first time in patients with chronic heart failure the 
renin inhibitor activity of aliskiren, confirming attenuation of the renin angiotensin 
aldosterone pathway consistently from its origin and in contrast the rise in renin activity 
seen with ACE inhibitors. 
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1 INTRODUCTION 
1.1 Heart  Failure 
1.1.1 A  DEFINITION 
Before discussing the neurohormones involved in the pathophysiology of heart failure 
and the complex vasoactive enzyme inhibitors offering new potential for treatment, it is 
important to define the syndrome to which I am referring. Heart failure is difficult to 
define since it encompasses a number of differing pathologies and different symptom 
profiles.  
Heart failure, by strict definition, is an inability of the heart to deliver sufficient blood 
and therefore oxygen to the tissues of the body.  
It may be an acute problem, for example as the result of arrhythmia or recent 
myocardial infarct. It may be as a result of chronic deterioration in cardiac function, for 
example as a result of valvular dysfunction, hypertension, alcohol excess or previous 
myocardial infarct.  
Many texts discuss left and right heart failure as two distinct diagnoses. This is 
misleading. Although it is true that different pathologies may affect the left and right 
ventricles to a varying degree, it is not helpful to discuss the two as entirely separate 
conditions. Traditionally right heart failure refers to patients with salt and water 
retention causing peripheral oedema, ascites and elevated jugular venous pressure.  Left 
heart failure refers to those with acute pulmonary oedema and hypotension. However, it 
is understood that salt and water retention is often the result of systemic neurohormonal 
activation, a consequence in many cases of left sided systolic dysfunction. In a 
significant number of patients it is a combination of left and right ventricular 
dysfunction that results in the symptoms and signs associated with heart failure.  
It might be suggested that a helpful definition of heart failure relies on a constellation of 
symptoms and signs or a syndrome. Defining heart failure as a group of symptoms 
however, excludes patients who despite impairment in myocardial contractility do not 
report symptoms.  Perhaps a group to which treatment offers considerable long term 
benefit. Also nearly half of all patients with the symptoms and signs of heart failure are   2
found to have a normal left ventricular ejection fraction (Sanderson 2007). The 
prognosis of the patient said to have a normal ejection fraction and the therapeutic 
approach to them has been shown to be different to that of the patient with systolic 
dysfunction heart failure (Vasan et al 1995). The terms used to describe this condition 
are numerous. Examples include ‘diastolic dysfunction’ and ‘preserved left ventricular 
systolic function heart failure’. Both terms are misleading. The term ‘diastolic 
dysfunction’ is often not based on objective evidence of diastolic impairment since 
traditional non invasive measurements require refinement. ‘Preserved left ventricular 
systolic function’ often relies on traditional assessments of ejection fraction which are 
not sensitive. Many of these patients clearly do not have normal systolic function. 
Indeed it is artificial to consider the two phases of the cardiac cycle as independent of 
one another. Ventricular filling or diastolic function is clearly dependent in part on 
effective ventricular emptying and left ventricular ‘suction’. Ventricular hypertrophy 
and fibrosis traditionally associated with impaired filling quite clearly affect 
contractility as well as relaxation of the myocardium.  
Most recently, studies of patients with symptoms of heart failure but apparently 
preserved left ventricular systolic function have suggested that there is primarily a 
problem with arterial compliance resulting in abnormal ventriculo – arterial coupling. 
(Burkhoff et al 2003, Balmain et al 2007). Endothelial function, key to maintaining 
normal vascular tone may play a significant role in this syndrome. Endothelial 
dysfunction or abnormal vasomotor control has been well documented in patients with 
impaired left ventricular systolic function, indeed many of the treatments, particularly 
involving neurohumoral modulation, target this pathophysiological process.  
Symptoms alone clearly cannot be relied on as a sensitive or specific indicator of left 
ventricular function.  
Since the advent of two-dimensional echocardiography many research groups have used 
objective measurement of left ventricular systolic dysfunction either with or without 
symptoms to define the population to be studied. Indeed, the development in recent 
years of newer echocardiographic techniques, such as tissue Doppler imaging, has 
enabled an even more accurate assessment of ventricular systolic function.   
Measurement of long axis left ventricular function demonstrates reduced function in   3
many patients with signs and symptoms of heart failure but ‘normal’ ejection fraction 
when compared to an asymptomatic age matched population (Yip et al 2002). 
In 2001 the European Cardiac Society (ESC) chose to define heart failure in terms of 
both symptom profile and objective evidence of left ventricular systolic dysfunction; 
‘typically breathlessness or fatigue, either at rest or during exercise, or ankle swelling; 
and objective evidence of cardiac dysfunction at rest (usually on 2D echocardiography) 
(Remme and Swedberg 2001).  
While clearly still excluding some patient groups the guideline has at least defined a 
relatively homogenous group of patients in whom useful research can be performed. 
This encourages large, well designed, randomised, controlled trials and epidemiological 
studies in populations that are well defined. The results of these studies can be 
appropriately applied to large patient groups.  
Brain natriuretic peptide (BNP) measurement perhaps offers an additional tool for 
diagnosis in the future. It has an exceptionally high negative predictive value (Cowie et 
al 1997) The negative predictive value of a normal electrocardiogram to exclude left 
ventricular systolic dysfunction is over 90%.(Gillespie et al 1997, Rihal et al 1995) 
However, many physicians are not sufficiently practised at interpreting 
electrocardiograms to confidently pass one as normal and several workers have 
suggested that estimation of plasma BNP in those who present with suspected left 
ventricular systolic dysfunction could be a more objective measure used to select 
patients for echocardiography (Yamamoto et al 2000, Cowie et al 1997).  The current 
ESC guidelines suggest estimation of plasma BNP levels as an aid in the diagnosis of 
heart failure when it is available (Remme and Swedberg 2001) 
In addition to being clear about the definition of heart failure, it is important clinically 
that the diagnosis is never considered in isolation but as the consequence of a primary 
underlying condition. Along with the initiaton of appropriate heart failure therapy, 
identification of the primary diagnosis also allows initiation of the appropriate treatment 
for that condition. For example the symptoms and signs of heart failure due to critical 
aortic stenosis may be similar to those seen in poor left ventricular systolic function 
secondary to previous coronary artery disease but clearly the pathophysiology and 
treatment of these conditions is very different.     4
For the purpose of this thesis when I refer to heart failure I talk specifically about 
symptomatic, echocardiographically confirmed left ventricular systolic dysfunction.  
1.1.2 EPIDEMIOLOGY   
Heart failure is recognised as a major cause of morbidity and mortality across the 
developed world. It is undoubtedly an increasing problem both in terms of incidence 
and prevalence.   
Perhaps the accessibility of two dimensional echocardiography and therefore 
improvement in diagnostic rates contributes to an increase in reported incidence. 
Perhaps improved data collection makes a difference, with improved consensus on the 
definition of heart failure playing a part. However with official statistics attributing only 
a small proportion of heart failure deaths to heart failure, tending instead to record the 
underlying aetiology, there is little doubt that the true contribution of heart failure to 
overall mortality continues to be significantly underestimated. 
The incidence of heart failure is reported at between 1 and 16/1000 persons. This figure 
increases with age and is significantly higher in men than in women (Ho, Pinsky et al 
1993, Cowie et al 1999).   
The prevalence of heart failure is more widely reported. Stewart et al estimated that in 
1995 there were almost one million patients in the United Kingdom with symptomatic 
heart failure requiring treatment (Stewart et al 2002).  An estimate, by the same group, 
of the burden on the National Health Service in 2000 suggested that heart failure was 
responsible for almost 2% of its total annual expenditure at that time. This rises to as 
much as 4% if hospital admissions in which heart failure is not the primary but the 
secondary or tertiary diagnosis are included. Only ten years previously it was suggested 
that heart failure was responsible for 1.2% of the National Health Service total 
expenditure. Clearly despite improvements in treatment the socioeconomic burden of 
heart failure continues to rise. There are a number of factors which may contribute to 
this.   
Firstly, the prevalence of heart failure is increasing because of, rather than despite, 
improvements in treatment. Advances in our understanding of and therefore our 
treatment of cardiovascular disease, particularly the use of thrombolysis in myocardial   5
infarction (GISSI 1986, ISIS-2 1988) and the use of angiotensin converting enzyme 
(ACE) inhibitors in heart failure (Garg and Yusuf 1995) have improved the longevity of 
these patients. Secondly, major advances in the treatments available for heart failure, 
while improving mortality and morbidity also mean an increase in the total cost per 
patient (Stewart et al 2002). Finally and perhaps most significantly, our population is an 
aging one and the prevalence of heart failure increases considerably with age. 
Population screening reported in the Framingham study shows a prevalence of 8/1000 
in those less than 60 years of age, rising to 23/1000 in those less than 70 years and as 
much as 91/1000 in those over the age of 80 years (Ho, Pinsky et al 1993). Studies of 
patients visiting general practitioners with symptoms suggestive of heart failure, 
identified as those being prescribed diuretics, report an overall prevalence of 3-15 cases 
per 1000, with 28-80 cases per 1000 in those over 65 years of age (McMurray and 
Stewart 2000). The population prevalence of left ventricular systolic dysfunction as 
determined by echocardiography, irrespective of the presence of symptoms, is reported 
as 29 per 1000 overall rising to 64 per 1000 in men over the age of 65 years (McDonagh 
et al 1997). 
1.1.3  PROGNOSIS 
As well as being relatively common, heart failure is a chronic, disabling condition with 
a very poor prognosis.  
It is worth highlighting that the standard method of classifying clinical severity of heart 
failure is the New York Heart Association (NYHA) Classification. (See table 1.1 
below). NYHA class is related to prognosis in patients with heart failure. 
However, the correlation between clinical features and echocardiographic assessment of 
left ventricular systolic function is poor. Some individuals with moderate to severe left 
ventricular systolic dysfunction on imaging exhibit only mild symptoms or are even 
asymptomatic. Indeed, it has been suggested that approximately half of all individuals 
with left ventricular systolic dysfunction are asymptomatic (Remme & Swedberg 2001). 
Conversely patients may exhibit severe symptoms of heart failure clinically with only 
mild left ventricular systolic dysfunction on imaging. Until the introduction of ACE 
inhibitors for the treatment of chronic heart failure the mortality of the condition had not 
improved in over 40 years (Ho, Anderson et al 1993). Even following their introduction   6
Table 1.1   New York Heart Association classification of heart failure. 
NYHA Class:  Symptoms: 
I  No limitation: ordinary physical exercise does not cause undue 
fatigue, dyspnoea or palpitations. 
II  Slight limitation of physical activity: comfortable at rest but less 
than ordinary activity results in fatigue. 
III  Marked limitation of physical activity: comfortable at rest but less 
than ordinary activity results in symptoms. 
IV  Unable to carry out any physical activity without discomfort: 
symptoms of heart failure are present even at rest with increased 
discomfort with any physical activity. 
 
the five year survival following diagnosis is as low as 25%, a poorer outcome than that 
seen in many forms of cancer (Stewart et al 2001). Almost half of patients can expect to 
die within a year of diagnosis, with the elderly having the worst prognosis (McMurray 
and Stewart 2000).  Women tend to live longer than men explaining a similar 
prevalence between the sexes despite a higher incidence in men (MacIntyre et al 2000). 
Improved blood pressure control has also had a more positive effect on the incidence of 
heart failure in women than in men. In men the improvement in blood pressure control 
is offset by an increased survival post myocardial infarction with heart failure. Although 
the mortality figures are alarming, the true overall mortality attributable to heart failure 
is likely in fact to be underestimated. Official records of cause of death often attribute 
the death to the primary condition for example coronary artery disease or valve disease 
rather than to the true terminal condition – heart failure.  
1.1.4  AETIOLOGY  
Prior to the availability of anti hypertensive drugs, the commonest cause of heart failure 
in the developed world was hypertension (Nicholls 1996). Indeed, during the same era, 
heart failure was reported as the commonest cause of death in patients with   7
hypertension. More recently outcomes of hypertension have been less accurately 
reported. Metanalyses often concentrate on stroke and myocardial infarction since the 
rate of heart failure as a consequence of hypertension is more difficult to assess in a 
standardised way.  
In the modern era it is more often stated that coronary artery disease is the commonest 
cause of heart failure (Gheorghiade and Bonow 1998, Fox et al 1999, Cowie et al 1999). 
A review of clinical trials and registers, between 1991 and 1999 attributed 54-71% of 
cases to ischaemia and no more than 20% to hypertension. Of some concern is the 
relative frequency of cases of heart failure described as of unknown aetiology (Cowie et 
al 1999). 
Some would suggest that myocardial ischaemia or infarct are simply the mechanism 
linking hypertension with heart failure (Nicholls 1996) Ischaemia being recognised 
more often now with improved access to diagnostic coronary angiography. 
Unfortunately the evidence provided is somewhat unreliable. Hypertension is largely 
asymptomatic until complications occur and with the onset of heart failure 
arterialpressure almost invariably falls. Hypertension becomes a hidden aetiology. 
There is consistent evidence however that effective treatment of hypertension reduces 
the incidence of heart failure by up to 50% (Moser and Herbert 1996). So why, as 
treatment of hypertension undoubtedly improves, is the incidence and prevalence of 
heart failure increasing? Firstly, inadequate control of hypertension is important, 
perhaps delaying rather than preventing heart failure. Secondly, as suggested 
previously, improved survival from myocardial infarction is an important contributor. 
1.1.5  PATHOPHYSIOLOGY 
Chronic heart failure (CHF) is a progressive pathological process. It develops initially 
as a physiological response to reduced cardiac output. Relative arterial under filling is 
detected by systemic baroreceptors and results in heightened sympathetic nervous 
system activation. This and renal hypoperfusion as a result of the reduction in cardiac 
output triggers activation of the renin angiotensin aldosterone system (RAAS). The 
consequences being vasoconstriction, sodium and water retention and vascular 
remodelling.   8
To be more specific, in the face of a disturbance in myocardial contractility the heart 
depends on three adaptive mechanisms to maintain adequate circulation. 1) an increased 
preload reflected in an elevation in end diastolic volume maintaining the Frank Starling 
mechanism and therefore cardiac output, 2) activation of neurohumoral systems, 
augmenting myocardial contractility and maintenance of arterial pressure and therefore 
vital organ perfusion and 3) myocardial remodelling possibly with ventricular dilatation 
in order to increase the mass of contractile tissue. The first two will occur rapidly, the 
latter perhaps over weeks or months.  
Unfortunately the capacity of each to maintain systemic vascular resistance and cardiac 
output is limited and when chronically maintained becomes maladaptive. The resulting 
reduction in vascular compliance increases not only cardiac preload but also afterload, 
to which the failing heart is particularly sensitive.  
Vasoconstriction, as a result of these physiological mechanisms combined with 
endothelial dysfunction (considered in greater detail in a later chapter), is the process 
responsible for much of the multi-system pathology associated with CHF.  
•  Vasoconstriction of skeletal muscle vasculature results in impaired vasodilatory 
capacity during exercise, contributing to the classic symptoms of fatigue and exercise 
intolerance (Zelis et al 1974). 
•  Increased pulmonary vascular resistance compromises right ventricular function 
resulting in secondary fluid retention and in the long term pulmonary hypertension. 
Patients are often short of breath even at rest. 
•  Renal vasoconstriction occurs early (Vanhoutte 1983) and results in further 
reduction in renal perfusion and therefore RAAS activation and increased sodium and 
water retention. 
The standard treatments for CHF, hypertension and ischaemic heart disease, act by 
systemic means to reduce vascular tone amongst other actions. However, locally acting 
factors and specifically endothelin-1, have been shown to be the most potent 
vasoconstrictors (Yanagisawa et al 1988). The production, action and degradation of 
these vasoactive peptides have therefore become exciting new therapeutic targets.   9
Though, at least initially, a primary mechanical and haemodynamic problem, it is 
recognised that neurohumoral activation characterises the more complex CHF syndrome 
(Cohn et al 1981, Francis 1998). Although initially a physiological response to reduced 
cardiac output, chronic activation of certain neurohumoral systems, e.g. The RAAS, 
seems to lead to undesirable renal effects and to functional and structural modifications 
of the heart and peripheral vasculature that result in hypertrophy and fibrosis (figure 
1.1). In addition to the detrimental haemodynamic effects described above. This 
pathological, sustained, neurohumoral over activity is believed to be a major cause of 
progression of CHF i.e. an explanation for the steady haemodynamic and symptomatic 
decline that characterises the CHF syndrome.   
Neurohormonal data from the SOLVD study show that there is a progressive increase in 
plasma concentrations of renin, noradrenalin, aldosterone and atrial natriuretic peptide 
(ANP) from normal to asymptomatic left ventricular dysfunction and from 
asymptomatic left ventricular dysfunction to overt heart failure (Francis et al 1990). An 
increase in plasma endothelin-1 has also been reported in severe heart failure (NYHA 
III-IV) with an inverse correlation between plasma endothelin-1 and ejection fraction 
(Wei et al 1994). Neurohormonal activation has also been reported in post infarction left 
ventricular systolic function (Rouleau et al 1993) even in the asymptomatic. It is said 
that neurohormonal activation correlates directly with severity of heart failure, more 
specifically ejection fraction than severity of symptoms (Benedict et al 1994). 
Neurohormonal activation has also been recognised as a predictor of cardiovascular 
mortality. In moderate and severe heart failure the highest mortality occurs in  patients 
with the highest plasma levels of noradrenaline, ANP and renin activity (Swedberg et al 
1990) Plasma ANP, renin activity and aldosterone are independent predictors of 
mortality and occurrence of acute heart failure following myocardial infarction 
(Rouleau et al 1994). Increased plasma concentrations of endothelin-1 and its precursor 
big endothelin-1 have also been associated with a poor prognosis. In fact it has been 
shown that the endothelins are more powerful predictors of mortality than many 
haemodynamic or other hormone studies (Tsutamoto et al 1995, Pacher et al 1996, 
Pousset et al 1997). 
Neurohormonal activation is often considered in terms of a balance between 
vasodilating or natriuretic and vasoconstrictive or antinatriuretic forces. In addition to    10
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The neurohumoral model of heart failure   11
improving our understanding of the pathophysiology of CHF, this neurohumoral 
paradigm has given us a framework for understanding therapeutic interventions in CHF.  
Initially, we recognised the value of antagonising neurohumoral systems likely to have 
detrimental actions in CHF; more recently it has become clear that to achieve this while 
simultaneously augmenting potentially desirable neurohumoral mediators may be the 
optimum strategy.  
ACE inhibitors (CONSENSUS 1987, SOLVD 1991, 1992), beta blockers (CIBIS II 
1999, Merit HF 1999) and spironolactone (Pitt et al 1999) inhibit undesirable 
neurohumoral pathways and are associated with significant improvements in the 
morbidity and mortality of heart failure. Diuretics therapy is a well established and 
effective treatment associated with symptom reduction in heart failure (Anand et al 
1990). However, they have been associated with raised plasma renin activity and 
aldosterone secretion. They may well stimulate these undesirable neurohumoral axes. 
The use of these agents should almost certainly be restricted to the management of 
discrete periods of fluid retention and lowered to the lowest effective dose once the 
acute episode is controlled (Bayliss et al 1987). We continue to look for more effective 
treatment strategies and most recently attention has turned to the possibility of 
stimulating beneficial neurohumoral systems such as the natriuretic peptides (Chen and 
Burnett 1999) in addition to inhibiting those which are detrimental. 
In summary, the natural history of patients with CHF, one of steady haemodynamic and 
symptomatic decline, is in part the result of a maladaptive physiological response to 
reduced myocardial contractility, mediated by the activation of multiple neural and 
humoral vasoconstrictor reflexes aimed at preserving cardiac output and vital organ 
perfusion.  
Over time this process results in increased systemic vascular resistance, further 
impairment of left ventricular ejection fraction, and vasoconstriction in the renal, 
muscle and pulmonary vasculature causing predictable clinical and pathophysiological 
deterioration. Despite remarkable advances in our understanding of CHF as a 
pathological process, it continues to be a leading cause of death in many countries of the 
world. It is not only a cause of great mortality but is also associated with significant 
morbidity. Quality of life due to reduced exercise tolerance and fatigue is often very 
poor in patients with chronic heart failure, while frequent, lengthy hospital stays, often   12
with intensive acute management, result in huge financial burden. The focus of 
scientific attention has been on neurohumoral systems with potentially undesirable 
effects in CHF and there is an excellent evidence base enabling firm recommendations 
to be made for the treatment of CHF. 
The work described in this thesis looks particularly but not exclusively at two recently 
developed molecules which have dual enzyme inhibitor activity. Omapatrilat, a 
molecule which inhibits both ACE and neutral endopeptidase (NEP), and SLV 306 
(active metabolite KC12615) a compound with both NEP and endothelin converting 
enzyme (ECE) inhibiting properties. It considers the therapeutic potential of these 
agents and also makes use of them as tools to further our understanding of the 
mechanisms involved. Particularly considering the unpredictable effects of enzyme 
inhibitors which act on multiple vasoactive mediators with potentially complex 
interactions.  
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1.2   NEUROHORMONES – targets for therapy 
Neurohormones are chemical substances, produced by specialized neurons, which act 
either locally or systemically to change the structure or function of target organs. These 
local and systemic mediators coordinate a complex system.  
The sympathetic nervous system stimulates the RAAS system which acts centrally and 
peripherally to further increase sympathetic activity and increase ET-1 and aldosterone 
production. The endothelium is a major source of paracrine mediators such as nitric 
oxide (NO) and endothelin (ET) -1. The natriuretic peptide system including ANP and 
BNP, of myocardial origin, and c-type natriuretic peptide (CNP), of endothelial origin 
counteract the RAAS and ET systems. The interaction between the components of this 
complex system is not fully understood. I will go on to discuss these neurohormones 
and others in more detail 
For some time it has been recognised that there is value in antagonising neurohumoral 
systems likely to have detrimental actions, more recently we have come to realise that 
the optimum strategy might be to achieve this while simultaneously augmenting 
potentially desirable neurohumoral mediators. (figure 1.2) 
1.2.1   THE RENIN ANGIOTENSIN ALDOSTERONE SYSTEM 
Renin initiates the RAAS cascade. It is produced by the juxtaglomerular cells of the 
kidney in response to stimulation from the sympathetic nervous system or in response to 
reduced renal perfusion, during periods registered as volume deficiency.  It controls the 
first rate limiting step of the RAAS system. It cleaves amino acids from a peptide 
produced in the liver, angiotensinogen to release angiotensin I. Angiotensin I is 
converted to angiotensin II via the action of ACE and chymase. ACE is an identical 
molecule to kininase II, the enzyme responsible for the metabolism of bradykinin (Yang 
et al 1970), it is found in abundance in the endothelium as well as in cardiac myocytes, 
fibroblasts and vascular smooth muscle cells. Chymase is a protease found in interstitial 
cells. It is thought that greater than 80% of the generation of angiotensin is via the ACE 
pathway (Zisman et al 1995). Studies in the failing human heart indicate that the ACE 
gene (Studer et al 1994) and protein expression and enzyme activity (Zisman et al 1998) 
are increased but chymase gene expression is not (Studer et al 1994).  
14
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Angiotensin II is the primary vasoactive hormone of the RAAS system. It is formed 
systemically as well as locally in cardiac, pulmonary and vascular tissue. The AT1 
receptor is believed to mediate all the conventionally understood actions of angiotensin 
II. The function of the AT2 and other putative receptors in humans is not known (Cao  et 
al 1999). Angiotensin II has both direct and indirect roles in the development of 
hypertension and in the establishment of the haemodynamic syndrome which 
characterises heart failure. It increases vascular resistance, a primary haemodynamic 
mechanism. The effects of angiotensin II on aldosterone results in an increase in 
reabsorption of sodium and water by the kidney, in turn thought to increase blood 
pressure and further increase cardiac afterload. Angiotensin II also accentuates 
sympathetic nervous system activity and Angiotensin II and aldosterone have both been 
found to increase fibrosis and inhibit fibrinolysis (Cody et al 1997). In addition, 
angiotensin II inhibits renin release, thus providing a negative feedback to the system. 
The degradation of angiotensin II is thought, in part at least, to be under the control of 
NEP (Richards et al 1993). 
Aldosterone is a mineralocorticoid produced by the outer layer or glomerulosa of the 
adrenal cortex. It has two important functions 1) regulation of extracellular fluid volume 
by its effect on sodium retention and 2) potassium metabolism. It acts predominantly on 
the distal convoluted tubule and collecting duct of the kidney where it promotes 
reabsorption of sodium. Potassium then diffuses into the lumen of the tubules because 
of the change in electromagnetic gradient produced by active reabsorption of the 
positively charge sodium ion. Hydrogen ions may also be more freely excreted. 
Aldosterone release is not only regulated by the renin angiotensin system, to which it is 
also linked in a negative feedback loop. Potassium regulates aldosterone secretion 
independent of the RAAS; an elevated potassium concentration increasing aldosterone 
secretion and vice versa. Elevated aldosterone levels have many detrimental effects in 
heart failure. 
In the failing heart it causes changes in blood pressure and cardiac afterload via its 
effects on salt and water and potassium metabolism. It also has an effect on cardiac 
fibrosis and remodelling (Cody et al 1997, Sun et al 2002) and the inflammatory 
response associated with microvascular disease. It causes an increase in sympathetic 
nervous system activity, evidenced by attenuation of the baroreflex and impaired heart  
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rate variability, which together with myocardial fibrosis reduces the arrhythmogenic 
threshold and increases the risk of sudden cardiac death. Increased plasma aldosterone 
levels in hypertensive patients are associated with reduced systemic arterial compliance 
(Blacher et al 1997) and plasma aldosterone levels closely correlate with left ventricular 
mass in this population (Schunkert et al 1997). 
As part of this thesis I further characterise a peptide which has been shown to inhibit 
ACE and NEP, Omapatrilat (Trippodo et al 1998). This molecule may overcome the 
problems faced by pure NEP inhibitors which were disappointing in the treatment of 
hypertension in randomized trials (Richards et al 1993) by offering the additional 
benefit of inhibition of the RAAS system. I also study a similar molecule in an earlier 
stage of development GW660511X.  Finally I study a recent development in the setting 
of chronic heart failure, an orally active renin inhibitor which promises to inhibit the 
RAAS system at its origin, Aliskiren. 
1.2.2   THE ENDOTHELIN SYSTEM 
Three structurally similar endothelin isopeptides have been isolated, ET-1, ET-2, and 
ET-3. It is ET-1 that has been measured as the predominant isoform in human plasma. It 
is a powerful vasoconstrictor; demonstrated to have ten times the vasoconstrictor 
potency of angiotensin II, a mitogenic and anti-natriuretic peptide which is produced in 
increased quantities in CHF (Yanagisawa et al 1988). ET-2 has not been measured in 
human plasma but can be found in endothelial cells and has been shown to have a 
similar effect on vascular tone. ET-3 has less potent vasoconstrictor activity and its 
physiological role remains less clearly understood. 
ET-1 stimulates the production of cytokines and growth factors (Hofman et al 1998, 
Matsuura et al 1998). It interacts with blood cells stimulating neutrophil adhesion 
(Lopez Farre et al 1993) and platelet aggregation (Knofler et al 1995). In summary it 
promotes vasoconstriction, cell growth, cell adhesion and thrombosis; it is believed 
therefore not only to contribute the progression of CHF but also to the development and 
progression of atherosclerosis and the development of hypertension.  
ET-1 is generated from a precursor peptide big ET-1, by ECE. ECE has not been found 
in human plasma suggesting that it is not systemically active but is produced and acts 
only locally in specific systems.  ECE shares structural and perhaps functional  
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similarities with NEP (Turner and Tanzawa 1997). It has been suggested that ECE is not 
selective for big ET-1 but also hydrolyzes peptides such as bradykinin (Hoang and 
Turner 1997) and substance P (Johnson et al 1999). 
ET-1 is predominantly released from the endothelium, abluminally toward the vascular 
smooth muscle again suggesting a paracrine role (Wagner et al 1992). It is also 
produced by other cells involved in vascular disease such as leukocytes (Sessa et al 
1991) and macrophages (Ehrenreich et al 1990). ET-1 production is regulated by 
physical factors such as shear stress (MacArthur et al 1994), pulsatile stretch (Malek 
and Izumo 1992) and pH (Wesson et al 1998). Hypoxia is a strong stimulus for ET-1 
synthesis perhaps important in ischaemia (Rakugi et al 1990). Synthesis is also 
stimulated by cardiovascular risk factors such as elevated levels of LDL cholesterol and 
glucose, obesity and ageing (Boulanger et al 1992, Yamauchi et al 1990, Barton et al 
2000) 
Infusion of thiorphan into the human forearm, leading to local NEP inhibition, causes 
vasoconstriction at least in part reversed by a co-administration of an ET receptor 
antagonist (Plumpton et al 1995, Haynes and Webb 1994, Love et al 1996, Ferro et al 
1998).   Candoxatril, another NEP inhibitor, increases plasma ET-1 concentrations 
(Ando et al 1995, McDowell et al 1997). Both these observations suggest that NEP may 
contribute to degradation of ET-1 (Russell et al 1996). This may in part explain the 
rather disappointing antihypertensive effects of NEP inhibitors in vivo (Richards et al 
1993).  
As part of this thesis I further characterise a peptide which has been shown to inhibit 
NEP and ECE, SLV 306 (Meil et al 1998). This molecule may offer more effective 
treatment for patients with hypertension or CHF. 
1.2.3   NATRIURETIC PEPTIDES 
The natriuretic peptides have potent natriuretic (de Bold et al 1981), vasodilator (Currie 
et al 1983, Webb DJ et al 1998), and antimitogenic (Itoh et al 1990) properties.  
ANP is produced primarily by the cardiac atria. Several hormones and 
neurotransmitters, such as ET, vasopressin and catecholamines directly stimulate the 
secretion of ANP. Increased atrial wall tension, reflecting increased intravascular  
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volume is the dominant stimulus for its release (Ogawa et al 1991) both in patients with 
heart failure and healthy individuals. Plasma concentrations of ANP are augmented in 
patients with increased intravascular volume, such as those with CHF. This includes 
patients with a raised left atrial pressure and normal left ventricle for example patients 
with atrial arrhythmia. 
BNP, originally identified in porcine brain tissue (Minamino et al 1988) is in fact 
predominantly produced by the cardiac ventricles (La Pointe et al 1996). Pro-BNP (108 
amino acids) is stored in myocardial cells and cleaved into BNP (32 amino acids) and 
the inactive N-terminal BNP when it is secreted. Patients with CHF have high plasma 
concentrations of BNP (Cowie 2000) while concentrations are extremely low in normal 
individuals. Increasing BNP levels correlate well with worsening NYHA class (Kuster 
et al 2002) offering a more objective measure.  Elevated BNP can be used to identify 
patients with previously undiagnosed heart failure, a recognised threshold being 
18pg/ml (McDonagh et al 1998) and higher levels taken to reflect more severe heart 
failure. 100pg/ml is recognised as evidence for decompensation (McCulloch et al 2003). 
At acute presentation an elevated BNP greater than 80-100pg/ml is highly accurate at 
differentiating decompensated heart failure from acute dyspnoea of other causes 
(McCulloch et al 2002).  BNP has an exceptionally high negative predictive value 
(Cowie et al 1997). The concentrations correlate with the extent of ventricular 
dysfunction, the development of cardiac arrhythmia and the degree of haemodynamic 
compromise. High concentrations predict poor long term survival (Gottlieb et al 1989). 
BNP correlates with outcome most closely (Motwani et al 1993) and evidence that it 
specifically predicts sudden death has been used to suggest a role for BNP in selection 
of patients for internal cardiac defibrillator (Berger et al 2002). There is some evidence 
that serial BNP measurement may be useful as a guide for uptitration of heart failure 
treatment with more effective inhibition of the RAAS than is seen with more traditional 
prescribing (Murdoch et al 1999).  
CNP predominates in the central nervous system, kidney and the vascular endothelium. 
Concentrations are very low in the plasma (Tawaragi et al 1990).  
Recently a novel natriuretic peptide was identified from the venom of the green mamba 
snake Dendroaspis angusticeps and consequently named Dendroaspis Natriuretic 
Peptide (DNP) (Schweitz et al 1992). Immunoreactivity to this peptide has been  
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detected in human tissue  and circulating levels have been demonstrated to correspond 
to the degree of heart failure (Schirger et al 1999). It is associated like the other 
natriuretic peptides with natriuresis and vasodilatation (Best et al 2002) but in animals 
at least appears to be resistant to degradation by NEP (Chen et al 2002) 
The natriuretic peptides reduce effective circulating volume by increasing venous 
capacitance (Abraham et al 1998), natriuresis and diuresis (de Bold et al 1981). They 
increase renal blood flow and antagonise the RAAS (Gottlieb et al 1989, Wada et al 
1994). ANP inhibits the production of catecholamines, renin, angiotensin II, aldosterone 
and ET-1 (Brands et al 1998, Atarashi et al 1984, Wada et al 1994) and suppresses ACE 
activity (Lang et al 1992). As a consequence there is reduced systemic vascular 
resistance, decreased intracardiac filling pressure and improvement in myocardial 
performance. There is a limit to cardiac remodelling (Wu et al 1997).  The natriuretic 
peptides also cause vasodilatation by reducing sympathetic outflow and damping 
baroreceptor function (Yang et al 1992, Jin et al 1992, Currie et al 1983, Webb DJ et al 
1998).  
Interestingly, if the inhibitory effects of BNP and ANP on the RAAS are blocked in 
experimental heart failure, then it progresses more rapidly (Stevens et al 1995). This 
underlines the key role of the activated RAAS in the progression of heart failure and the 
favourable effects of natriuretic peptides in the condition.  
The natriuretic peptides act through three receptors; A, B and C. The A receptor binds 
both ANP and BNP, but has a stronger affinity for ANP. ANP and BNP therefore have 
similar effects but ANP is the more important physiologically. This is reassuring when I 
consider the fact that natriuretic peptides are beneficial in heart failure but the effect of 
well established treatments is to lower the levels of BNP. They do not generally lower 
levels of ANP to the same extent.   
CNP is the natural ligand for the B receptor and natriuretic peptide receptor C is 
involved in the clearance of the peptides (Koller and Goeddel 1992). Circulating 
natriuretic peptides are also inactivated by cleavage at the hands of NEP, present within 
renal tubular cells and vascular cells (Levin et al 1998). Renal dysfunction impairs 
clearance of the natriuretic peptides and results in higher plasma levels. 
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1.2.4   BRADYKININ 
Bradykinin is released from the inactive precursor, kininogen, by the enzyme kallikrein. 
Bradykinin is a strong vasodilator agent (Fox et al 1961). The activity of bradykinin is 
mediated via binding with one of two identified receptors B1 and B2. Understanding of 
the role of these receptors in humans is limited. Animal in vitro studies have suggested 
that B1 receptors are normally induced following vascular trauma, while B2 receptors 
are expressed in endothelial cells (Drummond and Cocks 1995). B1 receptors are said to 
have a role in chronic pathophysiological processes while B2 receptors generally 
mediate most cardiovascular effects: hypotension, bronchoconstriction, plasma 
extravasation, regulation of smooth muscle tone, cell growth and acute inflammatory 
reactions (Schanstra et al 1998, Hall 1997, Marceau et al 1997, Kasel et al 1996, 
Schneck et al 1994).  
Bradykinin is metabolised by kininase II, an identical molecule to that which activates 
angiotensin II from angiotensin I, ACE (Yang et al 1970) and NEP (Graf 1993). In fact 
when parenterally active ACE inhibitors first became available they were known as 
bradykinin potentiating peptides (Gavras et al 1974). It is not known to what extent 
endogenous bradykinin potentiation contributes to the therapeutic or adverse effects of 
ACE inhibitors but since the major regulator of bradykinin degradation in human 
endothelial cells is ACE it is certainly true that the hypotensive and other effects of 
ACE inhibitors in vivo may be due not only to inhibition of angiotensin II formation, 
but also to accumulation of bradykinin (Kasel et al 1996, Graf et al 1993).  
It is possible that an increase in bradykinin activity is responsible for the relatively 
minor side effect of cough reported in a small number of patients and also the much 
more serious side effect of angioedema seen in a small but significant number of 
patients taking ACE inhibitors (Slater et al 1988, Kjekshus et al 1988, Israili and Hall 
1992, Kostis et al 1994, 1996, Nussberger et al 1998, Agostoni et al 1999).  
The effect on bradykinin activity of various neurohumoral modulators, and the 
association therefore with both therapeutic and potentially hazardous consequences, will 
be considered as part of this thesis. The implication that bradykinin may have a 
causative role in the potentially life threatening angioedema reported in a small number 
of patients taking omapatrilat is particularly interesting (Messerli and Nussberger 2000).  
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I look particularly at the effect on the bradykinin activity of the combined ACE/NEP 
inhibitor, omapatrilat and the combined ECE/NEP inhibitor, KC 12615.  
1.2.5  ADRENOMEDULLIN 
Adrenomedullin (ADM) is an amino acid peptide with structural similarity to calcitonin 
gene-related peptide (CGRP) sufficient to allow cross reactivity at receptors (Bunton et 
al 2004). It was originally isolated from human phaeochromocytoma. It is synthesized 
by a wide variety of tissues, including endothelial and vascular smooth muscle cells and 
acts as a circulating hormone and a local paracrine mediator. ADM production is up 
regulated by oxidative stress, pro inflammatory cytokines, angiotensin II and ET-1 
(Chun et al 1997, Sugo et al 1995). Plasma concentrations of ADM are raised in heart 
failure in proportion to symptomatic and haemodynamic severity of the syndrome 
(Nishikimi 1995). They correlate with rising levels of natriuretic peptide but show a less 
brisk response to treatment – perhaps reflecting disease severity more closely. ADM 
may have a role as a prognostic indicator in heart failure (Pousset et al 2000, Richards et 
al 2001). ADM binds to and activates a specific ADM receptor and CGRP receptors 
(Beltowski and Jamroz 2004). It is a peptide with vasodilator, natriuretic and mitogenic 
actions (Eto et al 1999, Charles et al 1996) playing a significant role in endothelial 
regulation of blood pressure. Low dose infusion of ADM has been shown to reduce 
afterload, increase ejection fraction and increase cardiac index without an effect on 
heart rate in healthy volunteers (Del Bene et al 2000) and with diminished potency in 
patients with heart failure (Nakamura et al 1997). Its mechanism of action is thought to 
be a combination of intracellular effects on NO synthase, and possibly direct inhibition 
of both ET-1 production by endothelial cells (Hillier, Petrie et al 2001, Kohno et al 
1996) and aldosterone production (Petrie et al 1999, Lainchbury et al 1999, Nagaya et al 
2000).  
The metabolism and clearance of ADM remains unclear. Since ADM shares structural 
similarities to the natriuretic peptides, NEP is a potential candidate. There is however 
conflicting data on the involvement of NEP in the degradation of ADM. Since an 
increase in natriuretic peptides levels has been directly associated with an increased 
plasma concentration of ADM and vice versa, interpretation of the data is complex 
(Bunton et al 2004). An effect of NEP inhibition on ADM degradation was 
demonstrated by Lisy et al in the dog (Lisy et al 1998) but inhibition of NEP was not  
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shown to augment ADM associated vasodilation, in the arteries of patients with heart 
failure (Petrie et al 2001). Further studies of the effects on ADM activity of NEP 
inhibition as well as vasopeptidase inhibition will be reported in this thesis. 
1.2.6  CALCITONIN GENE RELATED PEPTIDE  
CGRP is another amino acid peptide with a potent vasodilating action (Brain et al 
1985). CGRP and ADM bind to similar receptors and as such have similar effects 
(Beltowski and Jamroz 2004).  
Increased levels of CGRP activity are found in chronic heart failure suggesting a role in 
the regulation of vascular tone and the pathophysiology of this condition (Gennari et al 
1990). Finally, in human skin CGRP has been shown to cause persistent local 
reddening, thought to be secondary to dilatation of arterioles (Brain et al 1985). This 
raises the question of whether CGRP activity may be the mechanism by which some 
patients develop facial flushing as a side effect of vasopeptidase inhibition. Work 
looking at the effect of vasopeptidase inhibition on CGRP activity will be reported as 
part of this thesis. 
1.2.7  VASOACTIVE INTESTINAL PEPTIDE 
Vasoactive intestinal peptide (VIP) is a 28-amino acid peptide. It is involved in 
autonomic regulation of the cardiovascular system, where it exerts positive inotropic 
and chronotropic effects. It is a potent vasodilator particularly associated with coronary 
vasodilatation (Henning and Sawmiller 2001) and reduced pulmonary vascular 
resistance. Heart failure has been associated with a reduction in circulating and 
myocardial VIP concentration or with alteration of affinity, density and physiological 
responsiveness of VIP receptors (Brodde et al 1992). ACE inhibitors have been shown 
to attenuate this depletion of VIP activity in heart failure (Duggan and Ye 1998) 
suggested as an additional mechanism for their positive inotropic effect. It is certainly 
possible that augmentation of VIP activity mediates some of the effects of 
vasopeptidase inhibition and for this reason it is included in my studies of their 
vasoactive effects. 
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1.2.8  SUBSTANCE P  
Substance P is a member of the tachykinin family. Other members of this family include 
neurokinin A and neurokinin B. Its cardiovascular effects are largely mediated by the 
neurokinin receptor (Walsh and McWiliams 2006).  The precise role of substance P in 
human physiology has been difficult to elucidate. It is suggested that it stimulates 
plasma extravasation in an endothelium dependent manner therefore playing a 
prominent role in tissue oedema and inflammation (Walsh and McWilliams 2006). 
Substance P also regulates vascular tone and therefore blood pressure and heart rate 
both peripherally and via the central nervous system (Dzurik et al 2007).  It may relax 
vessels in some situations and constrict them in others, perhaps dependent on the 
condition of the endothelium. It is suggested that it has a complex perhaps otherwise 
compensated role in normal circumstances which becomes clinically apparent in 
disease.  
As part of this thesis I consider the possibility that substance P mediates some of the 
benefits and perhaps the problematic side effects, for example angiooedema, associated 
with omapatrilat. 
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1.3  NEUROHUMORAL MODULATION  
– Vasoactive Enzyme inhibition 
It is now broadly accepted that the manipulation of neurohumoral pathways offers 
significant benefit to patients with cardiovascular disease, reducing both morbidity and 
mortality (Garg and Yusuf 1995, Flather et al 2000, Yusuf et al 2000, Fox 2003) During 
the development of now well established treatments, such as ACE inhibitors, we have 
learnt that inhibition of the activity of one vasoactive hormone often results in clinically 
important inhibition or potentiation of other pathways. Clearly there is value in 
antagonizing neurohumoral systems likely to have detrimental actions, and it is likely 
that the optimum strategy is to achieve this while simultaneously augmenting 
potentially desirable neurohumoral mediators. However enzyme inhibitors which act on 
multiple vasoactive mediators with complex interactions have unpredictable effects. 
1.3.1   THE RENIN ANGIOTENSIN ALDOSTERONE SYSTEM 
Blockade of the RAAS improves symptoms and survival in heart failure and ischaemic 
heart disease (CONSENSUS 1987, SOLVD 1991, Yusuf et al 2000, Fox 2003). Indeed 
greater inhibition has been shown to result in greater benefit (Packer et al 1999).  
The current most popular approach to inhibition of this pathway is ACE inhibition. 
ACE inhibitors have been shown to improve mortality and morbidity in all classes of 
CHF, including asymptomatic left ventricular impairment post myocardial infarction 
(AIRE 1993).   
ACE inhibitors reduce the generation of angiotensin II, a powerful vasoconstrictor, from 
angiotensin I by ACE. As a result of reduced angiotensin II stimulation of the adrenal 
cortex, aldosterone production is also reduced by ACE inhibition.  
As ACE is also kininase II, ACE inhibitors have a second action, the reduction of the 
breakdown of bradykinin.  ACE inhibition has been shown to increase bradykinin levels 
(Pellacini et al 1994). Whether this is a beneficial or detrimental effect remains unclear. 
While the hypotensive and other effects of ACE inhibitors in vivo may be due not only 
to inhibition of angiotensin II formation but also to accumulation of bradykinin, it is 
also suggested that an increase in bradykinin levels is responsible for a number of the 
side effects associated with ACE inhibitor therapy, side effects which not infrequently   25
result in the drug being discontinued. Cough is the most commonly reported cause of 
drug discontinuation and potentially life threatening angioedema is seen in a small but 
significant number of patients (Yusuf et al 2000, Fox et al 2003, Fuller and Choudry 
1997). Both have been attributed to the rise in bradykinin activity in patients taking 
ACE inhibitors (Slater et al 1988, Kjekshus and Swedberg 1988, Israili and Hall 1992, 
Kostis et al 1994, 1996, Nussberger et al 1998, Agostoni et al 1999).  
As a result of the inhibition of its break down to form angiotensin II, ACE inhibition 
also causes an accumulation of angiotensin I. Increased levels of angiotensin I may 
competitively overcome enzyme inhibition and lead to "renin-angiotensin-aldosterone 
escape" (Pitt et al 1995).  Other enzymes, such as chymase, may continue to generate 
angiotensin II from angiotensin I (Urata et al 1990, McDonald et al 2001, Petrie et al 
2001). It is known that the reduction in circulating aldosterone levels as a result of ACE 
inhibition is variable and often poorly sustained (Struthers 1996). This has been 
demonstrated in both the hypertensive and CHF populations (Biollaz et al 1982, 
Clelland et al 1984). In particular, over a third of heart failure patients are found to have 
elevated levels of aldosterone. 
These and other considerations have led to the introduction and development of specific 
angiotensin II type 1 (AT1) receptor antagonists (Pitt et al 1995, 1997, 2000, Pfeffer et 
al 2003). The membrane bound AT1  receptor mediates the detrimental effects of 
angiotensin II in heart failure. While these agents are undoubtedly effective in the 
treatment of cardiovascular disease, with improvement in CHF and post myocardial 
infarction morbidity and mortality comparable to that seen with ACE inhibitors (Pitt et 
al 1995, 1997, 2000, Pfeffer et al 2003), angiotensin II receptor antagonists have been 
shown to result in accumulation of angiotensin II and the consequences of this, through 
the actions of angiotensin II at other receptors, are unknown (Gottlieb et al 1993, Cao et 
al 1999). 
Since it has been demonstrated that ACE inhibitors and angiotensin II receptor 
antagonists, while clearly offering considerable benefit in chronic heart failure offer 
only partial inhibition of the deleterious RAAS, it is not unexpected that large studies 
have been performed considering the addition of RAAS antagonism at its origin and its 
end point.    26
The aldosterone antagonist, spironolactone, has been studied widely in the chronic heart 
failure population and has been shown to reduce mortality and morbidity in patients 
with NYHA stage III and IV symptoms (Pitt et al 1999).  
Renin cleaves circulating angiotensinogen to angiotensin I which is then transformed 
into angiotensin II. This is the rate limiting step in the formation of angiotensin II 
(Fisher and Hollenberg 2001, Nussberger et al 2002). A functional membrane bound 
renin receptor has also been characterised (Nguyen et al 2002) and it has been suggested 
that receptor bound renin is able to activate angiotensinogen with a higher efficiency 
than renin in solution.  
Renin has very high substrate specificity; it’s only known substrate is angiotensinogen. 
In theory therefore renin inhibitors should specifically and efficiently block the 
formation of angiotensin II. 
Renin inhibitors should also have a therapeutic profile distinct from ACE inhibitors and 
angiotensin receptor antagonists. ACE inhibitors reduce the conversion of angiotensin I 
to angiotensin II and angiotensin receptor antagonists prevent binding of angiotensin II 
to the AT1 receptor. Both these inhibitors, however, also interrupt the normal feedback 
suppression of renin secretion from the kidneys, causing reactive rises in circulating 
renin, angiotensin I (in the case of ACE inhibitors) and angiotensin II ( in the case of 
angiotensin receptor antagonists) levels ( Hollenberg et al 1998). In the case of ACE 
inhibitors, the rise in circulating angiotensin I may lead to an increase in the formation 
of angiotensin II via pathways independent of ACE ( e.g. chymase) or even overcome 
the blockade of ACE. We know that beta blockers which reduce the release of renin are 
not associated with such escape processes (Buhler et al 1972). With angiotensin 
receptor antagonists, the reactive increase in angiotensin II may stimulate other 
angiotensin receptor subtypes, with unknown consequences. ACE inhibitors are of 
course also non substrate specific, inhibiting the breakdown of bradykinin and possibly 
other substances.  
As long ago as 1957, the potential benefits of specific inhibition of the renin system by 
diminishing renin activity and not other pathways, has been highlighted (Skeggs et al 
1957). Until recently, the introduction of renin inhibitors into clinical practice was 
limited by low oral bio-availability, poor efficacy, short duration of action and high cost   27
of chemical synthesis (Fisher and Hollenberg 2001, Nussberger et al 2002). These 
problems have in part been overcome with the development of the new, orally active, 
specific renin inhibitor, aliskiren (Nussberger et al 2002). The first work looking at the 
haemodynamic and neurohumoral effects of renin inhibition in patients with chronic 
heart failure is reported as part of this thesis.  
1.3.2   NEUTRAL ENDOPEPTIDASE INHIBITION    
The second major class of agents, to reach an advanced stage of clinical development, 
with the ability to regulate the production and degradation of vasoactive factors, was the 
NEP inhibitors.  
The success of ACE inhibitors has encouraged the development of alternative 
approaches to the blockade of the RAAS. It is acknowledged that ACE inhibition is 
poor at renin-angiotensin-aldosterone suppression in the long term (Rousseau et al 
1994, Kirlin et al 1995). NEP inhibition may offer us such an approach as well as 
augmenting the potentially beneficial natriuretic peptides.
 
NEP is a plasma membrane bound metalloprotease. It catalyzes the degradation of a 
number of endogenous vasodilator peptides, including ANP, BNP, CNP (Stephenson 
and Kenny 1987, Lang et al 1992, Kenny et al 1993), substance P (Skidgel et al 1984) 
bradykinin (Graf et al 1993) and possibly ADM. There are conflicting data regarding 
ADM degradation, with augmentation of ADM activity reported in dogs (Lisy et al 
1998) but no effect of NEP inhibition on ADM activity seen in humans (Petrie et al 
2001).  
Inhibition of the degradation of the natriuretic peptides, has been shown in vitro and in 
animal models to inhibit the RAAS in several ways, reducing the synthesis of renin and 
aldosterone and suppressing ACE activity (Brands and Freedman 1988, Atarashi et al 
1984, Lang et al 1992). These results support the suggestion that NEP inhibition is an 
attractive therapeutic option.  
Candoxatrilat is an orally active, selective NEP inhibitor. Sinorphan, a pro-drug of 
thiorphan, is also a selective NEP inhibitor. Both agents have been administered to 
humans with encouraging effect on circulating ANP levels and natriuresis but 
disappointing effect on blood pressure (Richards et al 1992). Systemic NEP inhibitor   28
administration did not cause reduction in the blood pressure of normotensive individuals 
(O’Connell et al 1992) and indeed there are reports of the blood pressure increasing in 
response to candoxatrilat. The lowering of blood pressure in hypertensive patients 
although reported was by no means universal (Richards et al 1993, Favrat et al 1995).  
These results were disappointing and prompted further work into the in vivo activity of 
NEP. While there is evidence that the vasodilator peptides are augmented in the 
presence of NEP inhibition, it has now been suggested that the predominant 
physiological substrates for vascular NEP are vasoconstrictor peptides and particularly 
ET-1 (Ferro et al 1998), explaining the contradictory haemodynamic results obtained 
after systemic dosing with NEP inhibitors. 
Infusion of thiorphan into the human forearm, leading to local NEP inhibition, causes 
vasoconstriction at least in part reversed by a co-administration of an ET receptor 
antagonist (Plumpton et al 1995, Haynes and Webb 1994, Love et al 1996, Ferro et al 
1998).   Candoxatril also increases plasma ET-1 concentrations (Ando et al 1995, 
McDowell et al 1997). Both these observations suggest that NEP may contribute to 
degradation of ET-1 (Russell et al 1996). There is some evidence, in guinea pig and rat 
lung, that NEP can also convert big ET-1 to the active ET -1 (Murphy et al 1994, Held 
et al 1997, Lebel et al 1996). Local vascular accumulation of ET-1 may counteract the 
blood pressure lowering effect of an increase in plasma natriuretic peptide 
concentrations after NEP inhibition, at least in healthy subjects and hypertensives 
(Ando et al 1995, Richards and Crozier et al 1992, Ferro et al 1998, McDowell et al 
1997). NEP may also degrade angiotensin II and this too may counteract the 
hypotensive effect of natriuretic peptides (Richards and Wittert et al 1992, Richards et 
al 1993).  NEP inhibition alone seemed to be more promising in CHF, compared to 
hypertension, possibly because of the much greater effect on circulating natriuretic 
peptide concentrations in this condition (Newby et al 1998, Northridge et al 1999).   
Even in CHF, however, a vasoconstrictor response to systemic NEP inhibition has been 
observed (Kentsch et al 1996).  
The physiological actions of NEP are presumed to be the result of a balance between the 
degradation of the vasoconstrictor and the vasodilator hormones (see figure 1.3.1). It is 
understood therefore that the effects of NEP inhibition are complex.   29
One possible solution to this is combined or dual enzyme inhibition. It seems reasonable 
to suggest that inhibition of NEP while at the same time inhibiting the vasoconstrictor 
pathways independently, for example the RAAS with ACE inhibition, or the ET system 
with ECE inhibition, should result in a more effective therapeutic strategy. Favrat and 
associates have shown that a combination of an ACE inhibitor, captopril, and a NEP 
inhibitor, sinorphan, results in a greater antihypertensive effect than either agent alone 
(Favrat et al 1995). Much of the work described in this thesis looks at two recently 
developed molecules which combine ACE and NEP inhibition, and ECE and NEP 
inhibition, omapatrilat and KC 12615 respectively. 
1.3.3  VASOPEPTIDASE INHIBITION   
The RAAS and natriuretic peptides have been the targets for new interventions over the 
past two decades. More specifically targeted are the enzymes responsible for regulation 
of the synthesis and degradation of the major peptides involved (Figure 1.3.1). A 
number of molecules which inhibit both ACE and NEP, known as vasopeptidase 
inhibitors, have been synthesized and are at various stages of clinical development. 
While there has been some cause for concern regarding the adverse effects of these 
molecules, it is acknowledged that there are likely benefits in dual enzyme inhibition, 
perhaps in a selected population (Coats 2000, 2002, Campbell 2003, Richards et al 
2003). 
Omapatrilat (BMS 186716) (figure 1.3.2) is the most clinically advanced agent in this 
class having been widely studied in both heart failure and hypertension in randomised 
controlled clinical trials. It was the first orally active molecule available and is a potent 
and specific inhibitor of both ACE and NEP activity, Ki of 6 and 9nmol/L respectively 
(Trippodo et al 1998). Other molecules have also now been given to humans (table 1.3) 
with encouraging effect on blood pressure when compared to ACE inhibitor or placebo 
in a hypertensive population.  
I report on the NEP and ACE inhibitory properties of one of the more recently 
developed molecules, GW660511X (‘511) as part of this thesis. The pharmacodynamic 
profile of the ACE and NEP inhibitor activity of '511 has not been fully described in 
humans. Initial studies have characterized the ACE inhibition by assessing plasma ACE   30
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Figure 1.3.1 
The pathways affected by vasoactive enzyme inhibition. ↑ = augmented, ↓ = inhibited 
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ACE inhibition TABLE  1.3    PUBLISHED STUDIES OF HAEMODYNAMIC EFFECTS OF VASOPEPTIDASE 
INHIBITORS 
Vasopeptidase inhibitor 
(reference) 
Number 
of 
patients
Population 
Mean age 
(yrs) 
Placebo / 
active 
control 
Doses used  
(number receiving) 
Means of 
administration 
Duration of 
therapy 
(observation) 
Reduction in blood 
pressure from 
baseline with highest 
dose (mmHg) 
Systolic (S) 
Diastolic (D) 
Mean arterial (M) 
Sampatrilat 
(Norton et al 1999) 
 Hypertensive
50 
Lisinopril  Lisinopril 10-20mg (30) 
Sampatrilat 50-100mg (28) 
Oral 
56 days 
S:    8 
D:    5 
MDL 100240 
(Rousso et al 1999) 
12 Healthy 
volunteers 
24 
Placebo  Placebo 
MDL 100240 6.25mg 
MDL 100240 25mg 
Intravenous 
Single dose 
(24hrs) 
S:    8 
D:    3 
Z13752A 
(Bani et al 2000) 
16 Healthy 
volunteers 
25 
Placebo Placebo 
Z13752A 10-800mg 
Oral 
Single dose 
(24hrs) 
No significant change 
Fasidotril 
(Laurent et al 2000) 
57 Hypertensive
50 
Placebo Placebo 
Fasidotril 100mg bd 
Oral 
42 days 
S:   18 
D:   10 
Mixanprilat / S21402 
(Chodjania et al 2002) 
10 Healthy 
volunteers 
 
Captopril 
 
Captopril 50mg 
Mixanprilat 250mg 
Oral  
Single dose 
No significant change 
GW660511X 
(Johnson et al 2006) 
123 Hypertensive
51 
Placebo Placebo  (62) 
GW660511X 200mg (61) 
Oral  
14 days 
S:    8 
D:    5 
Ilepatril / AVE 7688 
(Azizi et al 2006) 
24 Helathy 
volunteers 
 
Ramipril 
Irbesartan 
Placebo 
Ramipril 10mg 
Irbesartan 
Irbesartan and ramipril 
Ilepatril 5mg 
Ilepatril 25mg 
Oral 
Single dose 
(48hrs) 
M:   12   32
activity and have partially characterized markers of NEP inhibition. I compare it with an 
active control in a healthy population.  
Molecules which inhibit NEP, ACE and ECE are also in development but as yet not 
given to humans (Battistini et al 2005).    
OMAPATRILAT 
Administration of omapatrilat results in dose dependent increase in plasma ANP, 
plasma renin activity, plasma bradykinin levels and the urinary excretion of ANP and 
cGMP, characteristic of NEP inhibition (Hammett et al 1999, Vesterqvist et al 1999, 
McLean et al 2000, Campese et al 2001). Omapatrilat administration also results in a 
reduction in serum ACE activity despite an increase in plasma renin activity 
(Vesterqvist et al 1997, 1999, Campese et al 2001).  
A reduction in circulating levels of angiotensin II and therefore aldosterone, and 
augmentation of the natriuretic peptides, would be expected to lead to a reduction in 
vascular tone and therefore a reduction in blood pressure. The reported effects on blood 
pressure, of omapatrilat compared with placebo, are encouraging, with a number of 
groups reporting significant reduction in systolic and diastolic pressure (Ruddy et al 
1999, Zusman et al 1999, Aronoff et al 2000, Larochelle et al 2000, Mitchell et al 
2002). The challenge for the development of vasopeptidase inhibitors, as useful therapy 
in hypertension or heart failure, has been the need for demonstration of a beneficial 
effect over and above ACE inhibition. More significant, therefore, are those studies 
which demonstrate that omapatrilat results in greater blood pressure reduction than the 
ACE inhibitors, lisinopril and enalapril in patients with hypertension.  (Campese et al 
2001, Ferrario et al 2002, Mitchell et al 2002, Kostis et al 2004). 
One of these groups also reported a previously unknown property of omapatrilat. 
Vesterqvist et al noted that administration of omapatrilat resulted in an increase in ADM 
levels (2000). This could be explained by the theory that NEP is involved in the 
degradation of ADM, supporting the results of animal work by Lisy et al (1998). As 
previously described there are contradictory reports on this role (Petrie et al 2001).  
When compared with placebo, omapatrilat has also been associated with improved 
ejection fraction, and reduced systolic and diastolic blood pressure in heart failure   33
Figure 1.3.2 
The chemical structure of omapatrilat   34
patients, as well as increased urinary volumes and urinary excretion of sodium and 
ANP, demonstrating inhibition of NEP. Again however, the effects of omapatrilat, need 
to be compared with the effects of ACE inhibition alone in patients with heart failure.  
IMPRESS was a randomised study comparing the effects of omapatrilat and lisinopril in 
patients with heart failure over a period of 24 weeks (Rouleau et al 2000). 573 patients 
were randomised. The primary end-point was change in exercise tolerance but 
morbidity and mortality were also reported. All patients enrolled were required to be on 
an ACE inhibitor, a selected population therefore, but ACE inhibitor therapy was 
stopped prior to randomization.  
Importantly, in the primary end point, exercise tolerance, there was no difference 
between the two groups. More positively, the reported difference in mortality and 
hospital admission rates between the two patient groups did suggest benefit of 
omapatrilat over lisinopril, the Kaplan-Meier curve for the composite of death or 
admission for worsening heart failure, separating early but not reaching significance by 
the end of the 24 week period (p=0.052, figure 1.3.3) At the end of week 24 omapatrilat 
treatment had also led to more improvement and less worsening of NYHA class, in 
patients in NYHA class III or IV (figure 1.3.4), although not significant when patients 
in NYHA II were included. Overall these results were encouraging and led Bristol-
Myers-Squibb, the manufacturer and patent holder, to file a new drug application with 
the FDA.  
Unfortunately subsequent studies have been less well received. The new drug 
application for omapatrilat was voluntarily withdrawn in April 2000 because of reports 
of a significant number of cases of angioedema in patients taking omapatrilat. Initially it 
was hoped that the incidence of this potentially life threatening adverse event would 
compare well to that seen and accepted in patients taking ACE inhibitors. In fact the 
OVERTURE study published in 2000, confirms that the incidence of angioedema is 
significantly higher in patients taking omapatrilat, when compared to those taking ACE 
inhibitors. Angioedema was reported in 24 (0.8%) omapatrilat-treated and 14 (0.5%) 
enalapril-treated patients. Having been exposed to the drug for a relatively short period 
of time this apparently low incidence is very significant. The incidence of angioedema 
overall was however less than that previously reported in hypertension studies and it 
was suggested by the investigators that heart failure patients may be less vulnerable to   35
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Figure 1.3.3 
The IMPRESS study. Kaplan-Meier curve for the composite of death or admission for worsening heart failure, 
separating early but not reaching significance by the end of the 24 week period (p 0.052) 
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Figure 1.3.4 
The IMPRESS study. The effect of omapatrilat on NYHA class in patients in NYHA class III and IV 
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the effects of bradykinin augmentation (Packer et al 2002). CHF also carries a more 
serious prognosis than hypertension and risk/benefit ratios of therapeutic interventions 
must be assessed separately for the two indications (Willenheimer and Swedberg 2000). 
The mechanism by which patients taking omapatrilat develop angioedema is not fully 
understood. It is three times more common when a starting dose of 20mg is used than it 
was with lower doses, suggesting a pharmacodynamic rather than an allergic effect. 
Bradykinin is probably the mediator of the angioedema associated with ACE inhibitors 
(Nussberger et al 1998, Agostoni et al 1999, Israili and Hall 1992) and since we know 
NEP also metabolises bradykinin it is perhaps not unexpected that a combined 
ACE/NEP inhibitor would be associated with a higher incidence of angioedema. 
Aside from the angioedema story, the results of this study were not as impressive as had 
been hoped for following the IMPRESS trial. OVERTURE was designed to compare 
the efficacy of omapatrilat to that of an ACE inhibitor, enalapril, in patients with heart 
failure, encouraged by the positive findings of the IMPRESS trial and studying patients 
over a longer period. In fact, it reported no significant superiority of omapatrilat in the 
primary end point of all cause mortality or hospitalization for heart failure. On a more 
positive note, with regard to overall adverse event profile, both drugs were well 
tolerated in moderate to severe heart failure and interestingly, renal failure was less 
common in the omapatrilat group despite more reports of significant hypotension. This 
is consistent with previous reports that NEP inhibition has a protective effect on renal 
function particularly in the context of ACE inhibitor use (Chen et al 1999, Troughton et 
al 2000). The effects of NEP inhibition on renal function are thought to be due to an 
increase in glomerular filtration rate and renal blood flow, they are thought to be less 
significant in severe heart failure in which there is thought to be a degree of resistance 
to ANP mediated natriuresis (Chen et al 1999). 
The most recently published study OCTAVE (Kostis et al 2004) is a study in 
hypertension. A multicentre, randomised, double blind study over 24 weeks, it 
compared omapatrilat with enalapril as first line replacement for existing inadequate 
treatment or in addition to existing therapy in more than 25,000 patients with 
hypertension. It was primarily designed to see if starting with smaller doses of 
omapatrilat would result in a lower incidence of angioedema in this population.    38
Omapatrilat reduced systolic blood pressure by 3.6mmHg more than enalapril at week 8 
and was associated with less use of adjunctive therapy by week 24 (19% vs 27%; 
p<0.001 for both comparisons). In all three groups, patients treated with omapatrilat 
were more likely to reach target blood pressure. Angioedema however was still more 
frequent with omapatrilat (2.17% vs 0.68%), it occurred more quickly and was more 
likely to be severe. The risk of requiring hospitalisation 9.5 times higher in the 
omapatrilat group with two patients suffering airway compromise that was successfully 
treated.  
Overall in a setting resembling clinical practice omapatrilat provided broadly superior 
antihypertensive efficacy when compared to ACE inhibitor. However potentially life 
threatening side effects unlikely to be diagnosed and treated as effectively in clinical 
practice as they are in highly controlled clinical studies remain a real concern.   
Overall, it would seem that omapatrilat is an effective antihypertensive agent. Its 
superiority to the ACE inhibitors, lisinopril and enalapril in this population perhaps not 
fully explained by what we know already with regard to NEP inhibition. It is not 
however superior to enalapril in heart failure patients, contrary to what we expected 
following neurohumoral and pilot studies. Patients with hypertension aand heart failure 
may be an exception to this, if subgroup analysis is to be considered (Kostis et al 2004). 
Omapatrilat apparently does reduce morbidity and mortality more than enalapril in this 
population to an extent consistent with its antihypertensive efficacy. Finally and most 
significantly however, omapatrilat carries a significantly higher risk of the serious 
adverse event, angioedema in both populations, the mechanism of which is not well 
understood. 
With the OCTAVE results available to them in 2002 the FDA, again on balancing risk 
versus benefit, refused Bristol-Myers-Squibb application for a new drug licence. It 
would seem that this is the end of the omapatrilat story. Certainly OPERA (Omapatrilat 
in Persons with Enhanced Risk of Atherosclerotic Events, Kostis et al 2002)) which 
proposed to compare omapatrilat with placebo in 12,600 patients with borderline 
hypertension over five years has subsequently been dropped apparently due to poor 
recruitment.    39
Neurohumoral modulation undoubtedly has much to offer in the treatment of 
cardiovascular disease. More work looking at molecules that inhibit both ACE and NEP 
is clearly merited, if only to increase our understanding of the complex actions of these 
enzymes. In a selected population, particularly patients with renal dysfunction early in 
their heart failure course, or patients with resistant or complicated hypertension, there 
may be a role for omapatrilat. Unfortunately its role in the unselected hypertension 
population and perhaps even in unselected heart failure patients is seriously threatened  
by a significant risk of life threatening side effect. Further studies of the mechanism of 
the side effects is required and the work described in this thesis contributes to the 
debate. 
1.3.4  THE ENDOTHELIN SYSTEM 
Endothelin-1, the most important ET isopeptide in the human cardiovascular system, is 
a powerful vasoconstrictor and has renal, mitogenic and other actions to suggest that it 
might play an adverse role in CHF, hypertension and atherosclerosis (Grantham et al 
1998, Kedzierski et al 2001). It is a powerful vasoconstrictor; demonstrated to have ten 
times the vasoconstrictor potency of angiotensin II (Yanagisawa et al 1988). There are 
at least two distinct endothelin receptors; ET A and ET B. ET A receptors are found on 
the vascular smooth muscle cells and mediate vasoconstriction (Seo et al 1994). ET B 
receptors are found on both vascular smooth muscle cells mediating vasoconstriction 
and endothelial cells. They mediate endothelial cell release of NO and prostacyclin to 
mediate vasodilatation (Tsukahara et al 1994). In addition binding to ET B receptors 
represents the primary clearance mechanism for ET-1, particularly in the pulmonary and 
renal vascular beds (Dupuis et al 1996, Bohm et al 2003). The balance between ET A 
and ET B receptor activation undoubtedly plays a key role in the regulation of 
vasomotor tone. Like ACE inhibitors and angiotensin receptor antagonists, ET receptor 
antagonists might also improve prognosis in chronic heart failure. Indeed in 
experimental heart failure, they have been shown to improve survival (Sakai et al 1996). 
In patients with chronic heart failure both non selective and selective ET receptor 
antagonists reduce pulmonary and systemic vascular resistance and increase cardiac 
output (Kioski et al 1995, Sutsch et al 1998).   40
A number of endothelin receptor antagonists have been studied in patients with heart 
failure, including BQ 123, BQ 788, BMS193884, TBC 11251 (sitaxsentan), LU 135252 
(darusentan), Ro-61-0612 (tezosentan) and bosentan (Ro 47-0203). (Love et al 1996, 
2000, Cowburn et al 1998, Smith et al 2000, Torre-amione et al 2001, Givertz et al 
2000, Spieker et al 2000, Kiowski et al 1995).
 
Bosentan is a non-selective ETA/B antagonist, the most widely studied of this class. 
The REACH-1 (Research on Endothelin Antagonism in Chronic Heart failure trial, 
Packer et al 1998, 1999)
 studied the effect of prolonged treatment with Bosentan. This 
multi-centre, double-blind, placebo-controlled study assessed the effect of bosentan 
therapy for 6 months in patients with advanced heart failure.  370 patients with severely 
symptomatic chronic heart failure despite treatment with diuretics, digoxin and an ACE 
inhibitor were randomised to receive either bosentan (target dose 500 mg twice daily) or 
placebo.  The primary endpoint of the study was a clinical composite which assessed 
symptoms and major events.  The trial was stopped early because of an excess of 
asymptomatic, reversible elevations in hepatic transaminases and reductions in 
haematocrit in the bosentan group.  In the entire study population, there was no 
significant difference between bosentan and placebo.  However, only 173 patients 
(47%) had been followed for 6 months at the time of trail discontinuation.  In the sub-
group of patients followed for the intended 6 months duration of the study, bosentan 
significantly increased the likelihood of clinical improvement and decreased the 
likelihood of symptomatic deterioration.  Furthermore, bosentan reduced the total 
number of hospitalisations for any reason by 41%.  The benefits of bosentan seemed to 
increase with longer duration of therapy.  The REACH-1 trial was not powered to detect 
any effect on mortality.  
More recently the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac 
Events in Heart Failure) study (Coletta et al 2002) evaluated the effects of a lower dose 
of bosentan, again in patients with severe heart failure. A total of 1,613 patients were 
randomized to receive either bosentan (125 mg twice a day) or placebo. The preliminary 
results were presented in 2002. The primary endpoint of all-cause mortality or 
hospitalization for heart failure was reached in 321/808 patients on placebo and 312/805 
receiving bosentan. Treatment with bosentan appeared to confer an early risk of 
worsening heart failure necessitating hospitalization, as a consequence of fluid   41
retention. It has been suggested that further studies using even lower doses of bosentan 
or more aggressive concomitant diuretic therapy may avoid this adverse effect.  
The results from the REACH and ENABLE studies have undoubtedly thrown 
considerable doubt on the potential benefits of non-specific endothelin receptor blocker 
in chronic heart failure. Further studies have been carried out using a similar molecule 
but in the acute setting. 
Tezosentan is an intravenously administered competitive antagonist of both ET A and 
ET B receptors. As expected by inhibiting the effects of endothelin, it is a powerful 
vasodilator. The haemodynamic and clinical effects of tezosentan were studied in a 
series of large, double blind phase III studies, collectively known as the RITZ program. 
Patients with acute heart failure were treated with doses of 50-100mg/hr of tezosentan 
(Teerlink et al 2001, Torre – Amione et al 2003, O’Connor et al 2002, Kaluski et al 
2003). The results of the RITZ program while demonstrating haemodynamic benefit did 
not report clinical benefit at these doses. Further analyses of the results suggested that 
the doses used were at the top end of the dose response curve, causing an excess of side 
effects and, perhaps as a result of massive vasodilatation, limited efficacy. 
In a more recent phase II study, lower doses of tezosentan were used (0.2-25mg/hr), 
again in patients with acute heart failure who had failed to respond to intravenous 
diuretic therapy (Cotter et al 2004). Interestingly the overall haemodynamic response to 
these lower doses was found to be similar in magnitude to that seen at high dose but 
with a later onset and more prolonged duration. Only a trend toward improvement in 
patient symptoms was observed but a significant decrease in BNP levels, previously 
associated with improved outcome over the long term (Cheng et al 2004), was noted.  
It is suggested that, while higher doses of endothelin antagonist cause haemodynamic 
effects associated with excessive vasodilatation, decreased urine output and increased 
plasma endothelin levels in acute heart failure, lower doses may result in similar 
reduction in pulmonary wedge pressure but with longer term benefit and without the 
same adverse effects. This most recent study however is but a preliminary study, having 
recruited only a small number of patients (n=130) and therefore its interpretation has to 
be limited.    42
Further large studies are eagerly awaited, due to report late in 2007, looking particularly 
at a 1mg/hr dose and its effect on clinical outcome. The VERITAS program consists of 
2 identical, double-blind, randomized, placebo-controlled, concurrently conducted trials 
(VERITAS-1 and VERITAS-2), performed in 150 centers in Europe, Israel, Australia, 
and North America (Teerlink et al 2005). The program is designed to enroll at least 
1760 patients hospitalized with dyspnoea at rest because of acute heart failure, requiring 
intravenous therapy. In addition to conventional therapy, patients are randomized to 
receive tezosentan (5 mg/h for 30 minutes, then 1 mg/h for 24-72 hours) or matching 
placebo. The 2 prespecified primary end points are the incidence of death or worsening 
heart failure at 7 days in the combined studies and the change from baseline in dyspnea 
over the first 24 hours of treatment, measured using a visual analog scale in VERITAS-
1 and VERITAS-2, individually. Since no currently available agents have been shown 
in a prospective, randomized, clinical trial to improve outcomes in patients with acute 
heart failure, the VERITAS program will provide valuable insights into the effect of 
tezosentan on clinical outcomes as well as hemodynamics and clinical symptoms. 
Since selective ET B receptor blockade worsens haemodynamic variables in chronic 
heart failure (Wada et al 1997), selective ET A receptor antagonists might be thought 
preferable to mixed ones. EARTH, Endothelin Receptor Antagonist Trial in Heart 
Failure, is a multicentre randomized, double blind, placebo controlled, parallel, dose 
ranging study looked at the long term effects of different doses of the orally active ET A 
antagonist, darusentan on left ventricular remodeling, neurohormones and symptoms in 
patients with advanced chronic heart failure (Anand et al 2004). They were also unable 
to demonstrate benefit. Six months of treatment failed to improve left ventricular 
remodeling and offered no clinical benefit at any dose. This was despite a reduction in 
blood pressure and an increase in circulating endothelin levels suggesting effective 
receptor blockade. 
The EARTH investigators suggest that the background treatment of the heart failure 
population is particularly relevant. That ACE inhibition or angiotensin receptor 
antagonists, beta blockade and spironolactone, taken by 95%, 73% and 37% of their 
patients respectively might already have caused maximal remodeling effects.  
In summary neither ET A selective or non selective receptor antagonists have shown 
therapeutic benefit in chronic (bosentan in ENABLE, darusentan in EARTH) or acute   43
(tezosentan in RITZ) heart failure. While the results of VERITAS remain outstanding 
the emphasis in this class has understandably moved away from the CHF population 
concentrating instead on other pathology such as pulmonary hypertension and renal 
disease (Channick et al 2001, Neuhofer et al 2006, Benza et al 2007). Perhaps a 
subgroup of heart failure patients with these common comorbidities will ultimately find 
benefit. 
Endothelin converting enzyme (ECE) converts big ET to ET. SLV 306 is a dual 
metalloprotease inhibitor, inhibiting both NEP and ECE. An alternative inhibitor of the 
endothelin system, it is in phase II of development (figure 1.3.5).  
Combined NEP and ECE inhibition, leading to augmented natriuretic peptide and 
bradykinin concentrations, coupled with reduced ET-1 synthesis is an attractive 
therapeutic strategy in a range of cardiovascular diseases. The natriuretic peptides ANP, 
BNP and CNP are anti-mitogenic, natriuretic and vasodilatory peptides. Augmentation 
of their local and circulating concentrations is a new therapeutic strategy in CHF and 
atherosclerosis. Conversely ET-1 is a powerful vasoconstrictor, mitogenic and anti-
natriuretic peptide which is produced in increased quantities in CHF (Love and 
McMurray 1996, Petrie et al 1999). ET-1 is also believed to contribute to the 
development and progression of atherosclerosis. Inhibition of the action of ET-1 may be 
beneficial in CHF and atherosclerosis (Love and McMurray 1997).  
The NEP and ECE inhibitory properties of SLV 306 have been studied in animal 
models of acute and CHF, systemic and pulmonary hypertension. In all these models it 
has shown a very promising profile of activity. In animal studies a statistically 
significant diuretic and natriuretic activity was coupled with a dose dependent and 
statistically significant reduction in systemic systolic and diastolic blood pressure. In 
CHF models in animals SLV 306 improved cardiac performance, reduced lung oedema 
and cardiac remodelling and showed renal protective properties (Meil et al 1998). 
To date, 97 healthy male and female subjects have been exposed to SLV 306 in four 
studies. In healthy subjects, SLV 306 has been well tolerated and considered safe in the 
doses given. Following administration of SLV 306 it is quickly absorbed and 
hydrolyzed to the active metabolite KC12615 (Meil and Wurl et al 1998). After single 
dosing, a dose dependent increase in plasma ANP and cGMP concentrations from about   44
 
Figure 1.3.5  
The chemical structure of SLV 306 and its active metabolite KC 12615 
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50mg onwards has been observed; there is no demonstrable change in plasma ET-1 
concentrations at this dose and no effect on cardiac output, mean arterial pressure or 
total peripheral resistance. After multiple dosing, ANP and cGMP increases after 
200mg twice daily, while angiotensin II and renin decrease. Again there has been no 
change in plasma ET-1 concentrations demonstrated with this dosing regime (Meil and 
Rupp et al 1998). Clearly further investigation is required in order to fully establish the 
ECE inhibitory activity of SLV 306. Clear evidence of inhibition of the conversion of 
the precursor big ET-1 to the active vasoconstrictor peptide ET -1 is required. As part of 
this thesis I study further the pharmacologic actions of SLV 306. 
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1.4  ENDOTHELIAL FUNCTION  
– Vasomotor control 
The human vascular endothelium is not simply a semi permeable membrane allowing 
exchange of water and small molecules. It is also involved in vasomotor control, 
clotting homeostasis and regulation of vascular growth which are all key to 
cardiovascular health or disease. Vasomotor control has been adopted as the means by 
which endothelial function is assessed and certainly with regard to heart failure is often 
the focus of what is discussed when the term endothelial dysfunction is used. 
Endothelial cells lie between the vascular lumen and the smooth muscle cells of the 
vessel wall. They sense mechanical forces within the lumen and regulate vascular tone 
through the production of a variety of factors (Kinlay et al 1996, Mombouli and 
Vanhoutte 1999). The endothelium produces both potent vasodilators, such as 
endothelium derived relaxing factor (EDRF), prostacyclin, and endothelium derived 
hyperpolarizing factor (EDHF) and vasoconstrictors such as ET-1 and angiotensin II. 
Local blood flow is thus determined by a balance between the effects of vasodilators 
and vasoconstrictors on the underlying smooth muscle.                      
In 1980 Furchgott demonstrated that acetylcholine had a vasodilatory effect on blood 
vessels in the presence of the endothelium but was associated with vasoconstriction if 
the endothelium was removed (Furchgott 1996). It became apparent that vasodilatation 
was mediated by the endothelium and vasoconstriction by the vascular smooth muscle. 
In healthy vessels in vivo the endothelium dependent vasodilatation predominates.  
In 1986 Ignarro et al suggested that the mediator of endothelium dependent 
vasodilatation was the free radical NO (Ignarro et al 1987). NO appears to play a key 
role in many endothelial functions not least vasomotor control. NO is released as the 
product of a reaction between L-arginine and nitric oxide synthase (NOS) (Palmer et al 
1988). It has a very short half life and therefore works on a very local or paracrine basis. 
It is important for maintenance of arterial relaxation at rest, its availability is improved 
by increased intraluminal flow, hypoxia (Brown et al 1993), bradykinin and other 
hormonal mediators. It acts by reducing the intracellular calcium concentration of 
vascular smooth muscle and thereby inducing relaxation of that smooth muscle or 
vasorelaxation.   47
Impaired endothelial function is said to contribute to the impaired vasodilator capacity 
seen in the vessels of patients with heart failure. This has been demonstrated by studies 
which report a reduced endothelium-dependent vasodilatation in response to infused 
acetylcholine and restoration of this response by administration of L-arginine, the 
precursor of endothelium derived NO (Hirooka et al 1994). The mechanisms potentially 
responsible include impaired endothelial cell receptor function, abnormal expression of 
NOS and the impaired release or rapid degradation of the EDRF - NO. The reduced 
blood flow and reduced shear stress as a result of reduced circulating volume in heart 
failure and increased ACE, angiotensin II and ET-1 activity could certainly be 
associated with such changes. The elevated plasma concentrations of cytokines in heart 
failure upregulate inducible NOS and increase basal NO release. Acetylcholine acts 
only on endothelial NOS, not inducible NOS, to increase NO release from the 
endothelium. Thus, although basal release of NO is increased, acetylcholine-stimulated 
vasodilatation is impaired. Perhaps the increase in basal release of NO is a 
compensatory response to impaired endothelial response. Unfortunately while impaired 
vasodilatation results in impaired exercise capacity, high concentrations of basal NO are 
directly cardiotoxic and can impair cardiac function, perhaps by increased apoptosis and 
reduced mitosis (Drexler 1999). 
ET-1 is a potent vasoconstrictor released from the endothelium. It has a short half life 
like NO and is also involved in the maintenance of basal vascular tone (Haynes et al 
1996). There are at least two distinct endothelin receptors; ET A and ET B. ET A 
receptors are found on the vascular smooth muscle cells and mediate vasoconstriction 
(Seo et al 1994). ET B receptors are found on both vascular smooth muscle cells, 
mediating vasoconstriction and endothelial cells. They mediate endothelial cell release 
of NO and prostacyclin to mediate vasodilatation (Tsukahara et al 1994). It is possible 
that the availability of NO plays a key role in the balance between ET A and ET B 
receptor activation and therefore vasomotor tone in response to ET-1 (Verhaar et al 
1998).  
Angiotensin II is another potent vasoconstrictor released by the endothelium as a result 
of the interaction of angiotensin I and ACE. The effect of angiotensin II on the 
endothelium, via AT1 receptors is an increase in the production of superoxide anions 
which accelerate NO degradation and therefore reduces NO bioavailability (Griendling 
et al 1994). In contrast angiotensin II acts at AT2 receptors to promote NO release from   48
endothelial cells (Wiemer et al 1993). In this regard selective AT1 receptor antagonists 
may offer a benefit over ACE inhibition.  
ACE is found in abundance in the vascular endothelium. Obviously it also contributes 
to vascular tone, not only through production of angiotensin II from angiotensin I 
resulting in vasoconstriction but also by an increase in the degradation of bradykinin 
(Pellacani et al 1994). Bradykinin acts on the endothelium, releasing NO and therefore 
causing vasodilatation. ACE inhibitors, by inhibiting bradykinin degradation upregulate 
NO activity. Angiotensin II receptor blockers do not reduce bradykinin breakdown and 
therefore cannot increase NO bioavailability via this mechanism. This is an advantage 
that ACE inhibitors have over angiotensin II receptor antagonists. 
Overall it is suggested that ACE inhibitors and angiotensin II receptor antagonists 
improve endothelial function to a similar degree (Hornig et al 1997). 
While it is suggested that the degree of endothelial dysfunction predicts survival and 
established treatments for heart failure such as ACE inhibitors, angiotensin II receptor 
antagonists, selected beta blockers and spironolactone are clearly associated with 
mortality benefit as well as improved endothelial function (Farquharson & Struthers 
2000, Packer et al 1996, Pitt et al 1999) there is no direct evidence that improvement in 
endothelial function directly improves outcome. In fact there is some evidence to 
suggest that it does not. Endothelial dysfunction develops more rapidly in men than pre 
menopausal women (Taddei et al 1996) and post menopausal women have a rapid 
improvement in endothelial function following oestrogen therapy (Gilligan et al 1994) 
but hormone replacement therapy is not associated with improved outcome (Hulley et al 
1998). Tumour necrosis factor (TNF) reduces the synthesis of NO and is associated 
with worsening endothelial function (Agnoletti et al 1999) but trials with etanercept, an 
anti TNF  treatment, were not associated with improved outcome (Lisman et al 2002). 
It is also unclear whether endothelial dysfunction has a causative role in the 
development of systolic myocardial dysfunction or is simply a marker of it.  
Reduced effective circulating volume and therefore shear stress in heart failure means 
reduced production of NO. High levels of cytokines eg.TNF reduces the half life of 
NOS and therefore the synthesis of NO. Reduced bradykinin levels result in reduced 
NO production. The increase in oxygen free radicals as a result of activation of the   49
RAAS in heart failure accelerates NO degradation. Heart failure associated with 
myocardial ischaemia results in oxidative stress and an increase in oxygen free radicals 
which reduces NO bioavailability by these mechanisms. Overall heart failure reduces 
the availability of NO causing endothelial dysfunction. 
However, coronary artery disease and hypertension, common causes of heart failure are 
in part the result of endothelial dysfunction. Risk factors for coronary artery disease 
have been associated with endothelial dysfunction. Endothelial dysfunction may allow 
access of neurohormones to vascular smooth muscle cells resulting in vasoconstriction 
rather than endothelial cell mediated vasodilatation. Endothelial dysfunction affects 
arterial compliance, increased arterial stiffness causes increased cardiac afterload and 
accelerates ventricular remodelling both resulting in systolic impairment. 
The in vitro studies that form part of this thesis consider the vasoactive response of 
small resistance arteries to neurohormones and the effect of enzyme inhibition on this 
response. I hope to demonstrate the role of these enzymes in the production or 
degradation of each of the hormones. I am in effect measuring endothelial function in 
the presence of various neurohormones and their regulators.   50
1.5  Aims 
During the development of now well established treatments, such as ACE inhibitors, we 
have learnt that inhibition of the activity of one vasoactive hormone often results in 
clinically important inhibition or potentiation of other pathways. Clearly there is value 
in antagonizing neurohumoral systems likely to have detrimental actions, and it is likely 
that the optimum strategy is to achieve this while simultaneously augmenting 
potentially desirable neurohumoral mediators. However enzyme inhibitors which act on 
multiple vasoactive mediators with complex interactions have unpredictable effects. 
The work described in this thesis looks particularly but not exclusively at two recently 
developed molecules which have dual enzyme inhibitor activity. Omapatrilat, a 
molecule which inhibits both ACE and NEP, and SLV 306 (active metabolite 
KC12615) a compound with both NEP and ECE inhibiting properties. My intention is 
to further characterise these molecules and their therapeutic potential while utilising 
their inhibitory properties in further investigation of the human neurohumoral system. 
1.  To consider possible mediators of the unexpected and potentially life threatening 
side effect associated with omapatrilat; angioedema (chapter 3).  
−  Of course bradykinin is a likely mediator, ACE and NEP are both involved in 
the metabolism of bradykinin. Also of interest is the role of NEP in 
metabolizing the vasodilator ADM. Other candidate vasodilators include CGRP 
which is of interest as a cause of facial flushing, substance P, and VIP.  
2.  To consider the possible mechanisms by which omapatrilat affects a more 
impressive hypotensive response in patients with hypertension than expected.  
−  As ACE and probably NEP are both involved in the metabolism of bradykinin, 
this powerful vasodilator and others may play a role (chapter 3).  
−  It has been suggested that the predominant physiological substrates for vascular 
NEP are vasoconstrictor peptides and particularly ET-1, explaining the 
contradictory haemodynamic results obtained after systemic dosing with NEP 
inhibitors. Inhibition of the vasoconstrictor response to angiotensin I or ET-1 by 
omapatrilat, another dual inhibitor of ACE / NEP, GW660511X and SLV 306   51
may demonstrate their advantage over the pure NEP inhibitor (chapters 4, 5 and 
8). 
3.  To demonstrate the NEP and ECE inhibitory properties of SLV 306 in vitro - not 
previously demonstrated in human tissue either in vivo or in vitro (chapter 5). 
4.  To demonstrate the dose – response relationship for the ECE and NEP inhibitor 
activity of SLV 306 in healthy volunteers in vivo (chapter 7). 
−  I evaluate the effect of the main metabolite of SLV 306 (KC12615) on the 
pressor response to big ET-1 and on neurohormones. 
5.  To consider the ACE and NEP inhibitory activity in vivo of the dual ACE/NEP 
inhibitor GW660511X (chapter 8). 
−  a drug in early development which hopes to offer therapeutic benefit over that 
offered by pure ACE or NEP inhibitors but without the side effect profile of its 
forerunner omapatrilat. 
−  ACE inhibitors being of proven benefit in cardiovascular disease remain the 
gold standard against which this new molecule must be compared and an active 
control is included in my experiment. 
6.  To demonstrate the haemodynamic and neurohumoral affects of renin inhibition in 
patients with chronic heart failure specifically a recently developed renin inhibitor 
aliskiren (chapter 9).   
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2 METHODS 
2.1  PATIENTS AND HEALTHY VOLUNTEERS 
The University of Glasgow is located adjacent to the Western Infirmary which is a 
tertiary health care centre. Patients attending cardiology clinic with a history of 
ischaemic heart disease but normal left ventricular systolic function were invited to take 
part in my studies. Their physiological responses were studied ex vivo, using wire 
myography. Patients taking warfarin therapy were excluded in order to avoid excessive 
bleeding during or following subcutaneous fat biopsy. Patients with renal dysfunction 
(creatinine>200mmol/l) were excluded.  
Patients recruited for the in vivo study described in chapter 9 were required to meet the 
following criteria: 
Inclusion criteria 
•  Male 
•  Aged 50-80 years 
•  LVEF < 0.35 
•  Baseline treatment with ACE inhibitors and beta blockers stable for > 1 month 
•  Stable NYHA II-IV 
There were few exclusion criteria, mainly related to recent clinical instability (e.g. 
myocardial infarction), disorders that might impair absorption of therapy (e.g. 
pancreatic disease) or a contra-indication to ramipril (including renal artery stenosis). 
The Clinical investigation and research unit is based at the Western Infirmary. A large 
number of healthy volunteer studies have been conducted at the centre and the staff 
were able to provide a database of volunteers who had previously, but not recently, 
taken part in studies. From this database and by word of mouth I recruited healthy 
volunteers for the in vivo studies described in chapters 6,7, 8 and 10.  
Inclusion criteria 
•  Male 
•  Age 18 – 45 years 
•  Body mass index (BMI) of >20kg/m2 and <26kg/m2  
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•  Caucasion subjects judged to be in good health based on the results of medical 
history, physical examination, laboratory profile and 12 lead ECG 
•  Heart rate between 45 and 100 bpm at rest. 
•  Systolic blood pressure > 100mmHg and < 140mmHg , diastolic blood pressure > 
60mmHg and < 90mmHg. 
•  Written Informed consent given 
 
Exclusion criteria 
•  Abnormal findings in medical history, physical examination, laboratory profile or 
12 lead ECG 
•  Use of any prescribed and/or non-prescribed systemic or topically applied 
medication within 14 days or within 5 times the half-life of the respective drug, with 
the exception of paracetamol taken more than 48 hours prior to the start of the 
study.  
•  History of serious drug or allergic reaction 
•  Smoker 
•  Positive drug screen or suspicion of drug misuse (including alcohol) 
•  Participation in other clinical trials within the last three months  
•  Medical and nursing students 
 
All patients and healthy volunteers provided written informed consent and all studies 
were approved by the West Ethics Committee of the Western Infirmary, on behalf of 
North Glasgow Hospitals University NHS Trust. 
2.2  LEFT VENTRICULAR SYSTOLIC FUNCTION 
Transthoracic echocardiography was performed on all patients and healthy volunteers. 
Estimate of ejection fraction was made using Simpson’s biplane method (Schiller et al 
1979).  
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Small resistance arteries play a significant role in the regulation of vascular resistance 
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In vitro studies 
SMALL RESISTANCE ARTERIES  
Resistance arteries play a significant role in the regulation of vascular resistance and 
therefore blood flow and cardiac work load (Mulvany and Aalkjaer 1990) (figure 2.1). 
Small subcutaneous resistance arteries (SRA) of patients with normal left ventricular 
function were obtained by subcutaneous fat biopsy. Elliptical Subcutaneous gluteal 
biopsies were taken under aseptic conditions and local anaesthetic (1% lidocaine). The 
wound, approximately five centimetres in length was closed with absorbable suture to 
the deep layers and vicryl to the skin. The superficial suture was removed after seven 
days as long as the wound was found to be healing well on inspection. This method of 
obtaining SRA has been shown previously to provide arteries that are fully viable, 
demonstrated by a concentration dependent response to noradrenaline and angiotensin II 
with maximal force (Aalkjaer et al 1986) 
Dissected tissue was then placed into cold 0.9% NaCl and transported immediately to 
the laboratory. There it was transferred to cold physiological salt solution 
[PSS](composition in mM:  NaCl 118.4, KCl 4.7, MgSO4.H2O 1.2, KH2PO4 1.2, Na 
HCO3 24.9, CaCl2 2.5, glucose 11.1, EDTA 0.023 which gives a pH of 7.4 when gassed 
with a 5% CO2/95% O2 mixture).  Where possible, four SRA approximately 2mm in 
length, were isolated from each skin biopsy by careful dissection using surgical grade 
instruments and with the aid of a high power microscope. The dissection was performed 
in a Petri dish filled with the PSS buffer being changed regularly. The SRA were 
identified by their helical shape and opaque wall, in contrast to veins which are rather 
more elongated, flaccid and transparent. The dissection process could take anything up 
to two to three hours to complete. The dissected arteries were then stored in PSS at 4°C 
overnight. Storage of resistance arteries from rats in this way has been demonstrated to 
have no effect on their vasoactive properties (McIntyre et al 1998). It is now an 
established practice adopted by many groups reporting wire myography studies in both 
animal and human arteries. 
2.4 WIRE  MYOGRAPHY 
SRA wire myography is an in vitro technique which allows resistance arteries with a 
diameter of 100-500µm to be studied under precise and standardised conditions. Use of  
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this technique allows the study of a vessel’s contractile or relaxant properties under 
isometric tension (Mulvaney and Aalkjaer 1990, Mulvaney and Halpern 1977). 
Approximately 24 hours after the initial biopsy, each vessel was mounted on to two 
40µm diameter stainless steel wires, where one wire was attached to a force transducer 
and the other to a micrometer (figure 2.2).  The temperature was raised to 37
0C and a 
gas mixture (5% CO2/95% O2) was bubbled in for the duration of the experiment.   
All my studies were undertaken in paired vessels from the same patient in every case. If 
clear results were not obtained from any single vessel, a record of no data was made. 
The vessel was not replaced. 
After a rest period of one hour each artery was stretched at 1 minute intervals to 
determine the passive exponential wall tension-internal circumference (L) relationship.  
From the Laplace equation, P=T/r (where P is the effective pressure, T is the wall 
tension and r is the internal radius), the equivalent circumference (L100) for a transmural 
pressure of 100mmHg, was calculated for each vessel by an iterative computer method.  
Each vessel was then set to the normalised internal diameter, L1=0.9 x L100µ, at which 
contraction is thought to be optimal (Mulvaney and Aalkjaer 1990, Mulvaney and 
Halpern 1977, Petrie et al 2001). 
After this normalisation procedure the arteries were exposed twice to high concentration 
potassium (KPSS is identical to PSS but with KCl substituted for NaCl on an equimolar 
basis) and once to 10µmol/L of norepinephrine (NE). After a plateau contraction had 
been attained with NE, 3µmol/L of ACh was added to the bath in order to stimulate 
endothelium dependent vasodilation. Arteries that were not seen to contract in response 
to either KPSS or NE or showed no relaxation to ACh were deemed to have no 
functionally intact endothelium and were therefore discarded.   
The arteries were then incubated for a further 30 minutes in PSS before being set up for 
study protocol.  
In each of the studies PSS was then replaced by a solution of the enzyme inhibitor (table 
2.1) to be studied or vehicle. Cumulative concentration response curves (CCRC) were  
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Mulvany MJ, & Halpern W. (1976) Mechanical properties of 
vascular smooth muscle cells in-situ. Nature; 260: 617-619.
40 υm tungsten wire
One jaw is fixed,
the other is attached to
a force transducer
Vessel secured between two jaws
Figure 2.2 
Wire myography. Each vessel is mounted on to two 40µm diameter stainless steel wires, where one 
wire is attached to a force transducer and the other to a micrometer (Mulvaney and Halpern 1976) 
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Name Inhibitory  properties 
Omapatrilat  ACE / NEP 
KC12615  ECE / NEP 
Captopril ACE 
Phosphoramidon  ECE / NEP 
Thiorphan NEP 
 
Table 2.1  Vasoactive enzyme inhibitors 
then obtained to various vasoactive hormones. For vasodilator curves, the concentration 
of agonist was increased as the relaxation response rate at each respective dose levelled 
off. If spontaneous relaxation back to baseline was seen, a common problem, the 
experiment was abandoned; the vessel washed with PSS and allowed to rest for 30 
minutes, before a further attempt was made. For vasoconstrictor curves the 
concentration of hormone was increased after a minimum of five minutes, after 
contraction was seen and had peaked at each respective dose. At higher concentrations 
desensitisation or tachyphylaxis could be seen as the agonist became continually present 
at a receptor. After exposure to each hormone the vessels were washed with PSS again 
to re-establish baseline and inhibitors were again added to maintain the same 
relationship between inhibitor and vessel. After a further 30 minutes CCRC with other 
vasoactive hormones were obtained.Vessel relaxation in response to a hormone was 
reported as a percentage of the NE induced preconstricted diameter of the artery. 
Vasoconstriction was expressed as a percentage of that elicited by the second exposure 
to KPSS.  
In vivo studies  
2.6 INFUSIONS 
2.6.1 Big  endothelin-1   59
In order to assess the ECE inhibitory action of SLV 306 (chapter 7) I study the pressor 
response in healthy volunteers to big ET-1. The approach used is analogous to that used 
to study dose response relationships for ACE inhibitors (Biollaz et al 1981, Burnier et al 
1981, Wellstein et al 1987). Both big ET-1 and ET-1 are endogenously synthesised 
peptides. Both have been infused systemically in healthy volunteers and in patients with 
cardiovascular disease previously, without any report of adverse event. The maximum 
increase in mean arterial pressure has been 33mmHg with the concentrations of big ET-
1 used previously. The pressor response is known to develop slowly. From previous 
studies I had expected a peak increase in blood pressure after about 90 minutes from the 
start of the infusion, lasting for at least 90 minutes from completion of the infusion 
(Ahlborg et al 1994, Ahlborg et al 1996, Pernow et al 1996). In these previous studies a 
rising dose regime of 0.2, 1 and 8 pmol/kg/min, for 20 minutes each had been 
associated with a maximum increase in mean arterial pressure of 33mmHg. In my 
preliminary studies however this regime did not lead to a measurable increase in BP 
(BP monitored for 2 hours post infusion). The doses of big ET-1 used were therefore 
chosen from my pilot study (chapter 6), as ones likely to lead to a rise in mean arterial 
pressure of approximately 20 mmHg.   The timing of the infusions was chosen to 
coincide with peak plasma concentrations of KC12615 as demonstrated in the 
pharmacokinetic first stage of my study (chapter 7). Subjects were given a systemic, 
intravenous infusion of big ET-1 160 minutes after dosing with placebo or SLV306. 
The infusion was commenced at a rate of 8.0pmol/kg/min. After 40 minutes (220-240 
minutes post dosing) the infusion rate increased to 12pmol/kg/min and this rate of 
infusion continued for 20 minutes before being stopped. The big ET-1 was purchased 
from Clinalpha AG Laufelfingen, Switzerland. 
2.6.2  Angiotensin I 
In order to assess the ACE inhibitory action of GW660511X (chapter 8) I study the 
pressor response in healthy volunteers to angiotensin I. The approach has been used 
previously to study dose response relationships for ACE inhibitors (Biollaz et al 1981, 
Burnier et al 1981, Wellstein et al 1987). Both angiotensin I and angiotensin II are 
endogenously synthesised peptides. Both have been infused systemically in healthy 
volunteers and in patients with cardiovascular disease previously, without any report of 
adverse event. Ascending dose infusion of angiotensin I (0.1, 0.3, 0.9, 2.0, 3.9, 6.0, 9.0,   60
12.0, 15.0 and 18.0 µg/min, each dose given for 3 minutes) was used, given 2, 4 and 23 
hours after study medication was administered. The maximum increase in diastolic 
arterial pressure has been 25mmHg with the concentrations of angiotensin I when used 
previously. From these previous studies I expected a peak increase in blood pressure 
after about 3 minutes from the start of each dose of the infusion, lasting for approx. 1-3 
minutes from completion of the infusion (Essig et al 1989, Erb et al 1991, Wellstein et 
al 1987) The doses were chosen as those shown to cause a haemodynamic response 
sufficient to show an influence on it by pharmacological intervention in these previous 
studies.
 
During screening the healthy volunteers received an angiotensin I infusion and only 
those with a rise in systolic blood pressure of at least 10mmHg were eligible. 
The angiotensin I was purchased from Clinalpha AG, Laufelfingen, Switzerland. 
2.7  BLOOD PRESSURE READINGS 
Heart rate and arterial pressure were measured using an automated blood pressure 
recorder (Dinamap model 8262, 1846 SX Critikon inc., Tampa, Florida, USA). 
Measurements were taken from the contralateral arm to any infusion. Blood pressure 
measurements were made in duplicate on each occasion. 
2.8  NEUROHORMONE ASSAYS 
All blood samples taken during my studies were immediately placed on ice. They were 
then spun, as soon as possible in a refrigerated centrifuge (4°C). Plasma were spun at 
1500g and then stored at -70°C in polypropylene tubes until assay.   
In the SLV 306 studies, plasma big ET-1 and ET-1 levels were measured to assess the 
effect of SLV 306 and its metabolite on the conversion of big ET-1 to ET-1. Plasma 
ANP concentrations serve as a measure of the degree and time course of NEP 
inhibition.  
Dr. A. Davenport, University of Cambridge kindly performed the ET-1 and big ET-1 
assay by methods previously described (Plumpton et al 1995) and Dr. J.J. Morton, 
University of Glasgow kindly performed the ANP assays, again using methods 
previously described (McDonagh et al 1998).   61
In the GW660511X studies, blood samples were collected for measurement of plasma 
ACE activity, plasma ANP and plasma cyclic guanosine monophosphate (cGMP). 
Assays were performed by Dr. J.J. Morton, Glasgow University and Glaxo Smith Kline 
using methods previously described (McDonagh et al 1998, MacFadyen et al 1999, 
Nussberger et al 2002). 
In the Aliskiren studies, plasma BNP, angiotensin II and aldosterone concentrations 
were kindly measured by Dr. J.J. Morton, Glasgow University, using established assays, 
as previously reported (Murdoch et al 1997, Harrap et al 1996, MacFadyen et al 1995).   
Plasma renin activity was also measured using a recognised assay (Nussberger et al 
2002) by Dr. J. Nussberger, Lausanne, Switzerland. 
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3  Effects of Omapatrilat on the action of vasodilators in 
small human resistance arteries  
Background 
Omapatrilat, the lead orally active dual NEP and ACE inhibitor, has a particularly marked 
hypotensive action. Studies have demonstrated greater effect on blood pressure in humans 
in vivo than were expected following animal studies (Campese et al 2001, Asmar et al 
2000, Ferrario et al 2002, Mitchell et al 2002) or were predicted following studies with pure 
NEP inhibitors  (Richards et al 1993, Favrat et al 1995).  I studied the interaction of 
omapatrilat with vasoactive peptides. I included peptides not expected to be affected by its 
recognized pharmacological actions. 
In addition to inhibition of angiotensin II production and inhibition of natriuretic peptide 
degradation, omapatrilat may inhibit the breakdown of other vasoactive peptides in human 
vessels (the pharmacology of which differs from other species).   The studies described in 
this chapter focus specifically on the effects of omapatrilat on vasodilators while the 
subsequent chapter focuses on the effects of this inhibitor on vasoconstrictors.     
Augmentation of vasodilators particularly has been implicated in the increased incidence of 
angioedema seen in in vivo studies of omapatrilat.  
Of particular interest is the role of NEP in metabolizing the newly discovered vasodilator 
ADM.   Other candidate vasodilators include CGRP which is of particular interest as a 
cause of facial flushing (reported with omapatrilat) substance P, and VIP.   As ACE and 
probably NEP are both involved in the metabolism of bradykinin, this powerful vasodilator 
may also play a role in the hypotensive action of omapatrilat.   The vasodilator action of all 
of these peptides may be facilitated by the dual ACE/NEP inhibiting action of omapatrilat, 
compared to NEP inhibition monotherapy. 
The aim of these studies is to fully characterize the vascular actions of omapatrilat in 
human vessels, ex vivo. These actions will be compared to those of an ACE inhibitor and 
those of a NEP inhibitor.   This will reveal any "unrecognised" action of omapatrilat and/or 
synergy between NEP and ACE inhibition.   63
Methods 
Resistance arteries contribute the greatest resistance of all vessels to blood flow and 
therefore have a significant role in regulating capillary pressure (Mulvany and Aalkjaer 
1990). I studied the effects of two concentrations of omapatrilat, reflecting the therapeutic 
range, on the vasopressor response of these vessels to various vasoactive peptides. For 
comparison, equipotent concentrations of an ACE inhibitor, captopril and a NEP inhibitor, 
thiorphan, were also studied.  
SRAs were obtained from gluteal biopsies taken from patients with coronary artery disease 
but normal left ventricular systolic function not receiving ACE inhibitor therapy.   Up to 
four vessels were dissected from each biopsy. These vessels were studied, ex vivo, in a wire 
myograph, according to the methods described in chapter 2. As part of the standard 
normalization and start up process the vessels were set to the internal diameter at which 
contraction is thought to be optimal, they were then exposed to a strong potassium solution 
(100mmol/l) repeatedly until maximal contraction was achieved. The endothelial viability 
of the arteries was assessed by preconstriction with NE (10
-6 mol/l) followed by relaxation 
with acetyl choline (10
-6 mol/l). 
The arteries were then incubated for 30 minutes in PSS prior to the construction of 
cumulative concentration response curves (CCRC) with various vasoactive peptides as 
detailed below. The studies were undertaken with paired vessels from the same patient in 
every case. Any vessels from which clear results were not obtained were recorded as lost 
data and not replaced other than with results from another complete set of paired vessels 
from a further patient. 
Myography protocols 
1.  Vessels were incubated for 30 minutes with vehicle (100% dimethyl sulfoxide 
[DMSO], vessel 1), captopril (10
-5 mol/l, vessel 2), thiorphan (10
-5 mol/l, vessel 3) 
or with omapatrilat (10
-5 mol/l, vessel 4). The vessels were pre constricted with NE 
and CCRC were then obtained to CNP (dilatation). Responses to CNP are 
expressed as percent change to preconstriction with 10
-5M NE. This protocol was   64
performed in order to compare the effect of omapatrilat and the other inhibitors on 
NEP activity. 
2.  Vessels were incubated for 30 minutes with vehicle (100% dimethyl sulfoxide 
[DMSO], vessel 1), captopril (10
-5 mol/l, vessel 2), thiorphan (10
-5 mol/l, vessel 3) 
or with omapatrilat (10
-5 mol/l, vessel 4). The vessels were pre-constricted with NE 
and CCRC (dilatation) were then obtained to bradykinin (10
-14 – 3 x 10
-6M), ADM 
(10
-11 - 3x10
-7M), CGRP (10
-12 - 3x10
-7M), VIP and substance P. Responses to 
vasodilator are expressed as percent change to preconstriction with NE. This 
protocol was performed in order to compare the effect of omapatrilat and the other 
inhibitors on important vasodilator activity 
 
Statistical analysis 
Values are presented as mean + SEM. Statistical comparisons of pD2 (-log concentration 
required to produce 50% of the maximum response) and maximum response were 
performed with one-way analysis of variance (ANOVA) followed by Dunnet’s post hoc 
test for multiple comparisons. The pEC
50 was not determined where no maximum response 
was achieved at the concentrations used. Comparison of CCRC was by one-way ANOVA 
for repeated measures. Statistical significance was assumed at a value of p<0.05. 
Results 
Patient characteristics 
Biopsies were taken from 40 patients. The mean age of patients was 64 + 10 years and 27 
were male. All had a diagnosis of ischaemic heart disease but preserved LV function with 
mean ejection fraction of 51 + 8%. 10 patients had coexistent hypertension. No patients 
were taking ACE inhibitors, other medication is detailed in Table 3.1 
C-type natriuretic peptide CCRC: effect of captopril, thiorphan and omapatrilat. 
Compared to bradykinin, CNP was a weak vasodilator (maximal relaxation with vehicle 52 
± 13% (n=8). The action of CNP was not augmented by any of the three enzyme inhibitors   65
TABLE 3.1  Patient characteristics 
 
Patient characteristics 
 
 
Number of patients  40 
Gender, M/F  27/13 
Age, years  63.9 (10.4) 
Previous MI, n  7 
Previous CABG, n  6 
Previous PTCA, n  6 
Current smoker, n  9 
Co existent hypertension, n  10 
Mean ejection fraction, %  50.9(7.9) 
Drug therapy, n   
    ACE inhibitor  0 
    Diuretic  8 
    Digoxin  0 
    Calcium channel blocker  21 
    Oral nitrate  15 
    Beta-blocker  24 
    HMG-CoA reductase  23 
    Aspirin/clopidogrel  33 
Glucose 5.6  (1.1) 
Cholesterol 5.3  (1.1) 
Creatinine 99.5  (16.0) 
MI, myocardial infarction. CABG, coronary artery bypass grafting. PTCA, 
percutaneous transdermal coronary angioplasty. HMG CoA, 3-hydroxy-3-
methylglutaryl coenzyme A. 
Values are given as number or mean (SD).   66
(maximal responses: 39 ± 5% captopril (n=6), 37 ± 19% thiorphan (n=5) 28 ± 16% 
omapatrilat (n=5).   
Bradykinin CCRC (figure 3.1):  effect of captopril, thiorphan and omapatrilat. 
Bradykinin was a powerful vasodilator of preconstricted small arteries and its vasorelaxant 
effect was significantly augmented by thiorphan, captopril and omapatrilat (figure 3.1, 
p<0.01 for comparison of curves) with a leftward shift of the concentration response 
curves. Captopril and omapatrilat produced almost a hundredfold shift (pD2: 8.95 ± 0.09 
vehicle,10.62 ± 0.09 captopril, 10.58 ± 0.07 omapatrilat) Where as thiorphan produced only 
a ten-fold shift (pD2: 9.76 ± 0.14). The maximum responses with all 3 agents were, 
however, similar (94 ± 1% vehicle, 93 ± 3% captopril, 95 ± 1% thiorphan, 93 ± 2% 
omapatrilat).  
Adrenomedullin CCRC (see figure 3.2): effect of captopril, thiorphan and 
omapatrilat.   ADM was a more powerful vasodilator than CNP, but not as potent as BK. 
Neither captopril nor thiorphan augmented the vasodilator action of ADM, however, 
omapatrilat significantly potentiated the vasodilator response to ADM (figure 3.2, p<0.05, 
comparison of curves). Omapatrilat resulted in a shift of the concentration response curve 
to the left, at lower concentrations of ADM. The maximal response however did not differ 
between groups (75 ± 8% vehicle, 82 ± 3% captopril, 68 ± 9% thiorphan, 73 ± 15% 
omapatrilat). 
Calcitonin gene related peptide CCRC: effect of captopril, thiorphan and omapatrilat.   
None of the enzyme inhibitors affected the relaxation response to CGRP which was a 
potent vasodilator ((maximal responses: 96 ± 1% vehicle (n=13), 98 ± 1% captopril (n=4), 
88 ± 6% thiorphan (n=9), 96 ± 2% omapatrilat (n=7); pD2: 9.6 ± 0.1 vehicle, 9.8 ± 0.1 
captopril, 9.3 ± 0.1 thiorphan, 9.8 ± 0.1 omapatrilat). 
Vasoactive intestinal polypeptide CCRC: effect of captopril, thiorphan and 
omapatrilat. None of the enzyme inhibitors affected the relaxation response to VIP which 
was a moderately powerful vasodilator (maximal responses:  65 ± 9% vehicle (n=14), 78 ± 
6% captopril (n=11), 77 ± 7% thiorphan (n=8), 70 ± 8% omapatrilat (n=12); pD2: 8.2 ± 0.3   67
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Figure 3.1  
Cumulative concentration response 
(vasodilatation) curves for bradykinin 
(BK). Vasodilatation is expressed as 
percentage relaxation compared to 
the norepinephrine preconstricted 
baseline. There was a powerful 
vasodilator effect in response to 
bradykinin which was significantly 
augmented by thiorphan, captopril 
and omapatrilat, with all three 
inhibitors producing a leftward shift of 
the concentration response curve 
(p<0.01).  
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Figure 3.2 
Cumulative concentration response 
(vasodilatation) curves for 
adrenomedullin. Vasodilatation is 
expressed as percentage relaxation 
compared to the norepinephrine 
preconstricted baseline. Neither 
thiorphan nor captopril augmented 
the vasodilator response to 
adrenomedullin. Omapatrilat, 
however, produced a significant 
augmentation, evident at lower 
concentrations only (p<0.05 by 
ANOVA).   69
vehicle, 8.3 ± 0.4 thiorphan, 8.8 ± 0.1 omapatrilat; a pD2 could not be calculated for 
captopril).  
 Substance P CCRC:  effect of captopril, thiorphan, omapatrilat and the 
combination of both thiorphan and captopril.    Substance P was the most potent of 
the vasodilators studies.   Its action was not potentiated or inhibited by any of the 
enzyme inhibitors (maximal responses: 90 ± 2% vehicle (n=6), 90 ± 2% captopril (n=7), 
90 ± 2% thiorphan (n=5), 85 ± 5% omapatrilat (n=7); pD2: 12.8 ± 0.2 vehicle, 12.8 ± 
0.2 captopril, 12.6 ± 1.1 thiorphan, 13.0 ± 1.0 omapatrilat). 
Discussion  
Omapatrilat augmented the action of two important vasodilators in small resistance 
arteries from patients with coronary artery disease. Firstly, it markedly potentiated the 
vasorelaxation caused by bradykinin. NEP has been shown, experimentally, to 
metabolize bradykinin (Graf et al 1993, Blais et al 2000) and I have been able to 
confirm this in human arteries ex-vivo. However, thiorphan appeared to be less potent in 
this respect than captopril. Indeed, the range of captopril concentrations used in my 
study seemed to already maximally potentiate the effect of bradykinin (Graf et al 1993, 
Blais et al 2000) Consequently, omapatrilat did not enhance the vasodilator action of 
bradykinin more than captopril.   This is not to say that the NEP inhibiting action of 
omapatrilat might not further inhibit bradykinin breakdown at lower ACE inhibitor 
concentrations or in other tissues, where greater amounts of NEP relative to ACE, may 
be found e.g. the myocardium (Kokkonen et al 1999,Corti et al 2001).
 This potential 
synergistic effect of ACE and NEP inhibition on bradykinin breakdown has been 
identified as a possible cause for concern, clinically, in relation to the risk of angio-
oedema (Messerli and Nussberger 2000). 
Another interesting and novel finding in the present study was the augmentation of 
ADM mediated vasorelaxation by omapatrilat.  This has not been described previously 
though omapatrilat has recently been shown to increase plasma ADM concentrations in 
dogs with experimental heart failure (Cataliotti et al 2002). NEP inhibition is not the 
only explanation for my observations although perhaps the most obvious. Thiorphan did 
not have the same effect on the response to ADM as omapatrilat - either in the present   70
study or in a previous study (Messerli and Nussberger 2000).
   Others have, however, 
reported that an alternative NEP inhibitor, candoxatrilat, potentiates the renal actions of 
ADM in dogs (Lisy et al 1998).  This apparent difference may have arisen because the 
kidney is particularly rich in NEP or because thiorphan is a weaker NEP inhibitor than 
omapatrilat. I favour the latter explanation because another potent NEP inhibitor, SCH 
32615, increases plasma concentrations of ADM in sheep (Rademaker et al 2002). 
Regardless of its mechanism, this additional action may certainly go some way towards 
explaining the unusual antihypertensive efficacy of omapatrilat. As has been reported, 
and confirmed in this study, ADM is one of the most effective endogenous vasodilators 
recognized, being substantially more potent than CNP and VIP (Lainchbury et al 1997, 
Jougasaki and Burnett 2000, Troughton and Lewis et al 2000). Consequently, the 
augmenting action of omapatrilat on the arterial action of this peptide could lead to an 
additional hypotensive effect, incremental to that expected from inhibition of 
angiotensin II production and natriuretic peptide breakdown. 
As well as having a hypotensive effect, ADM may also protect the cardiovascular 
system against a number of noxious stimuli (Shimosawa et al 2002). It may also be 
important in other cardiovascular disease states. For example, ADM production is 
increased in CHF and ADM may have beneficial actions in this condition (Cataliotti et 
al 2002, Nagaya et al 2000, Jougasaki et al 1996). It has also been suggested that the 
pleiotropic actions of ADM are important in atherosclerosis (Nakayama et al 1999). 
Consequently, the augmenting effect of omapatrilat on the action of ADM could be 
therapeutically relevant in a number of cardiovascular conditions.  
Interestingly, however, the activity of CGRP, which has some structural homology with 
ADM, was not enhanced by omapatrilat. 
Similarly, omapatrilat did not augment the vasorelaxant action of CNP. At first sight, 
this might seem a curious finding given the role of NEP in natriuretic peptide 
catabolism.  Others, however, have also reported that acute NEP inhibition does not 
potentiate the cardiovascular actions of exogenous CNP (Brandt et al 1997). Brandt et 
all found that, when co-infused with CNP in dogs, candoxatrilat increased circulating 
CNP concentrations.  However, the haemodynamic (and renal) actions of exogenous 
CNP were not enhanced by candoxatrilat (Brandt et al 1997). Of course, my findings do   71
not preclude effects of NEP inhibition mediated by decreased clearance of ANP and 
BNP. Finally omapatrilat had no effect on the action of VIP or substance P in small 
resistance arteries. 
In summary, omapatrilat augmented the action of bradykinin and, unexpectedly, the 
action of ADM in small human resistance arteries. This range of actions may explain 
the powerful hypotensive effect of omapatrilat in vivo, it may go some way to 
explaining the potentially life threatening side effect of angioedema associated with 
omapatrilat and it suggests additional therapeutic applications, for example in heart 
failure and atherosclerosis.    72
4  Effects of omapatrilat on the action of vasoconstrictors 
in small human resistance arteries 
Background 
The hypotensive effects of omapatrilat, a combined ACE and NEP inhibitor, cannot be 
explained by inhibition of angiotensin II production or inhibition of natriuretic peptide 
degradation alone.  I have considered the effects of dual inhibition on the actions of 
vasodilators. The following group of studies aims to characterise the vascular actions of 
omapatrilat in human vessels, ex vivo, but concentrating on its effect on the potent 
vasoconstrictors angiotensin II and ET-1. These actions are compared with those of an 
ACE inhibitor and those of a NEP inhibitor in order to screen for any "unrecognised" 
action of omapatrilat and/or synergy between NEP and ACE inhibition. 
A synergistic interaction between ACE and NEP inhibition is of interest because of the 
possible role of NEP in metabolising angiotensin II.   Reduced breakdown of 
angiotensin II could offset the hypotensive action of augmenting plasma natriuretic 
peptide concentrations and, at least in part, account for the disappointing anti-
hypertensive action of NEP inhibitors.   Concomitant ACE inhibition should, of course, 
reduce the contribution of angiotensin II and allow full expression of the blood pressure 
lowering actions of natriuretic peptides. 
Omapatrilat may inhibit another important metalloprotease in human vessels, namely 
ECE.  Inhibition of the production of the potent vasoconstrictor ET-1 would be 
expected to further enhance the blood pressure lowering effect of a dual ACE/NEP 
inhibitor. 
Methods 
I studied the effects of two concentrations of omapatrilat, reflecting the therapeutic 
range, on the vasopressor response of SRA to various vasoactive peptides. For 
comparison, equipotent concentrations of an ACE inhibitor, captopril and a NEP 
inhibitor, thiorphan, were also studied. In some studies the dual NEP-ECE inhibitor 
phosphoramidon was also used.  Phosphoramidon is a well characterized inhibitor of 
NEP and ECE (Petrie, Hillier et al 2001, Jeng et al 1989, Ikegawa et al 1990).    73
SRA were obtained from gluteal biopsies taken from patients with coronary artery 
disease but normal left ventricular systolic function not receiving ACE inhibitor 
therapy.   Up to four vessels were dissected from each biopsy. These vessels were 
studied, ex vivo, in a wire myograph, according to the methods described in chapter 2.  
As part of the standard normalization and start up process the vessels were set to the 
internal diameter at which contraction is thought to be optimal, they were then exposed 
to a strong potassium solution (100mmol/l) repeatedly until maximal contraction was 
achieved. The endothelial viability of the arteries was assessed by preconstriction with 
NE (10
-6 mol/l) followed by relaxation with acetyl choline (10
-6 mol/l). 
The arteries were then incubated for 30 minutes in PSS prior to the construction of 
CCRC with various vasoactive peptides as detailed below. The studies were undertaken 
with paired vessels from the same patient in every case. Any vessels from which clear 
results were not obtained were recorded as lost data and not replaced other than with 
results from another complete set of paired vessels from a further patient. 
 
Myography protocols 
1.  Vessels were incubated for 30 minutes with vehicle (dimethyl sulfoxide 
[DMSO], vessel 1), captopril (both 10
-5 mol/l, vessel 2), thiorphan (10
-5 mol/l, 
vessel 3) or omapatrilat (10
-5 mol/l, vessel 4). CCRC were then obtained to 
angiotensin I (10
-11 - 3x10
-6 mol/l, constriction). This protocol was performed in 
order to compare the effect of omapatrilat and the other inhibitors on ACE 
activity. 
2.  Vessels were incubated for 30 minutes with vehicle (100% dimethyl sulfoxide 
[DMSO], vessel 1), phosphoramidon (10
-5mol/l, vessel 2), captopril (10
-5mol/l, 
vessel 3) or omapatrilat (10
-5 mol/l, vessel 4). CCRC were then obtained to big 
ET-1(10
-11 - 10
-6 mol/l, constriction). This protocol was performed in order to 
compare the effect of omapatrilat and the other inhibitors on ECE activity. 
Statistical analysis 
Values are presented as mean + SEM. Statistical comparisons of pD2 (-log 
concentration required to produce 50% of the maximum response) and maximum   74
response were performed with one-way ANOVA followed by Dunnet’s post hoc test for 
multiple comparisons. The pEC
50 was not determined where no maximum response was 
achieved at the concentrations used. Comparison of CCRC was by one-way ANOVA 
for repeated measures. Statistical significance was assumed at a value of p<0.05. 
Results 
Patient characteristics 
Further small resistance arteries were dissected from the same biopsies as those taken 
for the studies described in chapter 3. Patient characteristics are therefore as described 
in chapter 3 (Table 3.1).  
Angiotensin I CCRC (see figure 4.1): Characteristic bell shaped concentration 
response curves were obtained with angiotensin I.  As expected, the vasoconstrictor 
response was blocked by captopril (comparison of curves: p<0.05).  Omapatrilat had a 
similar inhibitory action (comparison of curves: p<0.05) whereas thiorphan did not 
block the vasoconstrictor effect of angiotensin I.  Indeed, there was a trend for enhanced 
vasoconstriction with thiorphan.  The maximum responses were 27 ± 8% vehicle, 6 ± 
2% captopril, 39 ± 10% thiorphan, 8 ± 7% omapatrilat;  The pD2 concentrations were: 
8.0 ± 0.3 vehicle, 8.4 ± 0.2 captopril, 8.0 ± 0.2 thiorphan, 7.5 ± 0.3 omapatrilat. 
Big endothelin-1 CCRC (see figure 4.2): As previously described, big ET-1 had a 
much more powerful vasoconstrictor action than angiotensin I and, as expected, this 
was significantly attenuated by phosphoramidon which shifted the concentration 
response curve to the right.(comparison of curves: p<0.05). Neither captopril nor 
omapatrilat had any effect on big ET-1 induced vasoconstriction. The maximal 
responses with vehicle, phosphoramidon, captopril and omapatrilat were 108 ± 14, 101 
± 18, 80 ± 13 and 95 ± 9%, respectively.  
Discussion 
Omapatrilat, as expected, attenuated the vasoconstrictor response to angiotensin I in 
small human resistance arteries. Interestingly, thiorphan, which only inhibits NEP, 
tended to enhance the vasoconstrictor response to angiotensin I (figure 4.1). This is in 
keeping with previous evidence that NEP may be involved in the degradation of    75
angiotensin II (Richards et al 1992) and underscores the synergistic basis of dual NEP-
ACE inhibition. Omapatrilat did not affect the response to big ET-1 i.e. it did not inhibit 
ECE.    76
 (a) 
-12 -11 -10 -9 -8 -7 -6 -5
0
10
20
30
40
50
Vehicle (n=13)
Captopril (n=8)
logM[AI]
%
K
C
l *
 
(b) 
-12 -11 -10 -9 -8 -7 -6 -5
0
10
20
30
40
50
Vehicle (n=13)
Omapatrilat (n=8) *
logM[AI]
%
K
C
l
 
(c) 
-12 -11 -10 -9 -8 -7 -6 -5
0
10
20
30
40
50
Vehicle (n=13)
Thiorphan (n=16)
logM[AI]
%
K
C
l
Figure 4.1 
Cumulative concentration response 
(vasoconstriction) curves for 
angiotensin I. Vasoconstriction is 
expressed as a percentage of that 
obtained with potassium chloride KCl. 
There was a typical bell shaped 
vasoconstriction response. Captopril 
and omapatrilat, but not thiorphan, 
blocked the response to angiotensin I 
(both p<0.05 by ANOVA).   77
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Figure 4.2 
Cumulative concentration response 
(vasoconstriction) curves for big 
endothelin-1. There was a powerful 
vasoconstrictor response with no true 
maximum attained within the range 
studied. Phosphoramidon blocked 
big endothelin-1 dependent 
vasoconstriction (p<0.05) whereas 
captopril and omapatrilat had no 
effect.   78
5  Characterisation of the human vascular actions of a novel 
dual inhibitor of neutral endopeptidase and endothelin 
converting enzyme  in human small resistance arteries 
 
Background 
A pathophysiological role for both the natriuretic peptides and ET-1 has been postulated in 
hypertension, heart failure and atherosclerosis (Burnett 1989, Lerman et al 1991, Love and 
McMurray 1997, Schirger et al 2000). Broadly, the natriuretic peptides are considered to 
exert beneficial effects in these cardiovascular diseases whereas ET-1 is thought to have 
adverse actions.   Consequently, augmentation of the effects of natriuretic peptides and 
inhibition of the actions of ET-1 are each considered desirable therapeutic strategies (Krum 
et al 1998, Northridge et al 1999, Best and Lerman 2000). Early clinical experience with 
NEP inhibitors, developed to block the breakdown of natriuretic peptides was, however, 
disappointing (Bevan et al 1992, Francis 1999). NEP inhibitors were ineffective anti-
hypertensive agents (Bevan et al 1992). This was probably because NEP also catabolises 
angiotensin II and possibly ET-1, emphasizing the important interactions between these 
cardiovascular peptides (Richards et al 1992, Richards et al 1993, Russell et al 1996).  A 
novel pharmacologic approach, taking advantage of this interaction and offering therapeutic 
synergy, is dual inhibition of NEP and ECE. I describe a series of experiments undertaken 
to characterise the actions of a new NEP-ECE inhibitor, KC 12615, in human blood vessels 
(Meil, Wurl et al 1998, Hillier, Berry et al 2001).
 While KC 12615 does appear to have 
NEP and ECE inhibitory actions in vitro, in tissues from experimental animals, they have 
not previously been demonstrated in human tissue in vitro or in vivo. 
Methods 
SRA were obtained from gluteal biopsies taken from patients with coronary artery disease 
but normal left ventricular systolic function. Regular medication, particularly the use or not 
of ACE inhibitors was noted.  
These vessels were studied, ex vivo, in a wire myograph, according to the methods 
described in chapter 2. After a standard normalisation and start-up protocol, involving   79
repeated washes with high potassium solution (60mM), the endothelial viability of the 
arteries was assessed by preconstriction with NE (10
-6M) followed by relaxation with 
acetyl choline (10
-6M). 
The arteries were then incubated for 30 minutes in PSS prior to the construction of CCRC 
with various vasoactive peptides as detailed below. The studies were undertaken with 
paired vessels from the same patient in every case. Any vessels from which clear results 
were not obtained were recorded as lost data and not replaced other than with results from 
another complete set of paired vessels from a further patient. 
 
Vasoconstrictor protocols    
After 30 minutes incubation of arteries with vehicle (PSS), phosphoramidon, (a dual NEP 
and ECE inhibitor) or KC 12615 (at 10
-4 M), CCRCs (vasoconstriction) were constructed 
with the ET-1 precursor, big ET-1 over the concentration range of 10
-10 to 3x10
-7 M. 
Vasodilator protocols 
Again after 30 minutes incubation of arteries with vehicle (PSS), phosphoramidon, 
thiorphan  or KC 12615 (at 10
-4 M), CCRCs were constructed with the following 
vasodilators in vessels pre-constricted with 10
-5M norepinephrine: ANP (10
-14 - 3x10
-7M ), 
bradykinin (10
-14 - 3x10
-6M), ADM (10
-11 - 3x10
-7M) and CGRP (10
-12 - 3x10
-7M). 
Statistical analysis 
Vasoconstriction data are presented as a percentage of the contraction achieved with 60 
mM potassium solution. Those for relaxation are represented as percent relaxation relative 
to the preconstricted baseline. Values are presented as mean + SEM. Statistical 
comparisons of pD2 (-log concentration required to produce 50% of the maximum 
response) and maximum response were performed with one-way ANOVA followed by 
Dunnet’s post hoc test for multiple comparisons. Where no maximum response was 
achieved at the concentrations used, the pD2 could not be determined and is not reported.   80
Comparison of CCRCs was by one-way ANOVA for repeated measures.   Statistical 
significance was assumed at a value of p< 0.05. 
Because prior treatment with an angiotensin converting enzyme (ACE) inhibitor was 
expected to affect the action of bradykinin, patients were split into an ACE inhibitor pre-
treated and ACE inhibitor untreated group to analyse the response to bradykinin (prior 
treatment with an ACE inhibitor did not influence the response to other vasodilators). 
RESULTS 
Patient characteristics 
Biopsies were taken from 49 patients. All had a diagnosis of ischaemic heart disease but 
preserved LV function. Medication is detailed in Table 5.1. Of note the group of patients 
taking ACE inhibitors is otherwise well matched to the group of patients not taking ACE 
inhibitors. 
Vasoconstrictor protocols  
Big endothelin-1 (figure 5.1): As previously described, big ET-1 had a powerful 
vasoconstrictor action. As expected, this was significantly attenuated by phosphoramidon 
(mean difference vs vehicle 12.05%, p<0.01, 95% CI 2.767 to 21.34). KC 12615 (10
-4 M), 
however, had the greatest inhibitory effect on big ET-1 induced vasoconstriction (mean 
difference vs vehicle 17.75%, p<0.01, 95% CI 1.940 to 33.57 both by ANOVA for repeated 
measures).  
Vasodilator protocols 
Bradykinin (figure 5.3): Bradykinin was a powerful vasodilator of preconstricted small 
arteries, producing similarly powerful maximum vasodilator responses in all groups 
(maximal response: 94 ±1% vehicle, 95 ± 2% phosphoramidon, 94 ± 2% thiorphan, 97 ± 
1% KC12615). However, a leftwards shift in sensitivity was evident with all three 
inhibitors (p<0.01, comparison of curves). This was also reflected in a reduced 
concentration of each inhibitor required to produce a 50% response (pEC50: 9.02 ± 0.06 
logM vehicle, 9.65 ± 0.08 logM phosporamidon, 9.95 ± 0.16 logM thiorphan, 9.58 ± 0.15    81
Table 5.1   Patient characteristics 
 
Patient characteristics 
 
Treatment includes ACE 
inhibitor 
Treatment does not include 
ACE inhibitor 
 
Number of patients 
 
22 
 
27 
 
Gender, M 
 
13 
 
16 
 
Age, years 
 
57.0 (16.1) 
 
60.3 (11.5) 
 
Previous MI, n 
 
7 
 
7 
 
Previous CABG, n 
 
6 
 
5 
 
Previous PTCA, n 
 
5 
 
7 
 
Current smoker, n 
 
4 
 
8 
 
Co existant hypertension, n 
 
7 
 
7 
 
Co existent T2DM, n 
 
1 
 
1 
 
Mean ejection fraction, % 
 
53.6 (8.7) 
 
51.6 (8.0) 
 
Drug therapy, n 
  
 
    ACE inhibitor 
 
22 
 
0 
 
    Diuretic 
 
9 
 
4 
 
    Digoxin 
 
0 
 
0 
 
    Calcium channel blocker 
 
7 
 
9 
 
    Oral nitrate 
 
5 
 
8 
 
    Beta-blocker 
 
17 
 
16 
 
    HMG-CoA reductase 
 
16 
 
12 
 
    Aspirin/clopidogrel 
 
18 
 
21 
 
Glucose 
 
6.5 (2.2) 
 
6.4 (2.9) 
 
Cholesterol 
 
4.9 (0.7) 
 
5.2 (0.7) 
 
Creatinine 
 
105.5 (16.4) 
 
104.4 (25.4) 
 
MI,myocardial infarction. CABG, coronary artery bypass grafting. PTCA, percutaneous transluminal 
coronary angioplasty. T2DM Type II diabetes mellitus. HMG CoA, 3-hydroxy-3-methylglutaryl coenzyme 
A. 
Values are given as number or mean (SD).   82
logM KC12615), although this effect only achieved statistical significance with KC12615 
(p<0.05, figure 3).  
When patients were separated into those taking and those not taking an ACE inhibitor, KC 
12615 was found to significantly augment bradykinin mediated vasodilatation only in the 
absence of an ACE inhibitor (pEC50: 8.66 ± 0.15 logM vehicle, 10.68 ± 0.38 logM 
KC12615, p<0.05). In patients pre-treated with an ACE inhibitor, the pEC50 was 8.75 ± 
0.10 logM for vehicle and 9.18 ± 0.04 logM for KC12615 (figure 5.4). This suggests that 
the effect of bradykinin is maximally augmented by ACE inhibition and that NEP 
inhibition does not lead to further augmentation.  
Adrenomedullin  (figure 5.5): ADM was also a potent vasodilator. As with ANP, the 
response to ADM was enhanced after incubation with both dual enzyme inhibitors (p<0.05, 
comparison of curves) but not with thiorphan. In contrast to ANP, however, no difference 
was observed in the maximal response (maximal response: 78 ± 6% vehicle, 79 ± 8% 
phosphoramidon, 74 ± 7% thiorphan, 75 ± 8% KC12615)  
Calcitonin gene related peptide (figure 5.6): Phosphoramidon significantly augmented the 
response to CGRP (p<0.05, comparison of curves). This effect was most marked at the low 
concentrations of CGRP. However neither the maximal response (96 ± 1% vehicle, 98 ± 
1% phosphoramidon, 93 ± 4% thiorphan, 97 ± 2% KC12615) nor the pEC50 (9.54 ± 0.08 
logM vehicle, 10.05 ± 0.24 logM phosphoramidon, 9.52 ± 0.04 logM thiorphan, 9.55 ± 
0.11 logM KC12615), were significantly different. The other inhibitors had no effect on the 
response to CGRP.   83
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FIGURE 1: BIG ENDOTHELIN INDUCED
VASOCONSTRICTION
Figure 5.1 
Cumulative concentration response curves (vasoconstriction) for big endothelin-1(big ET-1). 
Vasoconstriction is expressed as a percentage of that obtained with potassium chloride, (KCI). Big 
endothelin-1 has a powerful vasoconstrictor action. The curves are shifted to the right in the presence 
of 10-4M phosphoramidon and 10-4M KC 12615. The vasoconstrictor effect of big endothelin-1 is 
significantly attenuated by phosphoramidon (p<0.01) and more markedly by KC12615 (p< 0.01 by 
ANOVA for repeated measures).  
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FIGURE 2: ATRIAL NATRIURETIC PEPTIDE INDUCED
VASODILATATION
Figure 5.2 
Cumulative concentration response curves (vasodilatation) for atrial natriuretic peptide (ANP). Atrial 
natriuretic peptide is a relatively weak vasodilator. Its effects are augmented by phosphoramidon and 
KC12615 (both p<0.05), but not by thiorphan. 
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Figure 5.3 
Cumulative concentration response curves (vasodilatation) for bradykinin (BK). 
Vasodilatation is expressed as percent relaxation relative to the baseline norepinephrine 
preconstricted state. Bradykinin has a powerful vasodilator effect. This is significantly 
augmented by phosphoramidon, KC12615 and thiorphan (all p<0.01). [Includes patients 
taking and not taking ACE inhibtors]   86
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Figure 5.4 
Cumulative concentration response curves (vasodilatation) for bradykinin. Small resistance arteries taken from patients 
pre-treated or not pre-treated with angiotensin converting enzyme inhibitors (ACE I). KC 12615 only enhanced the 
vasodilator response to bradykinin in patients not pre-treated with an ACE inhibitor (p<0.05). 
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 FIGURE 5: ADRENOMEDULLIN INDUCED
VASODILATATION
Figure 5.5 
Cumulative concentration response curves (vasodilatation) for adrenomedullin 
(ADM). There is augmentation of the vasodilator effect of adrenomedullin by both 
phosphoramidon and KC12615 (both p<0.05), but not thiorphan.   88
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FIGURE 6: CGRP INDUCED VASODILATATION
Figure 5.6 
Cumulative concentration response curves (vasodilatation) for calcitonin gene related peptide 
(CGRP). The relaxation response to calcitonin gene related peptide was significantly augmented 
by phosphoramidon only (p<0.05).   89
Discussion 
I have shown that KC 12615, the active metabolite of SLV306, has comparable activity to 
phosphoramidon, a well characterized inhibitor of NEP and ECE (Petrie, Hillier et al 2001, 
Jeng et al 1989, Ikegawa et al 1990). Phosphoramidon, however, is neither orally active nor 
available for human use.   Though NEP inhibitors have been studied in humans, there are 
no reports of the use of orally active ECE inhibitors or dual NEP/ECE inhibitors.   By 
contrast, SLV306 is orally active and has recently been given to healthy volunteers and 
patients.   Other dual NEP/ECE inhibitors have been described, as has a triple enzyme 
(ACE/ECE/NEP) but none have been administered to humans (Trapani et al 1995, 2000, 
Ksander et al 1998). 
I have found that 10
-4 M KC 12615 significantly attenuated the contractile response to big-
ET-1, in keeping with inhibition of ECE mediated generation of ET-1.  
In addition, phosphoramidon and KC 12615, but not thiorphan, enhanced the vasorelaxant 
action of ANP, though this action was less marked with KC 12615 than with 
phosphoramidon. Enhancement, of the action of ANP is consistent with inhibition of NEP 
and  in keeping with the ability of SLV306 to augment blood natriuretic peptide 
concentrations in vivo. 
What is of particular interest in my study, however, is the effect of KC 12615 on other 
vasoactive peptides. Prior studies with NEP inhibitors, in a variety of experimental models, 
have suggested that NEP is also capable of catabolising substances other than natriuretic 
peptides (Lewis et al 1997, Kokkonen et al 1999, Katayama et al 1991).
 For that reason I 
also studied the effect of KC 12615, phosphoramidon and thiorphan on the action of several 
other vasodilators. All three drugs markedly enhanced the vasorelaxant action of 
bradykinin.   Interestingly, this action was only apparent in arteries taken from patients who 
had not been pre-treated with an ACE inhibitor.   Clearly, ACE also known as kininase II,  
breaks down bradykinin and ACE inhibition enhances the action of bradykinin (Linz et al 
1995). It seems that NEP inhibition does not further augment the effect of bradykinin when 
ACE has already been inhibited i.e. therapeutic ACE inhibition alone seems to maximally 
augment the action of bradykinin.   This finding has potential clinical implications as it is   90
likely that any dual NEP/ECE inhibitor will be used mainly in addition to an ACE inhibitor.   
This may also allay concerns about angioedema (Messerli and Nussberger 2000).   Of 
course, I have only studied small resistance arteries and the ratio of NEP and ACE differs 
in other tissues e.g. the myocardium (Blais et al 2000). Consequently, the effect of 
combined therapy with an ACE inhibitor and a dual NEP/ECE inhibitor could differ 
between tissues. 
Interestingly, I also found that phosphoramidon and KC 12615 (but not thiorphan) 
augmented the action of ADM, a recently described and powerful endogenous vasodilator 
which may protect against cardiovascular damage (Shimosawa et al 2002). NEP inhibition 
has been reported to increase plasma concentrations of ADM in sheep and enhance the 
renal actions ADM in dogs (lisy et al 1998, Rademaker et l 2002).
 I have now shown this 
action in human blood vessels. Phosphoramidon (but not thiorphan or KC 12615) also 
enhanced the action of CGRP, a peptide sharing structural homology with ADM.  
These actions of phosphoramidon and KC12615, in addition to the attenuation of big ET-1 
mediated vasoconstriction, almost certainly reflect inhibition of NEP. Thiorphan, however, 
did not share these actions, other than in the augmentation of the vasodilator effect of 
bradykinin. This may be because thiorphan is a relatively weak NEP inhibitor. 
This unexpectedly wide array of actions of effective dual NEP and ECE inhibitors makes 
such compounds, potentially, very attractive therapeutic agents. Diminished ET-1 
production, coupled with an augmented effect of natriuretic peptides, bradykinin and ADM, 
is of theoretical benefit in hypertension, heart failure, atherosclerosis (including saphenous 
vein grafts (Porter et al 2001) and, perhaps, renal failure and diabetes (Tikkanen et al 2002).
 
However, such benefits have to be demonstrated in properly designed clinical trials. 
In summary, my findings show that dual NEP and ECE inhibitors can modulate the action 
of vasoactive mediators other than ET-1 and natriuretic peptides. These further actions may 
indicate that this new class of pharmacological agent has anti-hypertensive, cardiovascular 
and renal benefits in addition to those anticipated.   91
6  A study to establish the pressor response to big endothelin-1 infusion 
in healthy volunteers. 
 
Background 
ET-1, a neurohumoral peptide, is a powerful vasoconstrictor, mitogenic and anti-natriuretic 
peptide which is produced in increased quantities in CHF. ET-1 is also believed to 
contribute to the development and progression of atherosclerosis and may have a role in the 
development of hypertension. ET-1 is generated from a precursor peptide, big ET-1, by a 
specific ECE. Studies in vivo have demonstrated a potent vasoconstrictor effect of both ET-
1 and its precursor big ET-1, with both peptides causing significant increase in mean 
arterial pressure (MAP).  
Currently there is much interest in the development of anti-endothelin drugs for the 
treatment of heart failure in particular and cardiovascular disease in general. One such 
group of drugs are ECE Inhibitors. To be able to evaluate the efficacy and dose response 
relationships for these new compounds it is necessary to demonstrate their ability to blunt 
the BP rise induced by big ET-1. In turn this requires an understanding of the relationship 
between big ET-1 dose and arterial pressure response.  
The purpose of this study is to find a dose of big ET-1 that gives a measurable but modest 
increase in arterial pressure in healthy volunteers. This would then permit evaluation of the 
efficacy and dose response relationship of SLV 306, a novel neurohumoral peptide with 
dual NEP and ECE inhibitory action.   
In previous studies a rising dose regime of 0.2, 1 and 8 pmol/kg/min, for 20 minutes each 
has been associated with a maximum increase in MAP of 33mmHg (Ahlborg et al 1994, 
1996, Pernow et al 1996). In my pilot studies however this regime did not lead to a 
measurable increase in blood pressure (monitored for 2 hours post- infusion). I aimed in 
this study to find a dose of Big ET-1 which consistently causes a blood pressure rise of 20 –
30 mmHg in the majority of volunteers.    92
Methods 
The design of this study was based on similar studies using angiotensin I, routinely carried 
out to determine pressor-dose response curves. These curves were then used to test the 
effect of ACE inhibitors. The Big ET-1 effect on blood pressure, however, is slower than 
that of angiotensin I and is sustained for about 90 minutes, preventing the use of a large 
range of doses. I therefore monitored the blood pressure at rest and following infusion of 
only three doses of Big ET-1 in 6 healthy male volunteers 
Healthy volunteers 
Six healthy male volunteers were enrolled following a screening visit to ensure eligibility. 
They were recruited from a volunteer database held in the research  unit.                        
Six  has been an adequate number, to give significant results, in previous studies using Big 
ET-1. 
 
Big endothelin infusions 
During the study session subjects were given three systemic, intravenous infusions of big 
ET-1.  
The first infusion was at a rate of 8 pmol/kg/min as given in previous studies, the second 
was at a rate of 10 pmol/kg/min. and the third was at a rate of 12 pmol/kg/min. Each 
infusion lasted for 20 minutes in total. 
Blood pressure measurements 
Blood pressure measurements were made at ten minute intervals from 30 minutes before 
until 2 hours after each infusion or until baseline values were obtained. 
Results 
I demonstrated that the highest Big ET dose of 12  pmol/kg/min gave a clear pressor 
response, whilst the 8 and 10 pmol/kg/min-doses showed a smaller effect (See figure 6.1).   93
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Figure 6.1  
The effect of three doses of big endothelin-1 on the mean arterial pressure of healthy volunteers (n=6) 
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Figure 6.2 
The effect of three doses of big endothelin-1 on the heart rate of healthy volunteers (n=6) 
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Discussion 
Overall, the results were not as impressive as described in the literature (Ahlborg et al 
1994, 1996, Pernow et al 1996). There was little difference in response between the two 
lower doses.   
Despite rigorous assessment of the methods used I was unable to explain this.  I used 
the same infusion methods, the same controlled conditions and the same non invasive 
method of assessing blood pressure.  
The pressor response to the higher dose was accompanied by the expected reflex 
bradycardia (see figure 6.2). With respect to both blood pressure and heart rate, the 
response to the highest big ET dose was large enough and most importantly 
reproducible enough to reliably show an influence on it by pharmacological 
intervention. 
This dosing study allowed me to choose doses of big ET for my SLV 306 dose response 
study which I knew were associated with clear reproducible pressor and heart rate 
response in my hands.  
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7  Dose response study with SLV306 in healthy human volunteers:  
effects on haemodynamic responses to big ET-1 infusion and 
hormonal actions 
Background 
SLV 306 is a molecule that has been shown to inhibit both ECE and NEP in animal 
tissues. ECE converts the inactive propolypeptide big ET-1 to ET-1. NEP breaks down 
ANP, BNP and CNP. SLV 306, therefore reduces ET-1 production and increases 
natriuretic peptide concentrations. SLV 306 is the first orally active dual ECE/NEP 
inhibitor in development as a therapeutic agent (see section 1.3.4). 
NEP inhibitors were ineffective anti-hypertensives, probably because NEP catabolises 
ET-1.  Dual NEP and ECE inhibition may be more useful therapeutically. 
The aim of this study was to establish the dose response (concentration response) 
relationship for the ECE and NEP inhibitor activity of SLV 306 in healthy volunteers. 
This is presently unknown but clearly key to choosing the appropriate dose range of 
SLV 306 for therapeutic studies in patients. One way in which I will assess the ECE 
inhibitory action of SLV 306 is to evaluate the effect of three plasma concentrations of 
the main metabolite of SLV 306 (KC 12615) on the pressor response to big ET-1. The 
approach used is analogous to that used to study dose response relationships for ACE 
inhibitors (Biollaz et al 1981, Burnier et al 1981, Wellstein et al 1987). I will also study 
the effect of the three doses of SLV 306 on neurohormones. 
The target parameters are the change from baseline in the MAP and the plasma levels of 
the neurohormones big ET-1, ET-1 and ANP before, during and after the big ET-1 
infusion. 
Methods 
There were two parts to this study.    
Due to a high inter-subject variability in the plasma concentrations of SLV306 and 
KC12615, a concentration controlled design was used. 29 Male volunteers attended for 
the first stage of the study which involved taking two different doses of SLV306  
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(400mg (n=29), and 600mg (n=6) or 800mg (n=23)) at least seven days apart.   Blood 
samples were collected after dosing for measurement of plasma concentrations of 
KC12615.  Pharmacokinetic modelling was used to calculate the individual doses of 
SLV306 needed to achieve average plasma concentrations of KC12615 of 
approximately 75ng/ml, 300ng/ml and 1200ng/ml over the first 6 hours. These values 
correspond roughly with the expected mean KC 12615 concentrations following single 
doses of 100 mg, 400 mg and 800 mg respectively of the parent compound SLV 306.   
The second part of the study was a double blind, placebo controlled, four period cross-
over study in 15 healthy male volunteers (mean age 22, range 18-38 years). It involved 
four further visits at least seven days apart.   For these, volunteers attended the clinical 
laboratory at 08.00h, having fasted from midnight.   An intravenous cannula was placed 
in each forearm.   After one hour of supine rest, baseline blood pressure and heart rate 
recordings were made and blood samples taken (see below).   Each subject then 
received either placebo or a single oral dose of SLV306.   A double-blind ascending 
dose protocol with random insertion of placebo was used to assign treatment.   160 
minutes after dosing, a 20 minute infusion of 8 pmol/kg/min of big ET-1 was 
administered (figure 7.1).   After a further 40 minutes (220-240 minutes post-dosing) a 
second 20 minute infusion of 12 pmol/kg/min of big ET-1 was given.    
Healthy volunteers 
29 healthy male volunteers were enrolled for the first part of the study following a 
screening visit to ensure eligibility. 15 of these proceeded to the second part of the 
study.  Subjects were excluded from the principal study if they had no measurable 
plasma levels or they needed more than 1600mg SLV 306 to achieve a plasma level in 
the required range. 15 subjects was thought to be an appropriate number since a similar 
number gave significant results, in studies of a similar type involving ACE inhibitors 
(Biollaz et al 1981, Burnier et al 1981, Wellstein et al 1987).  
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Figure 7.1 
Study protocol.  Subjects rested supine for 60 minutes before intake of study medication.  The first big endothelin-1 
infusion was commenced 160 minutes after dosing and the second after 220 minutes.   = neurohumoral   = blood 
pressure and    = pharmacokinetic measurements. 
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SLV 306 
In the pilot part of the study all 29 subjects were given 400mg on day 1, 6 of the 
subjects were then given 600mg on day 8. Once this dose was seen to be well tolerated, 
the remaining 23 subjects were given 800mg. This was for safety as the highest dose of 
SLV 306 previously given to humans was 400mg. 
In the principal part of the study the doses given were adapted individually. The doses 
given were those found to achieve target plasma concentrations of KC 12615 of 
75ng/ml, 300ng/ml, and 600ng/ml (comparable to 100, 400 and 800mg of SLV 306 
respectively) at the infusion time i.e. 3 hours post dose. 
Subjects were excluded if they had no detectable plasma levels or if they need more 
than 1600mg SLV 306 to achieve a plasma level in the required range. 
15 subjects who received 800 mg in the pilot part of the study (unless excluded) 
proceeded to the principal study, allowing up to eight subjects to remain in reserve, 
available to replace subjects that no longer complied with the study requirements.  
The subjects in the principal study were given one of the three doses of SLV 306 or 
placebo, on each study day, blinded in a double blind fashion. 
Big Endothelin-1 infusions 
In each of the principal study sessions subjects were given a systemic, intravenous 
infusion of big ET-1 160 minutes after dosing with placebo or SLV306. The infusion 
was commenced at a rate of 8.0pmol/kg/min. After 40 minutes (220-240 minutes post 
dosing) the infusion rate increased to 12pmol/kg/min and this rate of infusion continued 
for 20 minutes before being stopped. The doses of big ET-1 were chosen from the pilot 
study (chapter 6), as ones likely to lead to a rise in mean arterial pressure of 
approximately 20 mmHg.   The timing of the infusions was chosen to coincide with 
peak plasma concentrations of KC12615 as demonstrated in the pharmacokinetic first 
stage of the study. 
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Measurements of arterial pressure and heart rate 
Heart rate and arterial pressure measurements were made at ten minute intervals 
initially, then every 30 minutes until the start of the big ET-1 infusion. From the start of 
the infusion they were again taken every ten minutes until two hours after completion of 
the infusion (figure 7.1). 
Blood samples for neurohumoral measurements 
11ml of venous blood was collected from the contralateral forearm into chilled tubes at 
baseline and 160, 210, 240, 260, 280, 300 and 360 minutes after administration of study 
drug (figure 7.1).  
Plasma big ET-1 and ET-1 levels were measured to assess the effect of SLV 306 and its 
metabolite on the conversion of big ET-1 to ET-1. Plasma ANP concentrations serve as 
a measure of the degree and time course of NEP inhibition.  
Samples were handled,  stored and analysed as described in chapter 2. 
Statistical methods 
The treatment groups were compared using a two-way ANOVA with factors for 
treatment group, study period and subjects. In addition, least square mean changes were 
calculated for each treatment group and the three SLV 306 minus placebo differences 
were estimated. Each of the three comparisons was performed at the 5% significance 
level, without adjustment for multiple testing. 
Results 
Of the 15 volunteers taking part in the big ET-1 infusion studies, 1 withdrew for 
personal reasons and 1 was withdrawn because of an excessive rise in blood pressure 
(30 mmHg) and fall in heart rate (-15 beats/min).   No subjects experienced any 
significant adverse event. 
Plasma concentrations of KC12615:  Maximum plasma concentrations for KC 12615 
were achieved at about 3-4 hours following oral dosing of SLV 306.   The low, medium 
and high doses of SLV 306 resulted in clearly distinguishable plasma concentrations of  
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KC 12615.    The respective mean steady state concentrations were 30, 252 and 1674 
ng/ml. 
Arterial pressure:  The rise in systolic and diastolic arterial pressure following big ET-1 
infusion is shown in figure 7.2.   SLV 306 caused a dose dependent attenuation of the 
hypertensive response to big ET-1.   The mean peak (SE) increases in systolic, diastolic 
and mean arterial pressure were 19.2(2.1), 16.1 (1.5) and 15.9(1.6) mmHg after placebo 
pre-treatment.   The increases after 75ng/ml were, 18.3(3.0), 14.0 (2.1) and 15.0 (2.3) 
mmHg, respectively. The respective increases after 300ng/ml were 15.5(2.5), 13.3 (1.7) 
and 13.5(1.9) mmHg.  Those after 1200ng/ml were 10.4(2.8), 10.5(2.0) and 9.0 (2.1) 
mmHg, respectively. The differences between placebo and 1200 ng/ml were all 
significant for systolic, diastolic, and mean arterial pressure.  
Heart rate:  SLV 306 caused an inhibition of the reflex bradycardia induced by big ET-1 
infusion (figure 7.2).    During big ET-1 infusion, the mean peak decreases in heart rate 
were 12.1 (1.1), 11.2 (1.5), 10.2 (1.2) and 7.9 (1.4) beats per minute after pre-treatment 
with placebo, 75, 300 and 1200ng/ml, respectively.     
Atrial natriuretic peptide (ANP):  SLV 306 led to a dose dependent increase in plasma 
ANP concentrations (figure 7.3), consistent with systemic NEP inhibition.  The mean 
peak (SE) increases in plasma ANP after placebo, 75, 300 and 1200 ng/ml were 5.4 
(3.0), 11.0 (4.2), 24.0 (3.5) and 20.6 (4.0) pg/ml, respectively. The between-group 
differences for 300 ng/ml and 1200 ng/ml compared to placebo were statistically 
significant:  18.6 (4.7) [p=0.0004] and 15.3 (4.8) [p=0.003], respectively.    
Big ET-1 and ET-1:   SLV 306 caused a dose dependent increase in plasma big ET-1 
concentrations during and after the big ET-1 infusions (figure 7.3). The mean (SE) 
increases in plasma big-ET in the first hour following the completion of the big-ET 
infusions after treatment with placebo or 75, 300, and 1200 ng/ml were 96.3 (18.3), 
128.6 (25.8), 184.4 (21.6) and 216.1 (24.3) pmol/l.    The between group differences 
versus placebo were statistically significant for the 300 ng/ml and 1200 ng/ml doses: 
88.1 (28.6) [p=0.004] and 119.9 (29.6) fmol/l [p=0.0003], respectively.  
There was no evidence of any between group differences for plasma ET-1 levels during 
the same period.   
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Figure 3: Effect of oral pretreatment with placebo or SLV 306
on hemodynamic responses to big endothelin -1 infusion
Figure 7.2 
Change in (a) systolic, (b) diastolic and (c) mean arterial pressures, from baseline, during and after big endothelin-1 (big ET-1) infusion on 
each of the four study days (i.e. after pre-treatment with placebo or SLV 306) to give KC 12615 plasma concentrations of approximately 
75, 300 and 1200mg/ml.  "Baseline" was the average of the last 3 arterial pressure measurements made prior to commencement of the first 
big ET-1 infusion.  Change in heart rate (d) is shown in the same way 
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Figure 4: Hormonal changes following oral treatment with the dual NEP/ECE inhibitor 
SLV 306 (active metabolite KC 12615)
Figure 7.3 
Hormonal changes following oral dosing with placebo or SLV 306 and subsequent infusion of big endothelin-1.   
Changes in plasma Big ET-1, ET-1, ANP peptide levels in response to increasing doses of  KC12615 ( the active 
metabolite of SLV306). Each value represents the mean  increase in plasma levels measured in 13 volunteers in the 
first hour following completion of the big ET-1 infusion in either placebo (representing mean basal conversion 
indicated by horizontal line)  and each of the increasing doses. There was a significant dose dependent rise in Big ET-
1, (*P<0.005) consistent with inhibition of  ECE, and a rise in ANP consistent with inhibition of NEP activity.  ET-1 levels 
were unaltered.  
104
The ratio of big ET-1 to ET-1 dose dependently increased, consistent with systemic 
ECE inhibition preventing metabolism of the enzyme substrate (big ET-1) to its active 
metabolite (ET-1, figure 7.3). The mean (SE) ratio of plasma big-ET-1/ET-1  
concentration increased in a concentration dependent manner following the big ET-1 
infusion:   21.6 (3.0), 20.1 (4.2), 34.1 (3.5), and 41.5 (3.9) after placebo, 75, 300 and 
1200 ng/ml, respectively. The between group differences versus placebo were 
statistically significant for the 300 ng/ml and 1200 ng/ml doses: 12.5(4.6) [p=0.011] and 
20.0 (4.8) [p=0.0002], respectively.   
Discussion 
I have studied the first in a new class of orally active dual metalloprotease inhibitors.   
SLV306 and its active metabolite have in vivo pharmacologic actions consistent with 
inhibition of both NEP and ECE.    
I employed a similar experimental approach to that used to demonstrate the 
pharmacologic actions of ACE inhibitors (and dual NEP and ACE inhibitors) to confirm 
any ECE inhibiting action of SLV306 in vivo (Rousso et al 1998, Jardine et al 1990). I 
have shown that SLV306 dose dependently blocks the pressor response to big ET-1, in 
keeping with functional ECE inhibition in vivo. NEP inhibition alone might have been 
expected to augment the hypertensive effect of big ET-1 infusion (Ando et al 1995, 
McDowell et al 1997).   I also found that plasma concentrations of big ET-1 increased 
dose dependently on the SLV306 days when compared with the placebo day. Indicating 
that SLV 306 was inhibiting an increasing proportion of endogenous ECE activity. 
Interestingly, despite inhibition of NEP there was no significant change in plasma ET-1 
concentration during big ET-1 infusion. NEP is thought to metabolise ET-1 to 
biologically inactive fragments. Moreover, the big ET-1/ET-1 ratio significantly 
increased consistent with reduced conversion of big ET-1 to ET-1. Kuc et al have since 
carried out further analysis from our study which supports this interpretation. ECE is 
responsible for the conversion of big ET-1 to the active peptide ET-1 and the C terminal 
fragment (CTF). They measured CTF in blood samples taken from our study subjects. 
They demonstrated a significantly smaller rise in CTF in the presence of SLV 306 than 
in the presence of placebo (Kuc et al 2005).   
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I was also able to confirm that SLV306 is a NEP inhibitor in vivo.   SLV306 caused a 
dose dependent increase in plasma ANP concentration almost identical to that obtained 
with candoxatril in healthy volunteers (i.e. an approximate doubling of plasma ANP 
concentrations with the highest dose of inhibitor) (Northridge et al 1989, Jardine et al 
1990). 
In conclusion, I believe that an agent that is both a NEP inhibitor, augmenting 
circulating natriuretic peptide production and an ECE inhibitor, reducing ET-1 
production, is an attractive therapeutic option in a range of cardiovascular diseases.   
Such an agent overcomes the pharmacologic limitations of a sole NEP inhibitor, 
especially if used in combination with an ACE inhibitor or angiotensin II receptor 
antagonist. 
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8  A double blind, randomised, three-way crossover study in 
healthy human volunteers to compare the effects of two doses of 
GW660511X with ramipril on NEP and ACE activity 
 
Background 
GW660511X ('511) is an inhibitor of both ACE and NEP. The conversion of 
angiotensin I to angiotensin II is mediated by ACE. NEP breaks down ANP, BNP and 
CNP. '511 therefore reduces angiotensin II production and increases natriuretic peptide 
concentrations.   
The pharmacodynamic profile of neither the ACE inhibitor activity nor the NEP 
inhibitor activity of '511 has been fully described in humans. Initial studies have 
characterized the ACE inhibition by assessing plasma ACE activity and have partially 
characterized markers of NEP inhibition. This study is intended to compare the ACE 
inhibition of '511 with a clinically relevant comparator, ramipril. The challenge for the 
development of vasopeptidase inhibitors, as useful therapy in hypertension or heart 
failure, has been the need for demonstration of a beneficial effect over and above ACE 
inhibitors.  
The aim of this study was to compare ACE inhibition by plasma ACE activity and the 
in vivo haemodynamic effect of angiotensin I infusion. NEP inhibitor activity was 
further characterized by measuring plasma cGMP and plasma ANP.  
The study compares two dose levels of '511, 100 and 200mg, with a clinically relevant 
dose of the ACE inhibitor ramipril, 10mg.  
The design of this study is based on similar studies using angiotensin I which were 
carried out to determine the dose response relationships for ACE inhibitors (Biollaz et al 
1981, Burnier et al 1981, Wellstein et al 1987). 
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Methods 
Healthy volunteers 
18 healthy male volunteers were enrolled following a screening visit to ensure 
eligibility. Based on this sample size it was anticipated that at least 15 subjects would 
complete the clinical phase of the study (i.e. complete all treatment periods). 15 subjects 
was thought to be an appropriate number since a similar number gave significant 
results, in studies of a similar type involving ACE inhibitors (Biollaz et al 1981, Burnier 
et al 1981, Wellstein et al 1987).  
Following screening and then a preliminary visit which included an angiotensin I 
infusion challenge to check for hypertensive response (detailed below), each subject 
was given seven daily doses of either 10 mg ramipril or 100 mg '511 or 200 mg '511 
during each day of three seven day study periods. The volunteers were asked to attend 
each morning for observed dosing.  All study periods were conducted identically.  
On day 4 of each seven day period, the subjects should have reached steady state (based 
on the half life of '511 (12 hours) and ramipril (11 hours)). Day 4 was therefore chosen 
for the angiotensin I challenge. Volunteers were asked to attend the research unit for 24 
hours on this day. During this visit angiotensin I was administered at 2, 4 and 23 hours 
post dosing. These times were chosen to represent the predicted peak (2 hour), trough 
(23hours) and a convenient intermediate time point (figure 8.1). The dose of angiotensin 
I (µg/min) which increased systolic or diastolic blood pressure to a predefined level 
[infusion stopped if systolic BP increased to 180 mmHg or above (or by 40 mmHg or 
more) or diastolic BP increased to 110 mmHg or above (or by 25 mmHg or more)] in 
the presence of ‘511 or ramipril was determined.  These angiotensin I dose level values 
were compared to the angiotensin I dose level value which increased systolic or 
diastolic blood pressure to the predefined safety levels prior to drug treatment 
(baseline).  Mean (95% confidence interval) angiotensin I dose-blood pressure response 
(DR-1) for each drug at each post-dose time point were determined and plotted against 
time.  Individual DR  –  1 values were plotted against individual ‘511 concentration 
values.  
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Figure 8.1 
Study day 4 protocol. Subjects rested supine for 60 minutes before intake of study medication.  The first angiotensin I challenge was 
commenced 120 minutes after dosing, the second after 240 minutes and the third after 23 hours. 
   = blood pressure and    = pharmacokinetic measurements and Ang I = angiotensin I 
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Table 8.1 
Study day 7. Time and Events Schedule 
 
 
 
 
 
 
In bed for first 8 hours  
including giving urine samples  
Then for 1 hour before each blood 
sample 
In bed until 
after 1330 blood sample 
Lunch after 230pm  
Evening meal after 530pm  
 
In 
bed 
1630 
In 
bed 
2030 
In 
bed 
1230 
In 
bed 
0830 
Real  Time  0830 0925 0930 1000 1030 1130 1230 1330 1430 1730 2130 0130 0930 
 -1h  Pre-
dose 
0  0.5h  1h 2h 3h 4h 5h 8h 12h  16h  24h 
Resting Semi-Recumbent  X  X X X X X X X X X      
Study Medication Administration    X            
Drink  water  0.5L       0.2L 0.2L 0.2L 0.2L 0.2L 0.2L      
Pharmacodynamic Blood Sample    X   X X X X X   X X X X 
Pharmacokinetic Blood Sample    X   X X X X X   X X X X 
AE  collection  X X X X X X X X X X X X X  
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A two day period was left between the angiotensin I challenge and the next assessment to 
allow any effects of angiotensin I on hormones associated with renal handling to resolve.  
On day 7 volunteers were again asked to attend the research unit for 24 hours, a 24-hour 
pharmacokinetic profile and a 24-hour ACE & NEP inhibition profile were obtained (figure 
8.2). There was then a washout period of at least one week between study periods.   
5 to 10 days following the last study session subjects returned for a follow-up visit.  
Angiotensin I infusions 
Angiotensin I was given 2 hours, 4 hours and 23 hours after study medication was 
administered (figure 8.1). It was given by ascending dose infusion as described in chapter 2. 
During screening each volunteer received an angiotensin infusion according to this protocol 
and a rise in systolic blood pressure of at least 10mmHg was required for eligibility. 
Measurements of arterial pressure and heart rate 
Heart rate and arterial pressure were measured in the last thirty seconds of each dose of 
angiotensin I and for safety reasons within the first minute of each increase in infusion rate. 
Blood samples for pharmacokinetic assessments   
Blood samples (4 ml) for measurement of plasma '511 concentration were collected on four 
occasions on day 4 and on ten occasions on day 10. 
Blood samples for neurohumoral measurements 
Blood samples (13 ml) for measurement of plasma ACE activity, plasma ANP and plasma 
cGMP were collected on ten occasions on day 7 (table 8.2). These neurohumoral analyses 
were taken as a measure of the degree and time course of ACE and NEP inhibition. Samples 
were handled, stored and analysed as described in chapter 2. 
Statistical methods 
The primary comparisons of interest were between ‘511 100  mg and ‘511 200  mg and 
ramipril 10  mg, in terms of ACE activity. Least square means were calculated for each 
treatment group and the two ‘511 doses minus ramipril differences were estimated. Treatment 
ratios of all comparisons were calculated by taking the anti-log of the difference between the 
least squared means. Using pooled estimates of variance, 95% confidence intervals were  
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calculated for the difference then anti-logged. Comparisons were presented as a treatment 
ratio. 
Results 
A total of 16 subjects were enrolled in the study.   
Plasma concentrations of GW660511X:   
Maximum plasma concentrations of ‘511 were achieved at about 3 hours following oral 
dosing. The two doses of ‘511 (100mg and 200mg) resulted in approximately proportionate 
maximum and minimum plasma concentrations. The respective mean maximum 
concentrations were 10.9 and 25.1 µg/ml. The respective mean minimum concentrations were 
1.1 and 2.54 µg/ml.  
Arterial pressure:  
There was no notable change from baseline (0 hours) mean systolic or diastolic blood 
pressure at 2, 4 and 23 hours for the ‘511, 100 mg and 200  mg treatment groups (pre 
angiotensin I infusion).  There was a decrease in mean systolic and diastolic blood pressure at 
2 and 23 hours post-dose in the ramipril 10 mg treatment group (pre angiotensin I infusion).   
Mean (95% confidence interval) angiotensin  I DR-1 (dose response ratio -1) values at 
different times after administration of ‘511 and ramipril are shown in figure 8.3.  Maximum 
effect for ramipril was observed 2 hours post-dose.  This was followed by a time dependent 
reduction in the effect of ramipril with some inhibitory activity still apparent at 23 hours post-
dose.  For ‘511, only minimal inhibitory activity was observed at any given, post-dose time 
point.   
Serum ACE activity:  
There was a decrease in baseline median ACE activity from Day 1 to Day 7 for all three 
treatment groups.  The greatest change from baseline median ACE activity was following 
treatment with ramipril 10 mg; following ‘511 100 mg and ‘511 200 mg no significant change 
was detected. 
Thus starting (baseline) median ACE activity was different for the three treatment groups on 
Day 7; ‘511 100 mg was 29.5 u/l, ‘511 200 mg was 20.0 u/l whereas that for ramipril 10 mg 
was 8.0 u/l.    
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Figure 8.2  Study day 4: Mean (95% confidence interval) angiotensin I dose-blood pressure 
response curve (DR – 1) at different times after administration of ‘511 100 mg, 
‘511 200 mg, and ramipril 10 mg for 4 days  
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After dosing on Day 7, there was a reduction in median ACE activity from baseline 
irrespective of treatment. Treatment with ramipril 10 mg showed a significantly greater 
reduction in ACE activity when compared with ‘511 100 mg or ‘511 200 mg. The ratio 
of trough ACE activity with ‘511 100mg compared with Ramipril 10mg was 4.94 (95% 
CI: 2.98-8.17) and that of ‘511 200mg compared with Ramipril 10mg was 4.14 (95% 
CI: 2.56-6.68). 
The pattern of ACE activity followed a similar time course for each of the treatments, 
with the lowest ACE activity being achieved at approximately 3 hrs followed by a 
gradual return to baseline levels over the following 24 hrs.  
Neutral endopeptidase (NEP) activity:  
Plasma ANP  
On Day 7, baseline median plasma ANP concentration was similar for the ‘511 100 mg 
and 200mg treatment groups (19.65 pmol/ml and 18.00 pmol/ml respectively) and 
higher than in the ramipril 10 mg group (10.45 pmol/ml).   
After dosing on Day 7, ‘511 led to a dose dependent increase in plasma ANP 
concentration consistent with systemic NEP activity. The rise in median plasma ANP 
concentration following treatment with ‘511 100 mg and ‘511 200 mg was 23.40 and 
26.20 pmol/ml respectively.   
The pattern of plasma ANP concentration followed a similar time course following 
treatment with ‘511 100  mg and ‘511 200  mg with a peak of median plasma ANP 
concentration being achieved at approximately 16 hours.  This was followed by a 
gradual return to baseline levels over the next 24 hours. 
Plasma cGMP 
There was no notable change from baseline median plasma cGMP concentrations from 
Day 1 to Day 7 for all three treatment groups.  
On Day 7, baseline median plasma cGMP concentrations were similar for the ‘511 
100 mg and 200mg treatment groups, 12.9 pmol/ml and 12.50 pmol/ml, respectively, 
slightly higher than in  the ramipril 10 mg group, (9.80 pmol/ml).    
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After dosing on Day 7, there was a rise in median plasma cGMP concentrations 
irrespective of treatment (approximately 2 hr), although the change in plasma cGMP 
concentrations was significantly lower in those subjects treated with ramipril 10 mg, 
followed by a fall in median plasma cGMP concentration by 3 hr.  The pattern of 
median plasma cGMP concentrations followed a similar time course for each of the 
treatments gradually return to baseline levels over the next 24 h. 
Discussion 
NEP plays a role in the breakdown of several endogenous vasodilatory natriuretic 
peptides.  Blockade of NEP potentiates the action of these peptides by inhibiting their 
breakdown.  Thus far, the effect of NEP inhibitors on blood pressure has been modest 
and none of the candidate NEP inhibitors have been approved for clinical use.  It has 
been proposed that the additional ACE inhibition offered by dual ACE/NEP inhibitors 
has the potential to be more effective in hypertension and possibly heart failure by 
blocking the formation of the vasoconstrictor, angiotensin II and the breakdown of 
vasodilatory natriuretic peptides. 
The aim of this study was to further characterise the NEP activity of ‘511 a new dual 
inihibitor in vivo and to compare the potential of ‘511 to cause plasma ACE inhibition 
with that of a clinically relevant comparator, ramipril.  
I was able to demonstrate that ‘511 significantly and dose dependently inhibits NEP. 
ANP concentrations were significantly higher after dosing with ‘511 100 mg and ‘511 
200 mg when compared to ramipril 10 mg. In fact even the lower dose of ‘511 caused 
an increase in plasma ANP concentration comparable to that seen with candoxatril in 
healthy volunteers. Plasma levels of ANP more than doubled in response to treatment. 
(Northridge et al 1989, Jardine et al 1990).
 
A comparison with candoxatril is perhaps particularly relevant since it would appear the 
in vivo ACE inhibitory properties of ‘511 are limited. In support of previous in vitro 
demonstration of ACE inhibition by ‘511, I was able to demonstrate some dose 
dependent reduction in ACE activity. The comparison with ramipril however was 
disappointing. I demonstrated that ramipril has more than four times the inhibition of 
ACE activity and when compared with ramipril 10 mg there was very little reduction in 
the hypertensive response to angiotensin I infusion with either dose of ‘511.  
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Johnson et al have more recently studied the same doses of ‘511 but without active 
control in 123 patients with mild to moderate hypertension. They demonstrate a 
significant reduction in blood pressure associated with significant inhibition of ACE 
activity and an increase in serum ANP and urinary cGMP excretion. Interestingly 
plasma ANP changes resulting from NEP inhibition were the more powerful predictors 
of change in blood pressure when compared to serum ACE activity. Indeed the authors 
conclude that NEP and not ACE inhibition is important for the antihypertensive efficacy 
of ‘511 (Johnson et al 2006). 
In conclusion, I believe that an agent that is both a NEP inhibitor, augmenting 
circulating natriuretic peptide production and an ACE inhibitor, reducing angiotensin II 
production, is an attractive therapeutic option in a range of cardiovascular diseases.   
However ‘511 offers only limited ACE inhibition and most importantly in my 
experience poor clinical effect when compared to an established pure ACE inhibitor. 
The experience with ‘511 may be useful in the development of other dual NEP/ACE 
inhibitors.  
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9  Neurohumoral effects of the new orally active renin 
inhibitor, aliskiren, in chronic heart failure  
 
Background 
The success of ACE inhibitors as a treatment for CHF (CONSENSUS 1987, SOLVD 
1991)
 has encouraged the development of alternative approaches to the blockade of the 
RAAS (Pitt et al 1995, 1997, 2000).
 
In part, this is because ACE inhibitors also block the breakdown of bradykinin.   
Accumulation of bradykinin appears to cause certain adverse effects (e.g. cough and 
angio-oedema) which lead to ACE inhibitor intolerance in a proportion of patients.(Pitt 
et al 1995, Fuller and Choudry 1987, Kjekshus and Swedberg 1988, Kostis et al 1994, 
1996) A more specific inhibitor of the RAAS should avoid these problems (although 
accumulation of bradykinin could also have benefits by promoting vasodilatation and 
fibrinolysis (Pitt et al 1995, 1997, 2000).  
ACE inhibition also results in accumulation of angiotensin I, which may competitively 
overcome enzyme inhibition and lead to "RAAS escape" (Pitt et al 1995). Other 
enzymes, such as chymase, may also continue to generate angiotensin II (Urata et al 
1990, Petrie et al 2001, McDonald et al 2001).
 
These and other considerations have led to the introduction of specific angiotensin II 
type 1 receptor antagonists (Pitt et al 1995, 1997, 2000). AIIRAs, however, lead to 
accumulation of angiotensin II and the consequences of this, through the actions of 
angiotensin II at other receptors, are unknown (Gottlieb et al 1993, Cao et al 1999). 
Both ACE inhibitors and angiotensin II receptor antagonists interrupt the normal 
feedback suppression of renin from the kidneys; the rise therefore in renin leads to 
greater generation of angiotensin I and in turn angiotensin II.  
 
An alternative approach to blockade of the RAAS is inhibition of renin, the rate limiting 
enzyme for the formation of angiotensin II (Fisher and Hollenberg 2001, Nussberger et 
al 2002). Until recently, the introduction of renin inhibitors into clinical practice was 
limited by low oral bio-availability, poor efficacy, short duration of action and high cost 
of chemical synthesis (Fisher and Hollenberg 2001, Nussberger et al 2002). These  
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problems have in part been overcome with the development of the new, orally active, 
non-peptide, specific renin inhibitor, aliskiren (SPP 100) (Nussberger et al 2002). 
Aliskiren offers a longer duration of action and improved efficacy when compared to 
previous inhibitors but continues to have a poor bioavailability at only 2.5%.  A high-fat 
meal decreases the mean area under the curve (AUC) and peak concentration (Cmax) of 
aliskiren by at least 70%. Approximately 25% of absorbed aliskiren is excreted in the 
urine unchanged.   
This study describes the first administration of this agent to patients with CHF. 
Methods 
The primary scientific aims of this study were to compare the neurohumoral actions of 
aliskiren to (i) placebo, because aliskiren has never been given to patients with CHF 
before and also (ii) to compare the actions of aliskiren to those of an effective dose of an 
ACE inhibitor, because comparable or greater effects than an ACE inhibitor are 
desirable.   It is, however, practically and ethically difficult to design a comparison with 
placebo.  This is because it is both hard to identify patients not started on treatment with 
an ACE inhibitor therapy and undesirable to withdraw established ACE inhibitor 
treatment.   Consequently, I adopted the study design in figure 9.1, involving only a 
short period (up to two weeks) of ACE inhibitor withdrawal.  After a 5-7 day run-in 
period, patients were randomised to placebo (ACE inhibitor withdrawal), ramipril 5mg 
once daily or aliskiren 75 mg once daily for one week.  After this week, patients taking 
placebo switched to one or other of the active therapies for the remainder of the study (a 
further 5 weeks, figure 9.1). 
Study assessments.   The primary assessments in this study were i) change in plasma 
renin activity and concentration of angiotensin II and aldosterone concentration and 
BNP from baseline to the end of one week of treatment (visit 3) [this involved a 
comparison of placebo, ramipril and aliskiren] and ii) change in these neurohumoral 
measures from baseline (visit 2) over visits 4-6 (i.e. during a further 5 weeks of 
therapy). Other assessments included clinical examination (body weight, heart rate and 
sitting and standing blood pressure) and routine biochemical and haematological 
measurements, made at baseline and varying intervals during the 6 weeks of randomised 
therapy, as indicated in figure 9.1.   
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Neurohumoral assays.   Blood samples were collected for measurement of plasma BNP, 
angiotensin II and aldosterone concentrations. Plasma renin activity was also measured. 
Samples were handled, stored and analysed as described in chapter 2.  
Data analysis and presentation.   Comparisons between the change in the neurohumoral 
measurements from the pre-treatment visit (visit 2) and those made after one week of 
therapy (placebo, ramipril or aliskiren, visit 3) were made using a Wilcoxon matched 
pairs test and the comparisons between visit 2 and visits 4-6 were made using one way 
analysis of variance followed by Bonferroni’s test for multiple comparisons. 
Results 
Patient details:   The details of the patients studied are given in table 9.1. 27 patients (3 
female) were randomised. All had been taking an ACE inhibitor prior to randomisation. 
Two patients were withdrawn early from randomised therapy, because of worsening 
heart failure, one after 15 days and the other after 35 days. 
PLACEBO V. ALISKIREN V. RAMIPRIL 
One week, three way treatment comparison. 
Plasma renin activity (table 9.2):  Plasma renin activity did not change with placebo.  
Even within one week of therapy, plasma renin was suppressed by aliskiren.  As 
expected, plasma renin activity tended to increase with ramipril. 
Plasma angiotensin II concentration (table 9.2):  The plasma concentrations of 
angiotensin II did not change with placebo or ramipril.  Angiotensin II, however, was 
clearly reduced by aliskiren. 
Plasma aldosterone concentration (table 9.2): Plasma aldosterone concentration did not 
change significantly with any of the three treatments. 
Plasma BNP concentration (table 9.2):  Plasma BNP also did not clearly change with 
any of the 3 treatments. 
Blood pressure (table 9.3):  There were no significant changes in blood pressure in any 
of the three groups after one week of treatment.  
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1 
 
 placebo 
(4 subjects) 
    ramipril 10 mg  
(14 subjects) 
    ramipril  7.5  mg 
(14 subjects) 
 
  ramipril 5 mg 
(10 subjects) 
ramipril 5 mg 
(14subjects) 
  
5-7 days  1 week  1 week  2 weeks  2 weeks 
       
  aliskiren  75 mg  
(9 subjects) 
aliskiren 75 mg 
(13 subjects) 
  
       
      aliskiren 150 mg 
(12 subjects) 
 
 placebo 
(4 subjects) 
    aliskiren 300 mg  
(12 subjects) 
 
Visit no. 
BP/HR                     X                               X              X                              X                                    X                                 X                                     
 
Neurohumoral 
measurements  -                         -                   X                                     X                               X                                    X                                 X 
Haematology/ 
biochemistry             X                               -                                     X                                 -                                    X                                 X                   
Physical exam./ 
body weight             X                               -                                      -                                 -                                     -                                 X 
3 4  5  6  2 
Figure 9.1   Study design and assessments 
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Table 9.1     Baseline patient characteristics   
    
Initial treatment allocation  Patient characteristics
* 
Ramipril Aliskiren  Placebo 
      
Number of patients  10  9  8 
Age, years (SD)  66 (8)  65 (9)  60 (9) 
Left ventricular  
ejection fraction 
0.25 0.26  0.25 
      
Drug therapy       
Beta-blocker 10  8  7 
Spironolactone 0  1  0 
Diuretic 7  7  6 
Digoxin 5  3  2 
HMG-CoA reductase inhibitor  5  7  3 
Oral nitrate  4  1  0 
 
* number of patients, unless otherwise indicated. 
HMG CoA,  3-hydroxy-3-methylglutaryl coenzyme A  
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ALISKIREN V. RAMIPRIL 
Five week, two way treatment comparison.  
Baseline week 2 (follows 1 week drug free for all patients) compared to treatment 
weeks 4, 5 and 6. Week 3 is not reported since the only change at this timepoint was in 
the 4 patients who had continued on placebo for an extra week commencing treatment 
for the remaining 5 weeks. 
Plasma renin activity (figure 9.2):  As expected, aliskiren significantly reduced plasma 
renin activity whereas this increased with ramipril. 
Plasma angiotensin II concentration (figure 9.3):  Aliskiren also reduced plasma 
angiotensin II concentration whereas plasma concentrations of this peptide did not fall 
during ramipril treatment. 
Plasma aldosterone concentration (figure 9.4):  There was no clear change in plasma 
aldosterone concentration in response to either treatment. 
Plasma BNP concentration (figure 9.5):  There was no clear change in plasma BNP 
concentration in response to either treatment. 
Blood pressure (table 9.3):  There were comparable reductions from baseline in systolic 
and diastolic blood pressure with both treatments. 
Safety and tolerability 
Aliskiren and ramipril treatments were generally well tolerated. A total of 24 adverse 
events were reported in 9 patients during aliskiren treatment and 15 adverse events were 
reported in 9 patients during ramipril treatment. Dyspnoea (4 patients) and fatigue and 
dizziness (3 patients) were the most frequently reported adverse events. The frequency 
of adverse events did not increase with the dose of aliskiren or ramipril.  
  122
Table 9.2  Three way comparison of effect of one week of treatment with placebo, ramipril or aliskiren on plasma neurohumoral 
concentrations in patients with chronic heart failure 
 
  PRA 
ng/ml/hr 
Angiotensin II 
pg/ml 
Aldosterone 
ng/100ml 
BNP 
pg/ml 
 visit  2 visit  3 p  visit  2 visit  3 p  visit  2 visit  3 p  visit  2 visit  3 p 
placebo 3.1(5.1)  2.4(4.1)  ns  49(67)  41(63)  ns 18(13)  14(9)  ns  248(179)  202(316)  ns 
ramipril 0.9(0.8)  2.3(2.8)  0.03  10(9)  13(26)  ns 13(8)  12(10)  ns  224(326)  202(316)  ns 
aliskiren 1.6(1.5)  0.4(0.3)  0.01  20(17)  8(8)  0.01 14(7) 11(6) ns 126(102)  145(139)  ns 
 
Visit 2 = pre-treatment; visit 3 = one week post-treatment (end of the three way treatment comparison period) 
All values are means (+ standard deviation) 
PRA = plasma renin activity 
BNP = B-type natriuretic peptide  
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Table 9.3  Three way comparison of effect of one week of treatment with placebo, ramipril or aliskiren on systolic and diastolic blood 
pressure in patients with chronic heart failure 
SBP = systolic blood pressure 
DBP = diastolic blood pressure 
V2 = visit 2 (pre-treatment) 
V3 = visit 3 (1 week’s treatment) 
V6 = visit 6 (6 weeks treatment); placebo was given for 1 week only. 
* data for patients starting with ramipril/aliskiren only; patients switching placebo to ramipril/aliskiren after 1 week are not included.     
ŧ data presented as mean (standard deviation) 
  SBP (mmHg) ŧ DBP  (mmHg) ŧ  
Initial treatment  V2 V3 V6 V2 V3 V6 
placebo  (n=8)  133(11)  134(18)  -  75(6) 79(8) - 
ramipril (n=10)*  130 (24)  127 (22)  120 (21)  74 (14)  74 (15)  72 (13) 
aliskiren (n=9)*  139 (10)  133 (18)  130 (21)  78 (14)  74 (8)  73 (11)  
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Effect of aliskiren and ramipril on plasma renin activity (mean percentage change 
from visit 2 / baseline) *** p<0.0001
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Figure 9.2  
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Mean percentage change in plasma concentration of angiotensin II  
from visit 2 (baseline) * p<0.05 
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Figure 3: 
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*
Figure 9.3  
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Mean percentage change in plasma concentration of aldosterone  
from visit 2 (baseline).  No difference between treatments was defected. 
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Figure 4:  Figure 9.4 
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Mean percentage change in plasma concentration of BNP  
from visit 2 (baseline).  No difference between treatments was detected. 
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Figure 5:  Figure 9.5  
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Discussion 
Though a number of renin inhibitors have been studied in healthy volunteers and in 
patients with hypertension, there is very little prior experience with these agents in CHF 
(Delabays et al 1989, Boger et al 1990, Neuberg et al 1991, MacFadyen et al 1995,  Van 
den Meiracker et al 1999, Staessen et al 2006).  
The short-term haemodynamic effects of the selective dipeptide inhibitor enalkiren (A-
64662), administered intravenously, were reported over a decade ago (Neuberg et al 
1991).
 In that uncontrolled study, enalkiren resulted in favourable changes in cardiac 
index, systemic and pulmonary vascular resistance, left ventricular filling pressure and 
other indices of cardiac function.  I know of no other studies with renin inhibitors in 
CHF (Neuberg et al 1991). In particular, I know of no chronic dosing studies with an 
orally active renin inhibitor prior to my work.   
Aliskiren is an orally active renin inhibitor with a long duration of action. It has been 
studied in healthy volunteers (Nussberger et al 2002); doses of 40 to 640 mg daily were 
compared to 20 mg enalapril daily or placebo, with each drug given for eight days. 
Aliskiren was well tolerated and dose-dependently inhibited the RAAS to at least the 
same extent as enalapril (Nussberger et al 2002). Indeed, in healthy subjects, 160mg 
aliskiren gave equivalent suppression of angiotensin II as 20mg of enalapril. More 
recently, the efficacy of aliskiren (37.5mg, 75mg, 150mg and 300mg once daily for four 
weeks) has also been compared to losartan (100mg once daily) in patients with essential 
hypertension. In that study, 75mg and 150mg of aliskiren reduced blood pressure and 
300mg lowered blood pressure to the same extent as losartan 100 mg (Stanton et al 
2003). Subsequent studies have confirmed the effectiveness of aliskiren as an 
antihypertensive agent and compared it to other types of blood pressure lowering 
therapies (Gradman et al 2005, O’Brien et al 2007, Pool et al 2007, Jordan et al 2007, 
Oh et al 2007). The most recently published study looks at treatment of hypertension 
with aliskiren and with a combination of aliskiren and an angiotensin II receptor 
antagonist, valsartan. While again reporting significant reduction in blood pressure with 
aliskiren, -12.6mmHg systolic and -8.1mmHg diastolic, the combination provided only 
modest additional hypotensive effect, -4.4 mmHg systolic and -3.2 mmHg diastolic 
Oparil et al 2007). Concern has been expressed regarding the potential for life 
threatening adverse event with the combination, particularly as a result of  
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hyperkalaemia, hardly balanced by this modest benefit (Birkenhager and Staessen 
2007).  
I have now studied Aliskiren in CHF. At the doses used in my study, the orally active 
renin inhibitor, aliskiren was at least as effective at suppressing the RAAS as the ACE 
inhibitor ramipril over a six week period.  This was apparent acutely, where one week 
of treatment with 75 mg of aliskiren reduced plasma angiotensin II concentrations, in 
contrast to 5 mg of ramipril.  This effect was also apparent over the subsequent five 
weeks of treatment where 75–300 mg of aliskiren more clearly reduced angiotensin II 
than ramipril 5-10 mg.  
In the first study in hypertension mentioned above, angiotensin II was not measured but 
plasma renin activity was reduced from baseline by 55% with 37.5mg of aliskiren, by 
60% with 75mg, by 77% with 150mg and by 83% with 300mg (contrasting with a 
110% rise with losartan, Stanton et al 2003). I found a comparable reduction (-64%) in 
plasma renin activity with aliskiren in patients with chronic heart failure (compared with 
a 132% increase with ramipril) in the present study. 
Why might renin inhibitors be valuable in CHF? Renin is the rate limiting step in the 
RAAS cascade and has a very specific interaction with its substrate. Consequently, 
adverse effects should be uncommon with renin inhibitors. Secondly, renin inhibition is 
the only approach to RAAS suppression that reduces both angiotensin  I and II. This has 
several potentially favourable consequences. The reflex increase in angiotensin I which 
occurs during treatment with ACE inhibitors and angiotensin receptor antagonists does 
not occur during renin inhibition. This increase may ultimately overcome ACE 
blockade and lead to ‘renin-angiotensin-aldosterone escape’ (Pitt et al 1995). We know 
angiotensin I is also a substrate for other enzymes (eg chymase) capable of generating 
angiotensin II. Similarly, the excess angiotensin I produced during ACE inhibition (and 
the excess angiotensin I and II produced during treatment with an angiotensin receptor 
antagonist) may be converted to other angiotensin peptides which may directly and 
indirectly, produce both desirable and undesirable effects (Stegbauer et al 2003, Cesari 
et al 2002). Similarly the pros and cons of the bradykinin enhancing effects of ACE 
inhibitors (and the stimulating effect of angiotensin II on other angiotensin receptors 
during treatment with an angiotensin receptor antagonist) have already been alluded to. 
Overall the pharmacological consequences of each separate approach to inhibiting the  
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RAAS are myriad and quite different. Whether the different net pharmacological effect 
of each approach results in a different therapeutic action is unknown and difficult to 
predict. However, given the clinical success of the established pharmacological 
approaches to RAAS inhibition in cardiovascular and other diseases, it must be of 
interest to examine the clinical effects of renin inhibition, especially in CHF. 
As with any study of this type, there are limitations. A relatively small number of 
patients were randomized and treatment was administered for a comparatively short 
period. Necessarily, my patients were those tolerating chronic ACE inhibition and the 
study was really one of ACE inhibitor withdrawal (and placebo or aliskiren 
substitution). This may explain the somewhat curious observation that angiotensin II 
tended to increase over time in patients randomized to ramipril. The present study was 
not a dose response study and investigated only one target dose of aliskiren. This was 
because 300mg had already been identified as an effective and well tolerated dose in the 
first hypertension study described above (Stanton et al 2003). Though there were no 
safety concerns with aliskiren in the current study, the number of patients studied and 
the duration of treatment were too limited to draw any firm conclusion.  
In summary, this study shows that once daily dosing with aliskiren suppresses the 
RAAS as effectively as ramipril in the short term. This new approach to  neurohumoral 
modulation is theoretically therapeutically attractive, especially in CHF, given the 
clinical success of the established pharmacological methods of suppressing the RAAS 
in this syndrome. Further studies of renin inhibition in CHF are clearly justified, indeed 
preliminary results of a prospective, multicentre, randomized, double blind study – 
ALOFT have recently been presented to the European Society of Cardiology. 
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10 DISCUSSION 
The primary objective of this thesis was to characterise two recently developed 
molecules that have dual enzyme inhibitor activity, omapatrilat and SLV 306. Both are 
expected to augment the potent vasodilator natriuretic peptides via their effect on NEP. 
Both also inhibit potent vasoconstrictors, either angiotensin II or ET-1, via effect on 
ACE and ECE respectively. The combination in both instances promises significant 
therapeutic benefit in hypertension, CHF and even atherosclerosis and significant 
reduction in blood pressure in a hypertensive population has already been clearly 
demonstrated in the case of omapatrilat.  
I have demonstrated that both molecules act on multiple vasoactive mediators and I am 
therefore able to offer possible explanation for, as well as further demonstration of, their 
clinical characteristics. 
Omapatrilat is the most clinically advanced of the vasopeptidase inhibitors. It is orally 
active and offered great therapeutic potential in patients with hypertension or chronic 
heart failure. As an inhibitor of NEP in addition to ACE the challenge for this molecule 
was to achieve additional benefit over that achieved by ACE inhibition alone. It was 
hoped that the potential of NEP inhibition suggested by in vitro studies would finally be 
realised in vivo by the dual inhibitor. The explanation offered for failure to achieve this 
potential in the past with pure NEP inhibitors is that NEP not only has a role in the 
metabolism of the natriuretic peptides but also angiotensin II.    
We are encouraged by large randomised controlled studies which report significant 
reduction of blood pressure by omapatrilat when compared to ACE inhibition alone, in 
hypertensive patients (Rouleau et al 2000, Kostis et al 2004). Unfortunately, the 
potential for clinical use in this population has been severely limited by the incidence of 
the potentially life threatening side effect, angioedema. This was not predicted 
following the earlier IMPRESS study.  Perhaps explained by the fact that this was a 
selected population, already demonstrated to be ACE tolerant and the study was only 
over a short time period. We know that the occurrence of angioedema in patients taking 
ACE inhibitors can be as long as eight years following first prescription.  
In the CHF population, a group with a poor prognosis and quality of life even on current 
therapy including an ACE inhibitor, a risk of serious adverse event may have been  
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acceptable to some. Unfortunately in an unselected heart failure population studies have 
suggested no significant benefit from vasopeptidase inhibition over and above ACE 
inhibition alone. 
The profound effect of omapatrilat on systemic blood pressure, demonstrated in large 
randomised controlled trials and the unexpectedly high incidence of angioedema 
suggests that the inhibition of NEP and ACE has a more complex affect than simply 
natriuretic peptide augmentation and angiotensin II inhibition. 
It is clearly important that we more fully understand the mechanism by which 
angioedema occurs as well as the relative contribution of inhibition and augmentation of 
various vasoactive hormones, to the benefits associated with this group of molecules.  
CGRP and ADM are structurally similar peptides and bind to similar receptors. Both are 
powerful vasodilators and natriuretic peptides and CGRP particularly has been 
associated with dilatation of cutaneous arterioles and facial flushing, raising the 
suspicion that either or both of these molecules may play a role in the development of 
angioedema. Substance P and VIP are also powerful vasodilators with a suggested role 
in heart failure. 
The effect of vasopeptidase inhibition on the action of these peptides in humans has not 
previously been studied. There has been the suggestion that NEP is responsible for the 
degradation of CGRP and ADM but the evidence is contradictory. There is evidence 
that VIP is augmented by ACE inhibition.  
I was able to demonstrate that omapatrilat does indeed inhibit vasoconstriction in 
response to angiotensin I, consistent with ACE inhibition. Curiously however 
omapatrilat did not augment the vasodilatation response to CNP. I suggest that this 
reflects a difference between CNP metabolism and that of other natriuretic peptides 
rather than the absence of NEP activity with the dual inhibitor. Vasodilatation response 
to CNP has failed to be augmented in the presence of NEP inhibition previously (Brandt 
et al 1997). In retrospect it may have been more useful to study the effects of 
omapatrilat on the more consistent ANP or BNP than CNP in my studies.   Vasopeptidase (ACE /NEP) 
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Of particular interest from my studies is the demonstration of omapatrilat’s positive 
effect on the vasodilator response to ADM, raising the clear possibility that ADM 
contributes to the potent antihypertensive effects seen with the vasopeptidase inhibitor 
as well as perhaps the angiooedema known to be associated with it. 
With no such effect on the response to CGRP, substance P and VIP I can suggest no 
similar role for these molecules.  
NEP inhibition alone was not shown to augment the vasodilatory effects of ADM in a 
previous study in heart failure patients (Petrie 2001). My study population had a history 
of ischaemic heart disease but normal left ventricular function. A less potent effect of 
ADM in heart failure patients compared to those with normal left ventricular function 
has been demonstrated previously (Nakamura et al 1997).  
We know ADM is released by endothelial cells and that a suggested mechanism of 
action is its effect on NOS and secondary augmentation of endothelium mediated 
vasodilatation. The action of ADM is dependent to a degree therefore on endothelial 
function. We know that patients with ischaemic heart disease have a degree of 
impairment in endothelial function. There are studies that describe acetylcholine 
causing vascular smooth muscle mediated vasoconstriction rather than endothelial 
mediated vasodilatation of coronary arteries in this population (Ludmer et al 1986, 
Gordon et al 1989). However, the subcutaneous vessels from ischaemic heart disease 
patients in my study were first tested for endothelial viability and showed a 
physiological vasoconstrictor response to acetylcholine. In the heart failure population, 
a lack of augmentation of ADM mediated vasodilatation in response to NEP inhibition 
may not represent a lack of ADM augmentation but a relatively poor endothelial cell 
response to it. In rat pulmonary arteries, the endothelium is necessary for ADM 
mediated relaxation (Yang et al 1996) Further studies looking at the response to NEP 
inhibition of ADM mediated vasodilatation in vessels with the endothelium removed 
may be useful. A difference in endothelial function and therefore vessel response to 
augmented ADM between patients with normal left ventricular function and patients 
with heart failure may explain the disappointing results seen in the large heart failure 
studies after such positive results were reported in the hypertensive population.   
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Augmentation of ADM and its actions, in response to NEP inhibition, has been 
demonstrated by other groups. Lisy et al (1998) however were not measuring vasomotor 
response to ADM but serum plasma levels following infusion and natriuresis and 
diuresis as a result of decreased sodium absorption. Rademaker et al (2002) studied the 
effect of NEP inhibition in the setting of heart failure but on the response to intravenous 
ADM. They considered plasma levels of ADM and renal function as well as systemic 
blood pressure and peripheral resistance. Although both groups demonstrated 
augmentation of the response to ADM in the presence of NEP inhibition this is likely to 
be explained by systemic as well as local reflexes, natriuretic peptide may in some way 
reduce ADM clearance (Bunton et al 2004). Most recently, augmentation of 
adrenomedullin by omapatrilat was also demonstrated by another group (Cataliotti et al 
2002) in experimental heart failure although again at a systemic level. They 
demonstrated an increase in plasma levels of adrenomedullin following administration 
of omapatrilat.  
These results do not directly contradict the findings of Petrie et al, whose findings are 
perhaps more a measure of endothelial viability in heart failure.  
Perhaps more surprising from my studies is that while the dual inhibitor, omapatrilat, 
augmented the response to adrenomedullin, NEP inhibition alone was not associated 
with a more potent vasodilatation response than control. One suggested explanation is 
that the pure NEP inhibitor used, thiorphan, is a weaker NEP inhibitor than omapatrilat 
or the NEP inhibitors used in previous studies. However the effect of omapatrilat on 
ADM may also be more complex than NEP inhibition alone; angiotensin II has been 
associated with upregulation of ADM by an unknown mechanism (Pearson et al 2006). 
ACE inhibition may also play an important role in my findings. I do note however that 
captopril alone failed to augment ADM in my studies. It is possible to speculate that the 
augmented response to ADM at a local level is the result of the combined affect of ACE 
inhibition on endothelial function (particularly in ischaemic heart disease patients 
perhaps) and NEP inhibition on ADM degradation.  
Supporting this more complex explanation for my findings is the fact that candoxatrilat, 
a powerful pure NEP inhibitor, shown to augment the systemic effects of ADM by Lisy 
et al, was not associated with angioedema in the hypertensive population in which it 
was widely studied.  
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Another strong candidate, according to the literature, for a role in the incidence of 
angioedema seen with ACE inhibitor therapy is bradykinin. It has been suggested that 
the higher incidence associated with omapatrilat may be the result of a dangerous 
synergy between ACE and NEP inhibition on bradykinin metabolism. While I 
demonstrated an increased response to bradykinin in the presence of omapatrilat, the 
fact that it was only similar and not greater to that seen with the ACE inhibitor, 
captopril counters this concern. It would seem that bradykinin is maximally augmented 
by ACE inhibition and that NEP inhibition does not lead to further augmentation. This 
is supported by my work with the dual inhibitor SLV 306. The NEP and ECE inhibition 
offered by this molecule was also unable to further augment bradykinin in the presence 
of ACE inhibition. Perhaps this finding could allay concerns about angioedema 
(Messerli and Nussberger 2000).    Of course, I have only studied small resistance 
arteries and the ratio of NEP and ACE differs in other tissues e.g. the myocardium 
(Blais et al 2000). The effect of combined therapy with an ACE inhibitor and a dual 
NEP/ECE inhibitor could differ between tissues. 
When considering both the additional hypotensive effect of omapatrilat and the 
increased incidence of angioedema when compared with ACE inhibition alone, the clear 
difference between dual inhibitor therapy and pure ACE inhibitor therapy on the 
response to ADM would suggest that this hormone rather than bradykinin is the more 
significant.  
My findings support further work with other dual inhibitors. It is important that the 
results from studies of omapatrilat treatment and particularly the concerns regarding 
adverse events are not unreservedly extrapolated to newer molecules. Instead the 
encouraging results in a hypertensive population seen with omaptrilat and other 
vasopeptidase inhibitors should maintain enthusiasm for these potential therapies. A 
different balance of NEP and ACE inhibition may offer some but not all of the effects 
of ADM augmentation and a fear of more powerful bradykinin augmentation may not 
be valid. It is clear that development of other vasopeptidase inhibitors may still be of 
benefit.    
My studies of another such agent ‘511 were unfortunately disappointing in that I 
demonstrated predominantly NEP inhibition. ‘511 does not apparently offer significant 
inhibition of ACE activity. While NEP inhibition alone is potentially beneficial, it is  
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limited in practice by the augmentation of vasoconstrictors as well as vasodilators as 
demonstrated by candoxatrilat.  
Further work with this molecule has been reported more recently (Johnson et al 2006). 
A randomized double blind placebo controlled study in 123 patients with hypertension, 
using 100mg and 200mg of ‘511 as in my study, did demonstrate a significant reduction 
in systolic and diastolic blood pressure. Unlike my study an active control was not used 
but compared to placebo they did demonstrate a significant reduction in ACE activity as 
well as augmentation of ANP. Larger studies are obviously required. Of particular 
relevance is the fact that in Johnson’s study, although relatively short and with small 
numbers of mainly caucasion subjects, there were no cases of angioedema. The authors 
suggest that this molecule increases bradykinin accumulation to a much lesser extent 
than previous vasopeptidase inhibitors such as omapatrilat, perhaps offering benefit 
therefore without significant side effects in their view.  
The most advanced vasopeptidase inhibitor after omapatrilat, Ilepatril (AVE 7688), has 
been given to more than 1700 patients with hypertension in a recently closed study.  
This was a prospective, multicentre, randomized, double blind study with losartan as 
active control, designed to reflect clinical practice. As well as neurohumoral and 
haemodynamic data we await particularly the adverse events reported over the 52 weeks 
– a pre defined end point. 
The concept of triple inhibitors has recently also gained interest. For example, 
ACE/NEP inhibition supplemented by additional inhibition of ECE. Preliminary 
studies, in experimental settings such as spontaneously hypertensive rats and rats with 
CHF, have shown that these molecules (Battistini et al 2005, Mellin et al 2005, Daull et 
al 2005) dose dependently reduce blood pressure, angiotensin II and ET-1, with an 
increase in big ET-1, ANP and bradykinin. Clearly careful evaluation of the safety 
profile of this strategy is needed before these molecules are considered as treatment 
options in humans. 
We do not understand why some patients suffer angioedema with omapatrilat or ACE 
inhibitors and others do not. Studies have not reported a correlation between blood 
pressure response and risk of angioedema. It may be that the activity of one vasodilator 
when compared to another varies between patients. In some, ADM and bradykinin may  
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be the more active, putting the patient more at risk of side effects. In others the effect on 
natriuretic peptide activity may predominate and the contribution from the other 
vasodilators is enough to cause a reduction in vascular resistance without the unwanted 
adverse event. This argument supports a growing belief that bespoke medication on an 
individual patient basis is the way of the future (Evans and Relling 2004) but does not 
facilitate development of widely effective and safe vasopeptidase inhibitors.  
SLV 306 is the first dual NEP/ ECE inhibitor available in oral form and the first to be 
given to healthy volunteers or patients. Other molecules are in development but have 
not yet been administered to humans (Emoto et al 2005, Trapani et al 2002) Again these 
molecules hope to offer augmentation of natriuretic peptides as a result of NEP 
inhibition, without the augmentation of vasoconstrictors, specifically ET-1, another 
vasoconstrictor said to be metabolised by NEP and therefore augmented by NEP 
inhibition. Their role is likely to be in addition to ACE inhibition since Angiotensin II is 
also metabolised by NEP.  Any synergy between molecules such as SLV 306 and ACE 
inhibition may therefore be of concern.  
I was able to demonstrate potent ECE inhibition by this molecule with attenuation of the 
vasoconstrictor response to big ET-1 in vitro and attenuation of the pressor response to 
infused big ET-1. SLV 306 also caused an increase in the plasma big ET-1: ET-1 ratio 
following infusion of big ET-1 in vivo, with no increase in ET-1 but a dose dependent 
increase in big ET-1. I was able to demonstrate NEP inhibition with augmentation of the 
vasodilator response to ANP in vitro and an increase in plasma levels of ANP in vivo. 
Our experience now with omapatrilat in large studies of hypertensive and heart failure 
patients highlights the importance of studying the effects of molecules such as SLV 306 
on multiple vasoactive hormones. SLV 306 in addition to ACE inhibitor therapy offers 
broad vasoactive enzyme inhibition and the neurohumoral effects are likely to be 
complex and whilst beneficial potentially also detrimental. 
As expected, KC12615 augmented the vasodilator response to bradykinin. This is likely 
to be as a result of NEP inhibition in the most part, the pure NEP inhibitor thiorphan 
showed a similar response. Of particular interest is that SLV 306 does not offer 
additional bradykinin augmentation in the presence of ACE inhibition. Perhaps limiting 
its therapeutic potential but also allaying fears about the potential problems associated  
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with an increase in the activity of a hormone implicated in the common side effect, 
cough, associated with ACE inhibition and the poorly understood but potentially life 
threatening side effect, angioedema also seen with ACE inhibition but more frequently 
with omapatrilat.  
KC12615 does also augment the vasodilator response to ADM. It has been suggested 
that this hormone offers cardiovascular benefit in hypertension, atherosclerosis and 
heart failure (Shimosawa et al 2002, Cataliotti et al 2002, Nagaya et al 2000, Jougasaki 
et al 1996, Nakayama et al 1999) but my work raises concern regarding the role of 
ADM in angioedema and emphasises the need for caution with any broad vasoactive 
enzyme inhibition of this kind. 
We await with interest the results of two studies of SLV 306 recently closed to 
recruitment in patients with hypertension, particularly the incidence if any of 
angioedema in the study population. The first is a placebo controlled multicentre study 
giving patients one of three doses of SLV 306 (Daglutril) or amlodipine 5-10mg (study 
identifier NCT00160212, www.clinicaltrials.gov accessed July 07). The second from a 
single centre adding SLV 306 (Daglutril) to losartan in hypertensive, diabetic patients 
with nephropathy (study identifier NCT00160225, www.clinicaltrials.gov accessed July 
2007). 
Perhaps the principle motivation for the work reported in this thesis, is an appreciation 
of the complexity of the neurohumoral system in humans.  Omapatrilat being a recent 
example of how unexpected the results can be when interfering with this system. Our 
understanding is apparently particularly limited when we act on more than one pathway.  
Others also gain from the now broad experience with neurohumoral modulation in 
cardiovascular disease, utilizing therapies which modulate neurohumoral pathways in 
other systems.  
ET receptor antagonists have been associated with outcome benefit in patients with 
pulmonary hypertension not unexpected since ET is particularly active in the pulmonary 
vasculature (Channick et al 2001). Inhibition of the endothelin system either by ET 
antagonists or ECE/NEP inhibition with molecules such as SLV 306 has been 
associated with a reduction in pulmonary as well as systemic pressures. The NEP and 
ECE inhibitory properties of SLV 306 having been studied in animal models of  
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pulmonary hypertension have shown a very promising profile of activity (Meil et al 
1998). 
Vasopeptidase (ACE / NEP) inhibition and ECE / NEP inhibition have both been 
associated with beneficial renal effects thought to be secondary to a combination of 
inhibition of RAAS, ET-1 production and NEP all associated with increased glomerular 
filtration rate and renal blood flow (Troughton et al 2000, McLean et al 2000, Meil et al 
1998).  
Vasoconstriction and secondary reduction in vascular compliance, increased cardiac 
afterload, pulmonary hypertension and renal disease is mediated in CHF and other 
cardiovascular pathologies at least in part by stimulation of the complex neurohumoral 
pathways that I have described. It makes sense that inhibition of these pathways by 
whatever means will offer benefit perhaps in the general heart failure population, 
perhaps in subgroups of heart failure patients particularly affected by common 
comorbidities such as pulmonary hypertension and renal disease, perhaps also in 
patients with only these associated co morbidities. 
Renin inhibition, by acting at the origin of the RAAS perhaps offers patients much more 
specific neurohumoral modulation. The result being near to physiological is not 
associated with rises in undesirable reflex neurohormones such as angiotensin I and as a 
result is less likely to be associated with side effects. The pros and cons of complex 
neurohumoral modulation such as bradykinin or adrenomedullin augmentation have 
been well described. Whether there is also a difference in net pharmacological effect 
with each separate approach to inhibiting the RAAS or indeed other neurohumoral 
pathways remains unknown however and difficult to predict.  
It is encouraging to see from my data that aliskiren is at least as effective at suppressing 
the RAAS as an ACE inhibitor in the heart failure population, as seen previously in the 
hypertensive population. In the hypertensive population trials have demonstrated an 
associated clinical benefit (Oh et al 2007, Oparil et al 2007) and recent results in the 
heart failure population are similarly encouraging.  
Aliskiren has now been given to 302 patients with NYHA class II –IV heart failure, 
hypertension and a BNP concentration >100 pg/ml in a study recently reported to the 
European Society of Cardiology in Vienna. ALOFT, a prospective, multicentre,  
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randomized, double blind study was designed to reflect clinical practice. Patients had to 
be optimally treated with an ACE inhibitor or angiotensin II receptor antagonist and a β 
blocker, unless contraindicated or not tolerated. A group therefore in whom the 
compensatory rise in plasma renin, caused by loss of negative feedback inhibition of 
renin secretion, had occurred. They were studied for 3 months. Although primarily a 
safety and tolerability study, blood samples for neurohumoral analysis were taken. 
Compared to placebo, aliskiren reduced plasma BNP by 25%, p=0.0160 and urinary 
aldosterone by 21%, p=0.0150. There was also a favourable change in a Doppler-
echocardiographic measure of left ventricular filling pressure. Aliskiren was well 
tolerated and there was no significant excess of hypotension or renal dysfunction.  
Taking note of concerns expressed previously (Birkenhager and Staessen 2007), with 
regard to the combination of renin inhibition and ACE inhibition or angiotensin II 
receptor blockade, it is important to note that even in this carefully selected population 
there was a slight increase in the incidence of hyperkalaemia in the aliskiren treatment 
group, although  not reaching statistical significance. It is also important to emphasise 
that all of these patients had a history of hypertension as well as left ventricular 
impairment, with a slight difference in the mean blood pressure of treatment and 
placebo groups at baseline interpretation of the results is open to discussion although 
importantly there is no difference in blood pressure in either group between baseline 
and the end of the study. 
In summary, favourable neurohumoral and other effects in otherwise optimally treated 
patients with heart failure were seen. This study, in addition to my own, supports further 
evaluation of aliskiren as a possible future treatment for heart failure. However, 
experience with other strategies, not least omapatrilat, highlights the need for only 
guarded optimism when considering the therapeutic potential of this class in the more 
complex heart failure population. 
Of course ACE inhibition, now widely used in a broad spectrum of cardiovascular and 
related diseases, despite complex and not entirely understood effect on multiple 
neurohormones, is just one example of the potential gain from neurohumoral 
manipulation however and we should remain enthusiastic in our search for additional 
effective and safe therapies in this field.  
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